Kongeriget Danmark

DK/99/ 525

Patent application No.:   PA 1998 01261

Date of filing: 05 Oct 1998

Applicant: M & E Biotech A/S
Kogleallé 6
DK-2970 Hørsholm

This is to certify the correctness of the following information:

The attached photocopy is a true copy of the following document:

- The specification, claims and drawings as filed with the application on the filing date indicated above.

Patent- og
Varemærkestyrelsen
Erhvervsministeriet

TAASTRUP 18 Oct 1999

Lizzi Vester

Lizzi Vester
Head of Section

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

FIELD OF THE INVENTION

The present invention relates to novel methods for combatting diseases, such as cancers, which are characterized by the presence of cell-associated gene expression products which are

5 non-immunogenic or poorly immunogenic. In particular, the present invention relates to methods for inducing an immune response conducted by cytotoxic T-lymphocytes (CTLs), whereby cells carrying epitopes from the gene expression products are attacked and killed by the CTLs. The invention also relates to

10 a method of preparing immunogenic, modified polypeptide antigens which are derived from weakly immunogenic antigens.

The invention further relates to a series of applications of Applicant's AutoVac technology (which is the subject of WO 95/05849) within the field of therapeutic vaccination against

15 cancer.

BACKGROUND OF THE INVENTION

The idea of vaccinating against cancer has been around for more than hundred years and has enjoyed recurrent bursts of activity, particularly since the turn of this century.

20 However, during the past 10 years the understanding of the fundamental molecular mechanisms of the immune response has improved considerably. Among the most important milestones achieved during this period has been the discovery of the still growing list of cytokines and growth factors, the

25 understanding of the mechanisms of interaction between T and B cells as well as the establishment of the cellular antigen processing pathways including the role and structure of the MHC class I and II molecules in antigen presentation. Important discoveries with regard to cancer immunology -

30 although still not fully understood - were also the

elucidation of the mechanisms underlying induction cf
immunological tolerance in a host. All this research has led
to a huge amount of efforts in order to develop new treatments
for human cancer.

5 Depending on how tumour immunity is acquired by the patient,
immunotherapy regimens can be categorised as either passive or
active. In passive immunotherapy regimens the patient
passively receives immune components such as cytokines,
antibodies, cytotoxic T-cells, or lymphocyte activated killer
10 (LAK) cells. In contrast, active specific immunotherapy
protocols encompass actively inducing tumour immunity by
vaccination with the tumour cell or its antigenic components.
This latter form of treatment is preferred because the
immunity is prolonged.

15 Passive and active cancer vaccines have focussed on inducing
either humoral or cellular immune responses. For active
vaccines it is well established that induction of CD4 positive
T helper cells is necessary in order to secondarily induce
either antibodies or cytotoxic CD8 positive T cells.

20 *Passive vaccination with antibodies*

Since the discovery of the monoclonal antibody technology in
the mid-seventies, a large number of therapeutic monoclonal
antibodies directed against tumour specific or tumour
associated antigens has been developed. Monoclonal antibody
25 therapy, however, gives rise to several serious problems:

—   Injection of these foreign substances induces an immune
     response in the patient towards the injected antibodies,
     which may lead to less efficient treatment as well as to
     serious allergic side-effects in the patients.

–   Monoclonal antibodies usually must be administered in large amounts. This is a problem, since the production costs of monoclonal antibodies are huge.

5 –   Monoclonal antibodies must be administered via the parenteral route and due to the relatively large amounts needed, the patients frequently must be hospitalised during the treatment.

–   Injections of monoclonal antibodies must be repeated at rather short intervals (weeks) in order to maintain
10   therapeutic effect.

–   Monoclonal antibodies are usually not able to activate secondary effector systems of the immune system such as complement, NK-cells or macrophage killing of tumour cells.

15 The latter disadvantage is of particular importance in cancer therapy and may be an important reason why monoclonal antibody therapy of cancer in several cases has not been particularly successful. The so-called humanised monoclonal antibodies now used by many companies are less immunogenic, but unfortunately
20 they are even less capable of activating the secondary immune effector systems. Furthermore, examples of secondary out-growth of tumours lacking the original tumour antigen have been observed, since these antibodies do not induce "innocent bystander" effects on tumour cells not carrying the tumour
25 antigen.

The poor effector capability of the monoclonal antibodies has led to the development of monoclonal antibodies chemically conjugated to different toxins and radioisotopes. Pharmacia Upjohn AB has e.g. developed a conjugate between a monoclonal
30 tumour specific antibody and the *Staphylococcus aureus* toxin A

with the purpose of activating T cells in the tumour. Medarex Inc. has developed bispecific monoclonal antibodies containing a tumour specific Fab fragment as well as an Fc-receptor specific antibody fragment with the purpose of activating

5 macrophage killing of tumour cells. Both constructs are more effective than the monoclonal antibody alone, but they are also more expensive and immunogenic. Antibodies conjugated to radioisotopes are also expensive as well as immunogenic and other general toxic side-effects are observed.

10 The appearance of the monoclonal antibody technology was a major step forward which enabled the production of well-defined, high-affinity binding molecules. However, being monoclonal these antibodies only react with a single type of epitope on a tumour antigen. This is the major reason why they

15 usually are not able to activate the complement system or binding to the Fc-receptors of NK-cells and macrophages. These very powerful effector systems usually require the co-localisation of multiple Fc antibody fragments protruding from the antigen.

20 Other researchers have therefore attempted to use two monoclonal antibodies in combination and this has led to an improved effect. It therefore seems very reasonable instead to attack tumour cells with highly specific polyclonal antibodies directed against a tumour specific, or against (over-

25 expressed) tumour associated antigens or growth factor receptors. Such antibodies would be fully capable of activating the secondary effector systems mentioned above. Furthermore, it is likely that the local inflammatory reaction induced by these effector systems could lead to secondary

30 effects on "innocent bystander" cells not expressing the tumour antigen in question as well as to activation of tumour specific TIL´s (tumour infiltrating lymphocytes) in the tumour

tissue. Such effects have been observed by Medarex Inc. using their bi-specific monoclonal antibody conjugates.

Since the discovery of the monoclonal antibody technology the potential use of polyclonal antibodies for cancer therapy has
5 not been explored very much (except for the antigens described below). One major reason is that well-defined tumour specific or tumour associated surface antigens only have been characterised within the recent years, but - more importantly - many of these have turned out to be self-antigens and
10 therefore non-immunogenic. Accordingly, xenogenic polyclonal antibodies would necessarily have been used to study the effects. However, such antibodies induce a vigorous immune response towards the injected foreign polyclonal antibodies which rapidly eliminate the therapeutic effects.

15 *Active vaccination to induce antibodies*

Recent attempts to induce therapeutic polyclonal autoantibodies in cancer patients by active vaccination have been successful. Vaccines against membrane bound carbohydrate self-antigens (such as the O-linked aberrantly expressed Tn
20 and sTn-antigens and the ganglioside liposaccharides GM2 and GD3) have been developed. These small carbohydrate structures are, however, very poor antigens so conjugates of these molecules with carrier molecules such as keyhole limpet haemocyanin (KLH) or sheep mucins (containing Tn- and sTn)
25 must be used. In melanoma patients the induction of anti-GM2 antibodies were associated with a prolonged disease-free interval and overall survival after a minimum follow-up of fifty-one months. Also randomised phase II studies have been conducted on breast cancer patients using a conjugate of sTn
30 and KLH in the DETOX-B adjuvant (BIOMIRA Inc.) showing that sTn immune patients had a significantly longer median survival compared to controls. Another example of the active induction

of polyclonal antibodies in cancer is the use of idiotype specific vaccination against B-cell lymphomas, which - although it has been promising - is limited to this cancer type only.

5 Finally, the US company Aphton Inc. has developed active conjugate vaccines against gonadotropin releasing hormone (GnRH) and gastrin. It has been demonstrated, that this vaccine is capable of controlling the biological activity of these hormones, which also can function as autocrine growth

10 factors for certain tumour cells. Successful phase II clinical trials have been conducted on gastrointestinal cancer patients and phase III clinical trials are underway.

Cytotoxic T-cells

It has been clearly demonstrated by several groups that tumour

15 specific cytotoxic T cells (CTL´s) are present in many tumours. These CTL's are termed tumour infiltrating lymphocytes (TIL's). However, these cells are somehow rendered non-responsive or anergic by several different possible mechanisms including secretion of immunosuppressive cytokines

20 by the tumour cells, lack of co-stimulatory signals, down regulation of MHC class I molecules etc.

There has been many attempts to isolate the tumour specific HLA class I bound peptides recognised by TILs, and in some cases it has also been successful (e.g. peptides from the

25 melanoma associated antigens). Such peptides have been used to induce a tumour specific immune response in the host, but the practical use of tumour specific peptides in vaccines is restricted to a limited segment of the population due to the narrow HLA class I binding specificity of the peptides.

30 Furthermore, it is usually relatively difficult to evoke a CTL response *in vivo* using synthetic peptides due to the low

biological half-life of these substances as well as the difficulties with exogenous priming of MHC class I molecules.

Many other approaches have been attempted in order to evoke a tumour specific CTL response including the use of cytokines
5 (e.g. IL-2, IFN-γ, IL-6, IL-4, IL-10 or GM-CSF) or co-stimulatory molecules (B7) either in soluble form or expressed by the transfected tumour cell. Furthermore, immunisations with allogenic or autologous whole cells, or of tumour antigens prepared in specialised adjuvants designed to present
10 the antigen via the MHC class I antigen presentation route, or tumour antigens expressed in e.g. vaccinia vectors etc. have been used with varying success. Still the general belief among tumour immunologists is therefore that one of the best ways to eliminate tumours would be to induce a strong specific anti-
15 tumour CTL response.

Apart from the fact that these treatments usually are very expensive and difficult to reproduce, it has also turned out to be difficult to obtain a good immune response towards the tumour since many of the tumour associated antigens are true
20 self-proteins to which most T cells appear to be tolerant. Therefore, it seems necessary to induce a controlled cellular autoimmune condition in the patient.

OBJECT OF THE INVENTION

It is an object of the present invention to provide improved
25 methods and agents for inducing immune responses in host organisms against undesirable antigens, e.g. tumour antigens. It is a further object to provide a method for preparing polypeptide analogues of such undesirable antigens, analogues which are capable of inducing an effective immune response
30 against the undesired antigen.

SUMMARY OF THE INVENTION

Presentation of antigens has dogmatically been thought of as two discrete pathways, a class II exogenous and a class I endogenous pathway.

5   Briefly, a foreign protein from outside the cell or from the cell membrane is taken up by the APC as an endosome which fuses with an intracellular compartment which contains proteolytic enzymes and MHC class II molecules. Some of the produced peptides bind to class II, which then are
10 translocated to the cell membrane.

The class I endogenous pathway is characterised by the predominant presentation of cytosolic proteins. This is believed to occur by proteasome mediated cleavage followed by transportation of the peptides into the endoplasmic reticulum
15 (ER) via TAP molecules located in the membrane of the ER. In ER the peptides bind to class I followed by transportation to the plasma membrane.

However, these 2 pathways are not fully distinct. For example it is known that dendritic cells and to some extend
20 macrophages are capable of endocytosing (pinocytosing) extracellular proteins and subsequently present them in the context of MHC class I. It has also previously been demonstrated that using specialised administration routes, e.g. by coupling to iron oxide beads, exogenous antigens are
25 capable of entering the Class I pathway (Rock, 1996). This mechanism seems central, because of the importance of a concomitant expression of both class I and class II on the same APC to elicit a three cell type cluster. This three cell type cluster of interaction has been proposed by Mitchison
30 (1987) and later by other authors. They showed the importance

of concomitant presentation of class I and class II epitopes
on the same APC.

It has previously been demonstrated that insertion of a
foreign MHC class II restricted T helper cell epitope into a
5 self-antigen results in the provision of an antigen capable of
inducing strong cross-reactive antibody responses directed
against the non-modified self-antigen (cf. applicant's WO
95/05849). It was shown that the autoantibody induction is
caused by specific T cell help induced by the inserted foreign
10 epitope.

However, we have come to the conclusion that modified self-
antigens - with the aid of appropriate adjuvants - ought to be
capable of also inducing strong CTL responses against MHC
class I restricted self-epitopes and hence the technology
15 described in WO 95/05849 can be adapted to also provide
vaccination against intracellular and other cell-associated
antigens which have epitopes presented in the context of MHC
Class I.

The autovaccine technology described in WO 95/05849 has the
20 effect that specific T cell help is provided to self-reactive
B cells when a modified self-antigen is administered for
uptake into the MHC class II antigen processing pathway (cf.
Fig. 1, and Dalum I et al., 1996, J. Immunol. 157: 4796-4804).
It was shown that potentially self-reactive B-lymphocytes
25 recognizing self-proteins are physiologically present in
normal individuals. However, in order for these B-lymphocytes
to be induced to actually produce antibodies reactive with the
relevant self-proteins, assistance is needed from cytokine
producing T-helper lymphocytes (T_H-cells or T_H-lymphocytes).
30 Normally this help is not provided because T-lymphocytes in
general do not recognize T-cell epitopes derived from self-
proteins when presented by antigen presenting cells (APCs).

However, by providing an element of "foreignness" in a self-protein (*i.e.* by introducing an immunologically significant modification), T-cells recognizing the foreign element are activated upon recognizing the foreign epitope on an APC (such
5 as, initially, a mononuclear cell). Polyclonal B-lymphocytes (which present T-cell epitopes) capable of recognising self-epitopes on the modified self-protein also internalise the antigen and subsequently presents the foreign T-cell epitope(s) thereof, and the activated T-lymphocytes
10 subsequently provide cytokine help to these self-reactive polyclonal B-lymphocytes. Since the antibodies produced by these polyclonal B-lymphocytes are reactive with different epitopes on the modified polypeptide, including those which are also present in the native polypeptide, an antibody cross-
15 reactive with the non-modified self-protein is induced. In conclusion, the T-lymphocytes can be led to act as if the population of polyclonal B-lymphocytes have recognised an entirely foreign antigen, whereas in fact only the inserted epitope(s) is/are foreign to the host. In this way, antibodies
20 capable of cross-reacting with non-modified self-antigens are induced.

As mentioned above, CTL´s also require specific T cell help, although the mechanism for this is still not clear.

We have based the present invention on our novel theory that
25 the self-proteins containing foreign MHC class II epitopes, following exogenous uptake, can gain access into the MHC class I antigen processing pathway of e.g. macrophages and dendritic cells. In this way a strong CTL response against subdominant epitopes in the self-protein could be induced. Alternatively,
30 genes encoding modified tumour antigens could be administrated as nucleic acid vaccines eventually also leading to MHC class II as well as MHC class I mediated immune responses.

Tumour cells are very poor antigen presenting cells due to insufficient MHC class I expression, lack of co-stimulatory molecules or secretion of immunosuppressive cytokines etc. Using the autovaccine constructs and vaccination protocol

5 mentioned above the modified tumour antigen could be presented by MHC class I as well as by MHC class II molecules on professional antigen presenting cells. Co-presentation of subdominant self-epitopes on MHC class I and immunodominant foreign epitopes on MHC class II molecules would mediate a

10 direct cytokine help from activated MHC class II restricted T-helper cells to MHC class I restricted CTL's (Fig. 2). This will in our opinion lead to a specific break of the T cell autotolerance towards the tumour antigen and this is exactly what is desired in cancer immunotherapy.

15 Initial CTL experiments where mice have been immunised with dendritic cells pulsed with both a class I and a class II epitope show an enhanced CTL induction when they have been immunised as well as restimulated *in vitro* with both a class I and a class II peptide compared to an immunisation and

20 restimulation with just a class I epitope. This situation is comparable with immunisation with the autovaccine, where a foreign class II epitope is inserted in a self protein. Uptake and processing of these molecules by professional antigen precenting cells such as dendritic cells, leads to

25 presentation of the foreign class II epitope together with some self class I epitopes. It is known that it is possible to elicit autoreactive CTL's, but the presence of a foreign class II helper epitope very likely should enhance this CTL induction.

30 In conclusion, a vaccine constructed using the technology outlined above will induce a humoral autoantibody response with secondary activation of complement and antibody dependent cellular cytotoxicity (ADCC) activity. It is also expected

that it will induce a cytotoxic T cell response directed
against e.g. a tumour specific membrane antigen.

Hence, in the broadest and most general scope, the present
invention relates to a method for inducing an immune response
5   against a polypeptide antigen in an animal, including a human
being, said polypeptide antigen being weakly immunogenic or
non-immunogenic in the animal, the method comprising effecting
simultaneous presentation by antigen presenting cells (APCs)
from the animal's immune system of an immunogenically
10   effective amount of

1)   at least one CTL epitope derived from the polypeptide
     antigen and/or at least one B-cell epitope derived from
     the cell-associated polypeptide antigen, and

2)   at least one first T helper cell epitope (T_H epitope) which
15   is foreign to the animal.

In a more specific variant of the inventive method, the
invention relates to a method for down-regulating a cell-
associated polypeptide antigen in an animal, including a human
being, said polypeptide antigen being weakly immunogenic or
20   non-immunogenic in the animal, by inducing a specific
cytotoxic T-lymphocyte (CTL) response against cells carrying
the cell-associated polypeptide antigen on their surface or
harbouring the cell-associated polypeptide antigen in their
intracellular compartment, the method comprising effecting, in
25   the animal, simultaneous presentation by a suitable antigen
presenting cell (APC) of

1)   at least one CTL epitope derived from the cell-associated
     polypeptide antigen, and

2)   at least one first T-helper lymphocyte (T_H) epitope which
30   is foreign to the animal.

Also, the novel strategy for preparing an immunogenic agent is part of the invention. This novel strategy encompasses the selection and production of analogues of weak cell-associated antigens, where the preservation of a substantial fraction of

5 known and predicted CTL epitopes is aimed at while at the same time introducing at least one foreign T_H epitope.

Furthermore, the invention relates to certain specific immunogenic constructs based on known tumour-associated antigens as well as to compositions containing these

10 constructs.

Finally, the invention relates to nucleic acid fragments, vectors, transformed cells and other tools useful in molecular biological methods for the production of the analogues of the tumour-associated antigens.

15 LEGENDS TO THE FIGURE

Fig. 1: The traditional AutoVac concept. A: Tolerodominant self-epitopes presented on MHC class II are ignored due to depletion in the T cell repertoire. B: Inserted foreign immunodominant T cell epitopes presented on MHC class II

20 activate T helper cells. C: B cells specific for native parts of the self-protein presenting foreign immunodominant T cell epitopes on MHC class II are activated by the cytokine help provided by the T helper cell.

Fig. 2: The AutoVac concept for inducing a CTL response. A:

25 Tolerodominant self-epitopes presented on MHC class I are ignored due to depletion in the T cell repertoire. B: Inserted foreign immunodominant T cell epitopes presented on MHC class II activate T helper cells. C: CTL's recognising subdominant self-epitopes presented on MHC class I are activated by the

cytokine help provided by the adjacent activated T helper cell.

Fig. 3: A schematic representation of the Her-2 polypeptide with indications of epitopic regions and N-glycosylation
5   sites. The 4 extracellular domains, the transmembrane (TM) domain and the 2 intracellular domains are represented with indications of sites with varying degrees of homology and sites containing putative/determined CTL epitopes.

Fig. 4: A schematic representation of the human PSM
10 polypeptide with indications of insertion regions for the P2 and P30 epitopes.

Fig. 5: The FGF genes and proteins. A: Exon-intron structure of the human and mouse FGF8 genes. Below is illustrated the eight different splice forms (from Gemel 1996). B: Amino acid
15 sequence of the different FGF8 isoforms. The polypeptide stretches unique to FGF8b, FGF8f, and FGF8e are indicated by bold and italic or underlined typefaces. FGF8a is the shortest variant containing none of these highlighted sequences. The signal peptide is expected to be cleaved C-terminally to
20 Ala22. The two cysteine residues found in mature FGF8(all isoforms) are indicated by thick underlining. The two potential N-glycosylation sites of FGF8b are indicated by wavy underlining. Numbering is according to FGF8b.

Fig. 6: Illustrations of the four different variants of FGF8b
25 designed for autovaccination. Upper panel: Theoretical models of the insertion-points of the epitopes using the FGF2 crystal structure as template. Lower panel: Amino acid sequences of the wild type FGF8b (WT) and the four variants F30N, F2I, F30I, and F2C. The signal peptide is marked with single
30 underlining. The inserted peptides are marked with double underlining. The N-terminal sequence (MetAla) of all variants

is due to generation of a Kozak-sequence (Kozak 1991) for better translation in eucaryotic systems.

DETAILED DISCLOSURE OF THE INVENTION

Definitions

5 In the following a number of terms used in the present specification and claims will be defined and explained in detail in order to clarify the metes and bounds of the invention.

A "cell-associated polypeptide antigen" is in the present
10 specification and claims intended to denote a polypeptide which is confined to a cell which is somehow related to a pathological process. Furthermore, the cell presents CTL epitopes of the polypeptide antigen bound to MHC Class I molecules on its surface. Cell-associated polypeptide antigens
15 can therefore be truly intracellular antigens (and thereby unreachable for a humoral immune response) or antigens bound to the surface of the cells. The cell-associated antigen can be the product of the cell's own gene expression, of a intracellular parasite, of a virus, or of another cell. In the
20 latter case the polypeptide antigen is subsequently associated with the cell which is involved in the pathological process.

The terms "T-lymphocyte" and "T-cell" will be used interchangeably for lymphocytes of thymic origin which are responsible for various cell mediated immune responses as well
25 as for effector functions such as helper activity in the humoral immune response. Likewise, the terms "B-lymphocyte" and "B-cell" will be used interchangeably for antibody-producing lymphocytes.

An "antigen presenting cell" (APC) is a cell which presents
epitopes to T-cells. Typical antigen-presenting cells are
macrophages, dendritic cells and other phagocytizing and
pinocytizing cells. It should be noted that B-cells also
5   functions as APCs by presenting T_H epitopes bound to MCH class
II molecules to T_H cells but when generally using the term APC
in the present specification and claims it is intended to
refer to the above-mentioned phagocytizing and pinocytizing
cells.

10 "Helper T-lymphocytes" or "T_H cells" denotes CD4 positive T-
cells which provide help to B-cells and cytotoxic T-cells via
the recognition of T_H epitopes bound to MHC Class II molecules
on antigen presenting cells.

The term "cytotoxic T-lymphocyte" (CTL) will be used for CD8
15 positive T-cells which require the assistance of T_H cells in
order to become activated.

A "specific" immune response is in the present context
intended to denote a polyclonal immune response directed
predominantly against a molecule or a group of quasi-identical
20 molecules or, alternatively, against cells which present CTL
epitopes of the molecule or the group of quasi-identical
molecules.

A "weak or non-immunogenic polypeptide antigen" is herein
intended to denote polypeptides having the amino acid sequence
25 of the weak cell-associated protein antigens derived from the
animal in question (e.g. a human), but also polypeptides
having the amino acid sequence identical to analogues of such
proteins isolated from other species are embraced by the term.
Also forms of the polypeptides having differing glycosylation
30 patterns because of their production in heterologous systems
(e.g. yeasts or other non-mammalian eukaryotic expression

systems or even prokaryotic systems) are included within the boundaries of the term. It should, however, be noted that when using the term, it is intended that the polypeptide in question is normally non-immunogenic or only weakly
5` immunogenic in its natural localisation in the animal to be treated.

The term "polypeptide" is in the present context intended to mean both short peptides of from 2 to 10 amino acid residues, oligopeptides of from 11 to 100 amino acid residues, and
10 polypeptides of more than 100 amino acid residues. Furthermore, the term is also intended to include proteins, *i.e.* functional biomolecules comprising at least one polypeptide; when comprising at least two polypeptides, these may form complexes, be covalently linked, or may be non-
15 covalently linked. The polypeptide(s) in a protein can be glycosylated and/or lipidated and/or comprise prosthetic groups.

The term "subsequence" means any consecutive stretch of at least 3 amino acids or, when relevant, of at least 3
20 nucleotides, derived directly from a naturally occurring amino acid sequence or nucleic acid sequence, respectively.

The term "animal" is in the present context in general intended to denote an animal species (preferably mammalian), such as *Homo sapiens*, *Canis domesticus*, etc. and not just one
25 single animal. However, the term also denotes a population of such an animal species, since it is important that the individuals immunized according to the method of the invention all harbour substantially the same weak, cell-associated polypeptide antigen allowing for immunization of the animals
30 with the same immunogen(s). If, for instance, genetic variants of polypeptides exist in different human populations it may be necessary to use different immunogens in these different

populations in order to be able to break the autotolerance towards the weak, cell-associated polypeptide antigen in each population.

By the term "down-regulation a cell-associated polypeptide

5 antigen" is herein meant reduction in the living organism of the amount and/or activity of the antigen in question. The down-regulation can be obtained by means of several mechanisms: Of these, simple interference with the active site in the antigen by antibody binding is the most simple.

10 However, it is also within the scope of the present invention that the antibody binding results in removal of the polypeptide by scavenger cells (such as macrophages and other phagocytizing cells), and even more important, that cells carrying or harbouring the antigen are killed by CTLs in the

15 animal.

The expression "effecting simultaneous presentation by a suitable APC" is intended to denote that the animal's immune system is subjected to an immunogenic challenge in a controlled manner which results in the simultaneous

20 presentation by APCs of the epitopes in question. As will appear from the disclosure below, such challenge of the immune system can be effected in a number of ways of which the most important are vaccination with polypeptide containing "pharmaccines" (i.e. a vaccine which is administered to treat

25 or ameliorate ongoing disease) or nucleic acid "pharmaccine" vaccination. The important result to achieve is that immune competent cells in the animal are confronted with APCs displaying the relevant epitopes in an immunologically effective manner.

30 The term "immunogenically effective amount" has its usual meaning in the art, i.e. an amount of an immunogen which is capable of inducing an immune response which significantly

engages pathogenic agents which share immunological features
with the immunogen.

When using the expression that the weak cell-associated
polypeptide antigens have been subjected to a "modification"
5 is herein meant a chemical modification of the polypeptide
which constitutes the backbone of the polypeptide in question.
Such a modification can e.g. be derivatization (e.g.
alkylation) of certain amino acid residues in the amino acid
sequence, but as will be appreciated from the disclosure
10 below, the preferred modifications comprise changes of the
primary structure of the amino acid sequence.

When discussing "tolerance" and "autotolerance" is understood
that since the polypeptides which are the targets of the
present inventive method are self-proteins in the population
15 to be vaccinated or proteins which do not result in induction
of an effective immune response, normal individuals in the
population do not mount an immune response against the
polypeptide. It cannot be excluded, though, that occasional
individuals in an animal population might be able to produce
20 antibodies against the native polypeptide antigen, e.g. as
part of a autoimmune disorder. At any rate, an animal will
normally only be autotolerant towards its own polypeptide
antigen, but it cannot be excluded that analogues derived from
other animal species or from a population having a different
25 phenotype would also be tolerated by said animal.

A "foreign T-cell epitope" is a peptide which is able to bind
to an MHC molecule and stimulates T-cells in an animal
species. Preferred foreign epitopes are "promiscuous"
epitopes, i.e. epitopes which binds to a substantial fraction
30 of MHC class II molecules in an animal species or population.
Only a very limited number of such promiscuous T-cell epitopes
are known, and they will be discussed in detail below. It

should be noted that in order for the immunogens which are
used according to the present invention to be effective in as
large a fraction of an animal population as possible, it may
be necessary to 1) insert several foreign T-cell epitopes in
5 the same analogue or 2) prepare several analogues wherein each
analogue has a different promiscuous epitope inserted. It
should be noted that the concept of foreign T-cell epitopes
also encompasses use of cryptic T-cell epitopes, *i.e.* epitopes
which are derived from a self-protein and which only exerts
10 immunogenic behaviour when existing in isolated form without
being part of the self-protein in question.

A "CTL" epitope is a peptide which is able to bind to an MHC
class I molecule.

A "functional part" of a (bio)molecule is in the present
15 context intended to mean the part of the molecule which is
responsible for at least one of the biochemical or
physiological effects exerted by the molecule. It is well-
known in the art that many enzymes and other effector
molecules have an active site which is responsible for the
20 effects exerted by the molecule in question. Other parts of
the molecule may serve a stabilizing or solubility enhancing
purpose and can therefore be left out if these purposes are
not of relevance in the context of a certain embodiment of the
present invention. For instance it is possible to use certain
25 cytokines as a modifying moiety in the analogue (cf. the
detailed discussion below), and in such a case, the issue of
stability may be irrelevant since the coupling to the analogue
provides the stability necessary.

Preferred embodiments

30 In order to induce a CTL response against a cell which
presents epitopes derived from the polypeptide antigen on its

surface, it is normally necessary that at least one CTL epitope, when presented, is associated with an MHC Class I molecule on the surface of the APC. Furthermore it is preferred that the at least one first foreign T_H epitope, when

5 presented, is associated with an MHC Class II molecule on the surface of the APC.

Preferred APCs presenting the epitopes are dendritic cells and macrophages, but any pino- or phagocytizing APC which is capable of simultaneously presenting 1) CTL epitopes bound to

10 MHC class I molecules and 2) T_H epitopes bound to MHC class II molecules, is a preferred APC according to the invention.

According to the invention, the cell-associated antigen is preferably selected from a tumour-associated antigens and other self-proteins which are related to pathological

15 processes but also viral antigens and antigens derived from an intracellular parasite or bacterium will. It is well-known in the art that such pathogen-associated antigens are often relatively poor immunogens (e.g. antigens from mycobacteria such as *Mycobacterium tuberculosis* and *Mycobacterium leprae*,

20 but also from protozoans such as *Plasmodium spp.*). It is believed that the method of the invention, apart from rendering possible the production of antibody and CTL responses against true self-protein antigens, is capable of enhancing the often insufficient immune response mounted by

25 the organism against such intracellular antigens.

Normally, it will be advantageous to confront the immune system with a large fraction of the amino acid sequence of the polypeptide antigen which is the vaccine target. Hence, in a preferred embodiment, presentation by the APC of the CTL

30 epitope and the first foreign T_H epitope is effected by presenting the animal's immune system with at least one first analogue of the cell-associated polypeptide antigen, said

first analogue comprising a variation of the amino acid
sequence of the cell-associated polypeptide antigen, said
variation containing at least the CTL epitope and the first
foreign T_H epitope. This is in contrast to e.g. a DNA
5 vaccination strategy where the CTL and T_H epitopes are
expressed by the same cell but as parts of separate
polypeptides; such a DNA vaccination strategy is also an
embodiment of the invention, but it is believed that having
the two epitopes as part of the same polypeptide will normally
10 enhance the immune response and, at any rate, only one
expression product will be necessary.

In order to maximize the chances of mounting an effective
immune response, it is preferred that the above-mentioned
first analogue contains a substantial fraction of known and
15 predicted CTL epitopes of the cell-associated polypeptide
antigen, *i.e.* a fraction of the known and predicted CTL
epitopes which binds a sufficient fractions of MHC Class I
molecules in a population. For instance, it is preferred that
the substantial fraction of known and predicted CTL epitopes
20 in the amino acid sequence of the analogue are recognized by
at least 50% of the MHC-I haplotypes recognizing all known and
predicted CTL epitopes in the cell-associated polypeptide
antigen, but higher percentages are preferred, such as at
least 60, at least 70, at least 80, and at least 90%.
25 Especially preferred is the use of analogues which preserves
substantially all known CTL epitopes of the cell-associated
polypeptide antigen are present in the analogue, *i.e.* close to
100% of the known CTL epitopes. Accordingly, it is also
especially preferred that substantially all predicted CTL
30 epitopes of the cell-associated polypeptide antigen are
present in the at least first analogue.

Methods for predicting the presence of CTL epitopes are well-
known in the art, cf. the below discussion of specific

algorithms used for the identification of putative MHC I binding peptide fragments.

As will be apparent from the present specification and claims it is expected that the inventive method described herein will
5 render possible the effective induction of CTL responses against cell-associated polypeptide antigens.

In cases where the cell-associated polypeptide antigen is truly intracellular, the induction of a CTL response against cells harbouring the antigen is the only way to achieve its
10 down-regulation by specific immunological means. However, in the case of membrane-associated antigens, it is advantageous to induce a antibody response against the weak, cell-associated polypeptide antigen.

This can be achieved in a number of ways known to the person
15 skilled in the art. For instance, the at least one first analogue may, apart from the at least one CTL epitope and the at least one foreign T_H epitope, comprise a part consisting of a modification of the structure of the cell-associated polypeptide antigen, said modification having as a result that
20 immunization of the animal with the first analogue induces production of antibodies in the animal against the cell-associated polypeptide antigen. Alternatively, the method of the invention can involve effecting presentation to the animal's immune system of an immunogenically effective amount
25 of at least one *second* analogue of the cell-associated polypeptide antigen which contains such a modification. A convenient way to achieve that the modification has the desired antibody-inducing effect is to include at least one second foreign T_H epitope in the second analogue, *i.e.* a
30 strategy like the one used for the first analogue.

In the cases where it is desired to also mount an effective humoral immune response, it is advantageous that the first and/or second analogue(s) comprise(s) a substantial fraction of the cell-associated polypeptide antigen's B-cell epitopes.

5 The above-discussed variations and modifications of the weak, cell-associated polypeptide antigen can take different forms. It is preferred that the variation and/or modification involves amino acid substitution and/or deletion and/or insertion and/or addition. These fundamental operations
10 relating to the manipulation of an amino acid sequence are intended to cover both single-amino acid changes as well as operations involving stretches of amino acids (*i.a.* shuffling of amino acid stretches within the polypeptide antigen; this is especially interesting when the antigen is a true
15 intracellular antigen, since only considerations concerning preservation of CTL epitopes are relevant). It will be understood, that the introduction of e.g. one single amino acid insertion or deletion may give rise to the emergence of a foreign T_H epitope in the sequence of the analogue, *i.e.* the
20 emergence of an MHC Class II molecule binding sequence. However, in most situations it is preferable (and even necessary) to introduce a known foreign T_H epitope, and such an operation will require acid substitution and/or insertion (or sometimes addition in the form of either conjugation to a
25 carrier protein or provision of a fusion polypeptide by means of molecular biology methods. It is preferred that the number of amino acid insertions, deletions, substitutions or additions is at least 2, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 25 insertions,
30 substitutions, additions or deletions. It is furthermore preferred that the number of amino acid substitutions is not in excess of 150, such as at most 100, at most 90, at most 80, and at most 70. It is especially preferred that the number of substitutions, insertions, deletions, or additions does not

exceed 60, and in particular the number should not exceed 50 or even 40. Most preferred is a number of not more than 30.

Preferred embodiments of the invention includes modification by introducing at least one foreign immunodominant T_H epitope.

5   It will be understood that the question of immune dominance of a T-cell epitope depends on the animal species in question. As used herein, the term "immunodominance" simply refers to epitopes which in the vaccinated individual gives rise to a significant immune response, but it is a well-known fact that

10 a T-cell epitope which is immunodominant in one individual is not necessarily immunodominant in another individual of the same species, even though it may be capable of binding MHC-II molecules in the latter individual.

Another important point is the issue of MHC restriction of T-

15 cell epitopes. In general, naturally occurring T-cell epitopes are MHC restricted, *i.e.* a certain peptides constituting a T-cell epitope will only bind effectively to a subset of MHC Class II molecules. This in turn has the effect that in most cases the use of one specific T-cell epitope will result in a

20 vaccine component which is only effective in a fraction of the population, and depending on the size of that fraction, it can be necessary to include more T-cell epitopes in the same molecule, or alternatively prepare a multi-component vaccine wherein the components are OPGL variants which are

25 distinguished from each other by the nature of the T-cell epitope introduced.

If the MHC restriction of the T-cells used is completely unknown (for instance in a situation where the vaccinated animal has a poorly defined MHC composition), the fraction of

30 the population covered by a specific vaccine composition can be determined by means of the following formula

$$f_{population} = 1 - \prod_{i=1}^{n} (1 - p_i) \tag{II}$$

-where p_i is the frequency in the population of responders to the ith foreign T-cell epitope present in the vaccine composition, and n is the total number of foreign T-cell epitopes in

5 the vaccine composition. Thus, a vaccine composition containing 3 foreign T-cell epitopes having response frequencies in the population of 0.8, 0.7, and 0.6, respectively, would give

$$1 - 0.2 \times 0.3 \times 0.4 = 0.976$$

10 -i.e. 97.6 percent of the population will statistically mount an MHC-II mediated response to the vaccine.

The above formula does not apply in situations where a more or less precise MHC restriction pattern of the peptides used is known. If, for instance a certain peptide only binds the human

15 MHC-II molecules encoded by HLA-DR alleles DR1, DR3, DR5, and DR7, then the use of this peptide together with another peptide which binds the remaining MHC-II molecules encoded by HLA-DR alleles will accomplish 100% coverage in the population in question. Likewise, if the second peptide only binds DR3

20 and DR5, the addition of this peptide will not increase the coverage at all. If one bases the calculation of population response purely on MHC restriction of T-cell epitopes in the vaccine, the fraction of the population covered by a specific vaccine composition can be determined by means of the

25 following formula:

$$f_{population} = 1 - \prod_{j=1}^{3} (1 - \varphi_j)^2 \tag{III}$$

-wherein φ_j is the sum of frequencies in the population of allelic haplotypes encoding MHC molecules which bind any one of the T-cell epitopes in the vaccine and which belong to the jth of the 3 known HLA loci (DP, DR and DQ); in practice, it is first determined which MHC molecules will recognize each T-cell epitope in the vaccine and thereafter these are listed by type (DP, DR and DQ) - then, the individual frequencies of the different listed allelic haplotypes are summed for each type, thereby yielding φ_1, φ_2, and φ_3.

It may occur that the value p_i in formula II exceeds the corresponding theoretical value π_i:

$$\pi_i = 1 - \prod_{j=1}^{3} (1 - v_j)^2 \qquad \text{(IV)}$$

-wherein v_j is the sum of frequencies in the population of allelic haplotype encoding MHC molecules which bind the ith T-cell epitope in the vaccine and which belong to the jth of the 3 known HLA loci (DP, DR and DQ). This means that in $1-\pi_i$ of the population is a frequency of responders of $f_{residual\_i} = (p_i - \pi_i)/(1-\pi_i)$. Therefore, formula III can be adjusted so as to yield formula V:

$$f_{population} = 1 - \prod_{j=1}^{3} (1 - \varphi_j)^2 + \left(1 - \prod_{i=1}^{n} (1 - f_{residual\_i})\right) \qquad \text{(V)}$$

-where the term $1-f_{residual-i}$ is set to zero if negative. It should be noted that formula V requires that all epitopes have been haplotype mapped against identical sets of haplotypes.

Therefore, when selecting T-cell epitopes to be introduced in the OPGL analogue, it is important to include all knowledge of the epitopes which is available: 1) The frequency of responders in the population to each epitope, 2) MHC

restriction data, and 3) frequency in the population of the relevant haplotypes.

There exist a number of naturally occurring "promiscuous" T-cell epitopes which are active in a large proportion of
5 individuals of an animal species or an animal population and these are preferably introduced in the vaccine thereby reducing the need for a very large number of different OPGL analogues in the same vaccine.

The promiscuous epitope can according to the invention be a
10 naturally occurring human T-cell epitope such as epitopes from tetanus toxoid (e.g. the P2 and P30 epitopes), diphtheria toxoid, Influenza virus hemagluttinin (HA), and P. falciparum CS antigen.

Over the years a number of other promiscuous T-cell epitopes
15 have been identified. Especially peptides capable of binding a large proportion of HLA-DR molecules encoded by the different HLA-DR alleles have been identified and these are all possible T-cell epitopes to be introduced in the OPGL analogues used according to the present invention. Cf. also the epitopes
20 discussed in the following references which are hereby all incorporated by reference herein: Southwood S et. al, 1998, J. Immunol. 160: 3363-3373; Sinigaglia F et al., 1988, Nature 336: 778-780; Chicz RM et al., 1993, J. Exp. Med 178: 27-47; Hammer J et al., 1993, Cell 74: 197-203; and Falk K et al.,
25 1994, Immunogenetics 39: 230-242. The latter reference also deals with HLA-DQ and -DP ligands. All epitopes listed in these 5 references are relevant as candidate natural epitopes to be used in the present invention, as are epitopes which share common motifs with these.

30 Alternatively, the epitope can be any artificial T-cell epitope which is capable of binding a large proportion of

haplotypes. In this context the pan DR epitope peptides ("PADRE") described in WO 95/07707 and in the corresponding paper Alexander J et al., 1994, Immunity 1: 751-761 (both disclosures are incorporated by reference herein) are

5   interesting candidates for epitopes to be used according to the present invention. It should be noted that the most effective PADRE peptides disclosed in these papers carry D-amino acids in the C- and N-termini in order to improve stability when administered. However, the present invention

10 primarily aims at incorporating the relevant epitopes as part of the modified OPGL which should then subsequently be broken down enzymatically inside the lysosomal compartment of APCs to allow subsequent presentation in the context of an MHC-II molecule and therefore it is not expedient to incorporate D-

15 amino acids in the epitopes used in the present invention.

One especially preferred PADRE peptide is the one having the amino acid sequence AKFVAAWTLKAAA or an immunologically effective subsequence thereof. This, and other epitopes having the same lack of MHC restriction are preferred T-cell epitopes

20 which should be present in the OPGL analogues used in the inventive method. Such super-promiscuous epitopes will allow for the most simple embodiments of the invention wherein only one single analogue is presented to the vaccinated animal's immune system.

25 The nature of the above-discussed variation/modification preferably comprises that
    –   at least one first moiety is included in the first and/or second analogue(s), said first moiety effecting targeting of the analogue to an antigen presenting cell (APC),
30   and/or
    –   at least one second moiety is included in the first and/or second analogue(s), said second moiety stimulating the immune system, and/or

- at least one third moiety is included in the first and/or second analogue(s), said third moiety optimizing presentation of the analogue to the immune system.

5 The functional and structural features relating these first, second and third moieties will be discussed in the following:

They can be present in the form of side groups attached covalently or non-covalently to suitable chemical groups in the amino acid sequence of the cell-associated polypeptide antigen or a subsequence thereof. This is to mean that
10 stretches of amino acid residues derived from the polypeptide antigen are derivatized without altering the primary amino acid sequence, or at least without introducing changes in the peptide bonds between the individual amino acids in the chain.

The moieties can also be in the form of fusion partners to the
15 amino acid sequence derived from the cell-associated polypeptide antigen. In this connection it should be mentioned that both possibilities include the option of conjugating the amino acid sequence to a carrier, cf. the discussion of these below. In other words, in the present context the term "fusion
20 protein is not merely restricted to a fusion construct prepared by means of expression of a DNA fragment encoding the construct but also to a conjugate between two proteins which are joined by means of a peptide bond in a subsequent chemical reaction.

25 As mentioned above, the analogue can also include the introduction of a first moiety which targets the analogue to an APC or a B-lymphocyte. For instance, the first moiety can be a specific binding partner for a B-lymphocyte specific surface antigen or for an APC specific surface antigen. Many
30 such specific surface antigens are known in the art. For instance, the moiety can be a carbohydrate for which there is

a receptor on the B-lymphocyte or the APC (e.g. mannan or
mannose). Alternatively, the second moiety can be a hapten.
Also an antibody fragment which specifically recognizes a
surface molecule on APCs or lymphocytes can be used as a first
5 moiety (the surface molecule can e.g. be an FCγ receptor of
macrophages and monocytes, such as FCγRI or, alternatively any
other specific surface marker such as CD40 or CTLA-4). It
should be noted that all these exemplary targeting molecules
can be used as part of an adjuvant, cf. below. CD40 ligand,
10 antibodies against CD40, or variants thereof which bind CD40
will target the analogue to dendritic cells. At the same time,
recent results have shown that the interaction with the CD40
molecule renders the T_H cells unessential for obtaining a CTL
response. Hence, it is contemplated that the general use of
15 CD40 binding molecules as the first moiety (or as adjuvants,
cf. below) will enhance the CTL response considerably; in
fact, the use of such CD40 binding molecules as adjuvants and
"first moieties" in the meaning of the present invention is
believed to be inventive in its own right.

20 As an alternative or supplement to targeting the analogue to a
certain cell type in order to achieve an enhanced immune
response, it is possible to increase the level of
responsiveness of the immune system by including the above-
mentioned second moiety which stimulates the immune system.
25 Typical examples of such second moieties are cytokines, and
heat-shock proteins, as well as effective parts thereof.

Suitable cytokines to be used according to the invention are
those which will normally also function as adjuvants in a
vaccine composition, e.g. interferon γ (IFN-γ), Flt3 ligand
30 (Flt3L), interleukin 1 (IL-1), interleukin 2 (IL-2),
interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 12
(IL-12), interleukin 13 (IL-13), interleukin 15 (IL-15), and
granulocyte-macrophage colony stimulating factor (GM-CSF);

alternatively, the functional part of the cytokine molecule may suffice as the second moiety. With respect to the use of such cytokines as adjuvant substances, cf. the discussion below.

5   Alternatively, the second moiety can be a toxin, such as listeriolycin (LLO), lipid A and heat-labile enterotoxin. Also, a number of mycobacterial derivatives such as MDP (muramyl dipeptide), CFA (complete Freund's adjuvant) and the trehalose diesters TDM and TDE are interesting possibilities.

10   According to the invention, suitable heat shock proteins used as the second moiety can be HSP70, HSP90, and HSC70.

Also the possibility of introducing a third moiety which enhances the presentation of the analogue to the immune system is an important embodiment of the invention. The art has shown
15   several examples of this principle. For instance, it is known that the palmitoyl lipidation anchor in the Borrelia burgdorferi protein OspA can be utilised so as to provide self-adjuvating polypeptides (cf. e.g. WO 96/40718). It seems that the lipidated proteins form up micelle-like structures
20   with a core consisting of the lipidation anchor parts of the polypeptides and the remaining parts of the molecule protruding therefrom, resulting in multiple presentations of the antigenic determinants. Hence, the use of this and related approaches using different lipidation anchors (e.g. a myristyl
25   anchor) are preferred embodiments of the invention, especially since the provision of such a lipidation anchor in a recombinantly produced protein is fairly straightforward and merely requires use of e.g. a naturally occurring signal sequence as a fusion partner for the analogue. Another
30   possibility is use of the C3d fragment of complement factor C3 or C3 itself (cf. Dempsey et al., 1996, Science 271, 348-350 and Lou & Kohler, 1998, Nature Biotechnology 16, 458-462).

It is important to note that when attempting to use the method of the invention against e.g. membrane bound polypeptide antigens which are exposed to the extracellular compartment, it is most preferred that the first and/or second analogue(s)
5   has/have substantially the overall tertiary structure of the cell-associated polypeptide antigen. In the present specification and claims this is intended to mean that the overall tertiary structure of the *part* of the polypeptide antigen which is extracellularly exposed is preserved, since,
10 as mentioned above, the tertiary structure of the obligate intracellular polypeptides do not engage the humeral immune system. In fact, as part of the vaccination strategy it is often desired to avoid exposure to the extracellular compartment of putative B-cell epitopes derived from
15 intracellular part of the polypeptide antigens; in this way, potentially adverse effects caused by cross-reactivity with other antigens can be minimized.

For the purposes of the present invention, it is however sufficient if the variation/modification (be it an insertion,
20 addition, deletion or substitution) gives rise to a foreign T-cell epitope and at the same time preserves a substantial number of the CTL epitopes in the polypeptide antigen (and sometimes also a substantial number of B-cell epitopes). The following formula describes the constructs generally
25 covered by the invention:

$$(MOD_1)_{s1}(PAG_{e1})_{n1}(MOD_2)_{s2}(PAG_{e2})_{n2}\ldots(MOD_x)_{sx}(PAG_{ex})_{nx} \qquad (I)$$

-where PAG_{e1}-PAG_{ex} are x CTL and/or B-Cell epitope containing subsequences of the relevant polypeptide antigen which independently are identical or non-identical and which may
30 contain or not contain foreign side groups, x is an integer $\geq$ 3, n1-nx are x integers $\geq$ 0 (at least one is $\geq$ 1), MOD_1-MOD_x are x modifications introduced between the preserved epitopes,

and s1-sx are x integers $\geq$ 0 (at least one is $\geq$ 1 if no side groups are introduced in the sequences). Thus, given the general functional restraints on the immunogenicity of the constructs, the invention allows for all kinds of permutations
5 of the original antigen sequence, and all kinds of modifications therein. Thus, included in the invention are analogues obtained by omission of parts of the polypeptide antigen sequence which e.g. exhibit adverse effects in vivo or omission of parts which are normally intracellular and thus
10 could give rise to undesired immunological reactions, cf. the detailed discussion below.

It is furthermore preferred that the variation and/or modification includes duplication, when applicable, of the at least one B-cell epitope, or of at least one CTL epitope of
15 the cell-associated polypeptide antigen. This strategy will give the result that multiple copies of preferred epitopic regions are presented to the immune system and thus maximizing the probability of an effective immune response. Hence, this embodiment of the invention utilises multiple presentations of
20 epitopes derived from the polypeptide antigen (i.e. formula I wherein at least one B-cell epitope is present in two positions).

This effect can be achieved in various ways, e.g. by simply preparing fusion polypeptides comprising the structure $(PAG)_m$,
25 where m is an integer $\geq$ 2 and then introduce the modifications discussed herein in at least one of the polypeptide antigen sequences. It is preferred that the modifications introduced includes at least one duplication of a B-lymphocyte epitope and/or the introduction of a hapten.

30 An alternative embodiment of the invention which also results in the preferred presentation of multiple (e.g. at least 2) copies of the important epitopic regions of OPGL to the immune

system is the covalent coupling of OPGL, subsequence or variants thereof to certain molecules. For instance, polymers can be used, e.g. carbohydrates such as dextran, cf. e.g. Lees A et al., 1994, Vaccine 12: 1160-1166; Lees A et al., 1990, J

5 Immunol. 145: 3594-3600, but also mannose and mannan are useful alternatives. Integral membrane proteins from e.g. *E. coli* and other bacteria are also useful conjugation partners. The traditional carrier molecules such as keyhole limpet haemocyanin (KLH), tetanus toxoid, diphtheria toxoid, and

10 bovine serum albumin (BSA) are also preferred and useful conjugation partners.

Maintenance of the sometimes advantageous substantial fraction of B-cell epitopes or even the overall tertiary structure of a protein which is subjected to modification as described herein

15 can be achieved in several ways. One is simply to prepare a polyclonal antiserum directed against the polypeptide antigen (e.g. an antiserum prepared in a rabbit) and thereafter use this antiserum as a test reagent (e.g. in a competitive ELISA) against the modified proteins which are produced. Modified

20 versions (analogues) which react to the same extent with the antiserum as does the polypeptide antigen must be regarded as having the same overall tertiary structure as the polypeptide antigen whereas analogues exhibiting a limited (but still significant and specific) reactivity with such an antiserum

25 are regarded as having maintained a substantial fraction of the original B-cell epitopes.

Alternatively, a selection of monoclonal antibodies reactive with distinct epitopes on the polypeptide antigen can be prepared and used as a test panel. This approach has the

30 advantage of allowing 1) an epitope mapping of the polypeptide antigen in question and 2) a mapping of the epitopes which are maintained in the analogues prepared.

Of course, a third approach would be to resolve the 3-dimensional structure of the polypeptide antigen or of a biologically active truncate thereof (cf. above) and compare this to the resolved three-dimensional structure of the

5 analogues prepared. Three-dimensional structure can be resolved by the aid of X-ray diffraction studies, circular dichroism studies, NMR-spectroscopy etc. Of these, circular dichroism has the advantage of merely requiring the polypeptide in pure form (whereas X-ray diffraction requires

10 the provision of crystallized polypeptide and NMR requires the provision of isotopic variants of the polypeptide) in order to provide useful information about the tertiary structure of a given molecule. However, ultimately X-ray diffraction and/or NMR are necessary to obtain conclusive data since circular

15 dichroism only provides indirect evidence of correct 3-dimensional structure via information of secondary structure elements.

In essence there are three feasible ways of obtaining the presentation of the relevant epitopes to the immune system:

20 Traditional sub-unit vaccination with polypeptide antigens, administration of a genetically modified live vaccine, and nucleic acid vaccination. These three possibilities will be discussed separately in the following:

Polypeptide vaccination

25 This entails administration to the animal in question of an immunogenically effective amount of the at least one first analogue, and, when relevant, administration of an immunologically effective amount of the at least one second analogue. Preferably, the at least one first and/or second

30 analogue(s) is/are formulated together with a pharmaceutically and immunologically acceptable carrier and/or vehicle and/or diluent and/or excipient and, optionally an adjuvant.

When effecting presentation of the analogue to an animal's immune system by means of administration thereof to the animal, the formulation of the polypeptide follows the principles generally acknowledged in the art.

5 Preparation of vaccines which contain peptide sequences as active ingredients is generally well understood in the art, as exemplified by US Patents 4,608,251; 4,601,903; 4,599,231; 4,599,230; 4,596,792; and 4,578,770, all incorporated herein by reference. Typically, such vaccines are prepared as
10 injectables either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified. The active immunogenic ingredient is often mixed with excipients which are pharmaceutically acceptable and
15 compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering
20 agents, or adjuvants which enhance the effectiveness of the vaccines; cf. the detailed discussion of adjuvants below.

The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously, intradermally, subdermally or intramuscularly. Additional formulations which
25 are suitable for other modes of administration include suppositories and, in some cases, oral, buccal, sublinqual, intraperitoneal, intravaginal, anal and intracranial formulations. For suppositories, traditional binders and carriers may include, for example, polyalkalene glycols or
30 triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of

mannitol, lactose, starch, magnesium stearate, sodium
saccharine, cellulose, magnesium carbonate, and the like.
These compositions take the form of solutions, suspensions,
tablets, pills, capsules, sustained release formulations or
5 powders and contain 10-95% of active ingredient, preferably
25-70%. For oral formulations, cholera toxin is an interesting
formulation partner (and also a possible conjugation partner).

The polypeptides may be formulated into the vaccine as neutral
or salt forms. Pharmaceutically acceptable salts include acid
10 addition salts (formed with the free amino groups of the
peptide) and which are formed with inorganic acids such as,
for example, hydrochloric or phosphoric acids, or such organic
acids as acetic, oxalic, tartaric, mandelic, and the like.
Salts formed with the free carboxyl groups may also be derived
15 from inorganic bases such as, for example, sodium, potassium,
ammonium, calcium, or ferric hydroxides, and such organic
bases as isopropylamine, trimethylamine, 2-ethylamino ethanol,
histidine, procaine, and the like.

The vaccines are administered in a manner compatible with the
20 dosage formulation, and in such amount as will be
therapeutically effective and immunogenic. The quantity to be
administered depends on the subject to be treated, including,
e.g., the capacity of the individual's immune system to mount
an immune response, and the degree of protection desired.
25 Suitable dosage ranges are of the order of several hundred
micrograms active ingredient per vaccination with a preferred
range from about 0.1 µg to 2000 µg (even though higher amounts
in the 1-10 mg range are contemplated), such as in the range
from about 0.5 µg to 1000 µg, preferably in the range from 1
30 µg to 500 µg and especially in the range from about 10 µg to
100 µg. Suitable regimens for initial administration and
booster shots are also variable but are typified by an initial

administration followed by subsequent inoculations or other
administrations.

The manner of application may be varied widely. Any of the
conventional methods for administration of a vaccine are
5 applicable. These include oral application on a solid
physiologically acceptable base or in a physiologically
acceptable dispersion, parenterally, by injection or the like.
The dosage of the vaccine will depend on the route of
administration and will vary according to the age of the
10 person to be vaccinated and the formulation of the antigen.

Some of the polypeptides of the vaccine are sufficiently
immunogenic in a vaccine, but for some of the others the
immune response will be enhanced if the vaccine further
comprises an adjuvant substance. It is especially preferred to
15 use an adjuvant which can be demonstrated to facilitate
breaking of the autotolerance to autoantigens.

Various methods of achieving adjuvant effect for the vaccine
are known. General principles and methods are detailed in "The
Theory and Practical Application of Adjuvants", 1995, Duncan
20 E.S. Stewart-Tull (ed.), John Wiley & Sons Ltd, ISBN 0-471-
95170-6, and also in "Vaccines: New Generationn Immunological
Adjuvants", 1995, Gregoriadis G et al. (eds.), Plenum Press,
New York, ISBN 0-306-45283-9, both of which are hereby
incorporated by reference herein.

25 Preferred adjuvants facilitate uptake by APCs, such as
dendritic cells, of the at least first and/or second
analogues. Non-limiting examples are selected from the group
consisting of an immune targeting adjuvant; an immune
modulating adjuvant such as a toxin, a cytokine, and a
30 mycobacterial derivative; an oil formulation; a polymer; a
micelle forming adjuvant; a saponin; an immunostimulating

complex matrix (ISCOM matrix); a particle; DDA; aluminium adjuvants; DNA adjuvants; γ-inulin; and an encapsulating adjuvant. In general it should be noted that the disclosures above which relate to compounds and agents useful as first,

5 second and third moieties in the analogues also refer *mutatis mutandis* to their use in the adjuvant of a vaccine of the invention.

The application of adjuvants include use of agents such as aluminum hydroxide or phosphate (alum), commonly used as 0.05

10 to 0.1 percent solution in buffered saline, admixture with synthetic polymers of sugars (e.g. Carbopol®) used as 0.25 percent solution, aggregation of the protein in the vaccine by heat treatment with temperatures ranging between 70° to 101°C for 30 second to 2 minute periods respectively and also

15 aggregation by means of cross-linking agents are possible. Aggregation by reactivation with pepsin treated antibodies (Fab fragments) to albumin, mixture with bacterial cells such as C. parvum or endotoxins or lipopolysaccharide components of gram-negative bacteria, emulsion in physiologically acceptable

20 oil vehicles such as mannide mono-oleate (Aracel A) or emulsion with 20 percent solution of a perfluorocarbon (Fluosol-DA) used as a block substitute may also be employed. Admixture with oils such as squalene and IFA is also preferred.

25 According to the invention DDA (dimethyldioctadecylammonium bromide) is an interesting candidate for an adjuvant as is DNA and γ-inulin, but also Freund's complete and incomplete adjuvants as well as quillaja saponins such as QuilA and QS21 are interesting as is RIBI. Further possibilities are

30 monophosphoryl lipid A (MPL), the above mentioned C3 and C3d, and muramyl dipeptide (MDP).

Liposome formulations are also known to confer adjuvant
effects, and therefore liposome adjuvants are preferred
according to the invention.

Also immunostimulating complex matrix type (ISCOM® matrix)
5 adjuvants are preferred choices according to the invention,
especially since it has been shown that this type of adjuvants
are capable of up-regulating MHC Class II expression by APCs.
An ISCOM® matrix consists of (optionally fractionated)
saponins (triterpenoids) from Quillaja saponaria, cholesterol,
10 and phospholipid. When admixed with the immunogenic protein,
the resulting particulate formulation is what is known as an
ISCOM particle where the saponin constitutes 60-70% w/w, the
cholesterol and phospholipid 10-15% w/w, and the protein 10-
15% w/w. Details relating to composition and use of
15 immunostimulating complexes can e.g. be found in the above-
mentioned text-books dealing with adjuvants, but also Morein B
et al., 1995, Clin. Immunother. 3: 461-475 as well as Barr IG
and Mitchell GF, 1996, Immunol. and Cell Biol. 74: 8-25 (both
incorporated by reference herein) provide useful instructions
20 for the preparation of complete immunostimulating complexes.
Another highly interesting (and thus, preferred) possibility
of achieving adjuvant effect is to employ the technique
described in Gosselin et al., 1992 (which is hereby
incorporated by reference herein). In brief, the presentation
25 of a relevant antigen such as an antigen of the present
invention can be enhanced by conjugating the antigen to
antibodies (or antigen binding antibody fragments) against the
Fcγ receptors on monocytes/macrophages. Especially conjugates
between antigen and anti-FcγRI have been demonstrated to
30 enhance immunogenicity for the purposes of vaccination.

Other possibilities involve the use of the targeting and
immune modulating substances (i.a. cytokines) mentioned above
as candidates for the first and second moieties in the

modified analogues. In this connection, also synthetic inducers of cytokines like poly I:C are possibilities.

Suitable mycobacterial derivatives are selected from the group consisting of muramyl dipeptide, complete Freund's adjuvant, 5 RIBI, and a diester of trehalose such as TDM and TDE.

Suitable immune targeting adjuvants are selected from the group consisting of CD40 ligand and CD40 antibodies or specifically binding fragments thereof (cf. the discussion above), mannose, a Fab fragment, and CTLA-4.

10 Suitable polymer adjuvants are selected from the group consisting of a carbohydrate such as dextran, PEG, starch, mannan, and mannose; a plastic polymer such as; and latex such as latex beads.

Recent findings that the co-administration of H2 agonists 15 enhances the in-tumour survival of Natural Killer Cells and CTLs. Hence, it is also contemplated to include H2 agonists as adjuvants in the methods of the invention.

It is expected that the vaccine should be administered at least once a year, such as at least 1, 2, 3, 4, 5, 6, and 12 20 times a year. More specifically, 1-12 times per year is expected, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 times a year to an individual in need thereof. It has previously been shown that the memory immunity induced by the use of the preferred autovaccines according to the invention 25 is not permanent, and therefor the immune system needs to be periodically challenged with the analogues.

Due to genetic variation, different individuals may react with immune responses of varying strength to the same polypeptide. Therefore, the vaccine according to the invention may comprise

several different polypeptides in order to increase the immune response, cf. also the discussion above concerning the choice of foreign T-cell epitope introductions. The vaccine may comprise two or more polypeptides, where all of the

5 polypeptides are as defined above.

The vaccine may consequently comprise 3-20 different modified or unmodified polypeptides, such as 3-10 different polypeptides. However, normally the number of peptides will be sought kept to a minimum such as 1 or 2 peptides.

10 ## Live vaccines

The second alternative for effecting presentation to the immune system is the use of live vaccine technology. In live vaccination, presentation to the immune system is effected by administering, to the animal, a non-pathogenic microorganism

15 which has been transformed with a nucleic acid fragment encoding the necessary epitopic regions or a complete 1st and/or 2nd analogue. Alternatively, the microorganism is transformed with a vector incorporating such a nucleic acid fragment. The non-pathogenic microorganism can be any suitable

20 attenuated bacterial strain (attenuated by means of passaging or by means of removal of pathogenic expression products by recombinant DNA technology), e.g. *Mycobacterium bovis* BCG., non-pathogenic *Streptococcus* spp., *E. coli*, *Salmonella* spp., *Vibrio cholerae*, *Shigella*, etc. Reviews dealing with

25 preparation of state-of-the-art live vaccines can e.g. be found in Saliou P, 1995, Rev. Prat. 45: 1492-1496 and Walker PD, 1992, Vaccine 10: 977-990, both incorporated by reference herein. For details about the nucleic acid fragments and vectors used in such live vaccines, cf. the discussion below.

As for the polypeptide vaccine, the T_H epitope and/or the first and/or second and/or third moieties can, if present, be in the form of fusion partners to the amino acid sequence derived from the cell-associated polypeptide antigen.

5 As an alternative to bacterial live vaccines, the nucleic acid fragment of the invention discussed below can be incorporated in a non-virulent viral vaccine vector such as a vaccinia strain.

Normally, the non-pathogenic microorganism or virus is
10 administered only once to the animal, but in certain cases it may be necessary to administer the microorganism more than once in a lifetime.

Also, the microorganism can be transformed with nucleic acid(s) containing regions encoding the 1st, 2nd and/or 3rd
15 moieties, e.g. in the form of the immunomodulating substances described above such as the cytokines discussed as useful adjuvants. A preferred version of this embodiment encompasses having the coding region for the analogue and the coding region for the immunomodulator in different reading frames or
20 at least under the control of different promoters. Thereby it is avoided that the analogue or epitopes are produced as fusion partners to the immunomodulator. Alternatively, two distinct nucleotide fragments can be used as transforming agents.

25 <u>Nucleic acid vaccination</u>

As an alternative to classic administration of a peptide-based vaccine, the technology of nucleic acid vaccination (also known as "nucleic acid immunisation", "genetic immunisation", "gene immunisation" and "DNA vaccination) offers a number of
30 attractive features.

First, in contrast to the traditional vaccine approach, nucleic acid vaccination does not require resource consuming large-scale production of the immunogenic agent (e.g. in the form of industrial scale fermentation of microorganisms

5 producing the analogues necessary in polypeptide vaccination). Furthermore, there is no need to device purification and refolding schemes for the immunogen. And finally, since nucleic acid vaccination relies on the biochemical apparatus of the vaccinated individual in order to produce the

10 expression product of the nucleic acid introduced, the optimum posttranslational processing of the expression product is expected to occur; this is especially important in the case of autovaccination, since, as mentioned above, a significant fraction of the original B-cell epitopes should be preserved

15 in the analogues derived from extracellularly exposed polypeptide sequences, and since B-cell epitopes in principle can be constituted by parts of any (bio)molecule (e.g. carbohydrate, lipid, protein etc.). Therefore, native glycosylation and lipidation patterns of the immunogen may

20 very well be of importance for the overall immunogenicity and this is best ensured by having the host producing the immunogen.

Hence, an important embodiment of the method of the invention involves that presentation is effected by *in vivo* introducing,

25 into the APC, at least one nucleic acid fragment which encodes and expresses the at least one CTL epitope and/or the at least one B-cell epitope, and the at least one first foreign T_H epitope (an alternative encompasses administration of at least 2 distinct nucleic acid fragments, where one encodes the at

30 least one CTL epitope and the other encodes the at least one foreign T_H epitope). Preferably, this is done by using a nucleic acid fragment which encodes and expresses the above-discussed first analogue. If the first analogue is equipped with the above-detailed T_H epitopes and/or first and/or second

and/or third moieties, these are then present in the form of
fusion partners to the amino acid sequence derived from the
cell-associated polypeptide antigen, the fusion construct
being encoded by the nucleic acid fragment.

5 As for the traditional vaccination approach, the nucleic acid
vaccination can be combined with *in vivo* introduction, into
the APC, of at least one nucleic acid fragment encoding and
expressing the second analogue. The considerations pertaining
to 1st, 2nd and 3rd moieties and T_H epitopes apply also here.

10 In this embodiment, the introduced nucleic acid is preferably
DNA which can be in the form of naked DNA, DNA formulated with
charged or uncharged lipids, DNA formulated in liposomes, DNA
included in a viral vector, DNA formulated with a
transfection-facilitating protein or polypeptide, DNA
15 formulated with a targeting protein or polypeptide, DNA
formulated with Calcium precipitating agents, DNA coupled to
an inert carrier molecule, and DNA formulated with an
adjuvant. In this context it is noted that practically all
considerations pertaining to the use of adjuvants in
20 traditional vaccine formulation apply for the formulation of
DNA vaccines. Hence, all disclosures herein which relate to
use of adjuvants in the context of polypeptide based vaccines
apply *mutatis mutandis* to their use in nucleic acid
vaccination technology. The same holds true for other
25 considerations relating to formulation and mode and route of
administration and, hence, also these considerations discussed
above in connection with a traditional vaccine apply *mutatis
mutandis* to their use in nucleic acid vaccination technology.

Furthermore, the nucleic acid(s) used as an immunization agent
30 can contain regions encoding the 1st, 2nd and/or 3rd moieties,
e.g. in the form of the immunomodulating substances described
above such as the cytokines discussed as useful adjuvants. A

preferred version of this embodiment encompasses having the coding region for the analogue and the coding region for the immunomodulator in different reading frames or at least under the control of different promoters. Thereby it is avoided that

5 the analogue or epitope is produced as a fusion partner to the immunomodulator. Alternatively, two distinct nucleotide fragments can be used, but this is less preferred because of the advantage of ensured co-expression when having both coding regions included in the same molecule.

10 Under normal circumstances, the nucleic acid of the vaccine is introduced in the form of a vector wherein expression is under control of a viral promoter. For more detailed discussions of vectors according to the invention, cf. the discussion below. Also, detailed disclosures relating to the formulation and use

15 of nucleic acid vaccines are available, cf. Donnelly JJ et al, 1997, Annu. Rev. Immunol. 15: 617-648 and Donnelly JJ et al., 1997, Life Sciences 60: 163-172. Both of these references are incorporated by reference herein.

An important part of the invention pertains to a novel method

20 for selecting an appropriate immunogenic analogue of a cell-associated polypeptide antigen which is weakly immunogenic or non-immunogenic in an animal, said immunogenic analogue being capable of inducing a CTL response in the animal against cells displaying an MHC Class I molecule bound to an epitope derived

25 from the cell-associated polypeptide antigen. This novel method comprises the steps of

a) identifying at least one subsequence of the amino acid sequence of the cell-associated polypeptide antigen which does not contain known or predicted CTL epitopes,

30 b) preparing at least one putatively immunogenic analogue of the cell-associated polypeptide antigen by introducing, in the amino acid sequence of the cell-associated polypeptide antigen, at least one T_H epitope foreign to the animal in a

position within the at least one subsequence identified in
step a), and

c) selecting the/those analogues prepared in step b) which
are verifiably capable of inducing a CTL response in the
5   animal.

Alternatively, the above selection method involves the
preparation of a nucleic acid fragment for nucleic acid
vaccination purposes. In that situation, it is required that
the encoded peptide includes at least one T_H epitope.

10 When the analogue is derived from an antigen which is exposed
to the extracellular phase, it is preferred that the
subsequence identified in step a) further does not contain
cysteine residues, or, alternatively, that the T_H epitope
introduced in step b) does not substantially alter the pattern
15 of cysteine residues. This approach facilitates the
preservation of spatial B-cell epitopes in the resulting
construct which are similar to the B-cell epitopes in the
weak, cell-associated polypeptide antigen.

For the same reasons it is preferred the subsequence
20 identified in step a) further does not contain known or
predicted glycosylation sites, or, alternatively, wherein the
T_H epitope introduced in step b) does not substantially alter
the glycosylation pattern.

Certain of the weak, cell-associated polypeptide antigens
25 exert undesired effects by having a pathophysiological role.
It is desired that these effects are not exerted by the
vaccination constructs, and therefore it is preferred that the
subsequence identified in step a) contributes significantly to
a pathophysiological effect exerted by the cell-associated
30 polypeptide antigen, and that the introduction in step b) of

the foreign T_H epitope reduces or abolishes said
pathophysiological effect.

Another important consideration pertains to the question of
immunological cross-reactivity of the vaccine's polypeptide
5 product with other non-pathological self-proteins. Such cross-
reactivity should preferably be avoided and hence an important
embodiment of this method of the invention is one where the
subsequence identified in step a) is homologous to an amino
acid sequence of a different protein antigen of the animal,
10 and where the introduction of the T_H epitope in step b)
substantially removes the homology.

Related to this embodiment is an embodiment where any amino
acid sequences which 1) are not normally exposed to the
extracellular phase and 2) which may constitute B-cell
15 epitopes of the weak, cell-associated polypeptide antigen, are
not preserved in the analogue. This can be achieved by
exchanging such amino acid sequences with T_H epitopes which do
not constitute B-cell epitopes, by completely removing them,
or by partly removing them.

20 On the other hand, it is preferred that any "true" B-cell
epitopes of the weak cell-associated polypeptide antigen are
preserved to a high degree, and therefore an important
embodiment of the selection method of the invention involves
that the introduction in step b) of the foreign T_H epitope
25 results in preservation of a substantial fraction of B-cell
epitopes of the cell-associated polypeptide antigen. It is
especially preferred that the analogue preserves the overall
tertiary structure of the cell-associated polypeptide antigen.

The preparation in step b) is preferably accomplished by
30 molecular biological means or by means of solid or liquid
phase peptide synthesis. Shorter peptides are preferably

prepared by means of the well-known techniques of solid- or liquid-phase peptide synthesis. However, recent advances in this technology has rendered possible the production of full-length polypeptides and proteins by these means, and therefore

5 it is also within the scope of the present invention to prepare the long constructs by synthetic means.

After having identified the useful analogues according to the above-discussed method, it is necessary to produce the analogue in larger scale. The polypeptides are prepared

10 according to methods well-known in the art.

This can also be done by molecular biological means. This comprises a first step of preparing a transformed cell by introducing, into a vector, a nucleic acid sequence encoding an analogue which has been selected according to the method

15 and transforming a suitable host cell with the vector. The next step is to culture the transformed cell under conditions facilitating the expression of the nucleic acid fragment encoding the analogue of the cell-associated antigen, and subsequently recovering the analogue from the culture

20 supernatant or directly from the cells, e.g. in the form of a lysate). Alternatively, the analogue can be prepared by large-scale solid or liquid phase peptide synthesis, cf. above.

Finally, the product can, depending on the cell chosen as a host cell or the synthesis method used, be subjected to

25 artificial post-translational modifications. These can be refolding schemes known in the art, treatment with enzymes (in order to obtain glycosylation or removal of undesired fusion partners, chemical modifications (again glycosylation is a possibility), and conjugation, e.g. to traditionally carrier

30 molecules.

Specific exemplary targets for the method of the invention

As discussed above, preferred weak, cell-associated polypeptide antigens are tumour-associated antigens. A non-limiting list of these consists of prostate-specific membrane antigen (PSM), Her2,

5 fibroblast growth factor, e.g. FGF-8 such as FGF-8A and FGF-8b, human chorionic gonadotropin (hCG), BAGE, beta-actinin, Carcino Embryonic Antigen (CEA), Cathepsins, CD33, CDK-4, E6, E7, EGFR, EGP40 (KSA), GAGE, Gastrin-releasing peptide (bombesin), GnTV, GP1, gp100 (melanoma-associated), gp75

10 (melanoma-associated), IGFR1, K3, MAGE such as MAGE1 and MAGE3, MART, Matrix Metalloproteinases such as MMP2, MMP3, MMP7, and MMP9, aberrantly glycosylated Mucin, such as MUC-1, MUC-2, MUC-3, and MUC-4, MUM-1, p15 (melanoma-associated), PAI-1, PDGF, Plasminogen such as uPA, RAGE, TGF-α,

15 TRP-1/gp-75, TRP-2, Tyrosinase, and ZAG.

In the following, 3 specific tumour-associated antigens will be discussed in detail.

Prostate-specific membrane-associated antigen, PSM

In U.S.A., prostate cancer is the second leading cause of

20 cancer death (app. 40,000 per year), and 200,000 patients per year are diagnosed (Boring 1993). Approximately 1 out of 11 men eventually will develop prostatic cancer. Furthermore, approximately 40-60% of prostate cancer patients eventually develop extraprostatic extension of the disease (Babaian

25 1994). The main strategy in the present invention is to use a therapeutic vaccine as a supplementary therapy to prostatectomy in order to eliminate residual tumour tissue and metastases.

Several pathologic conditions are located to the prostate

30 gland, including benign growth (BPH), infection (prostatitis) and neoplasia (prostatic cancer).

The biological aggressiveness of prostatic cancer is variable. In some patients the detected tumour remains a latent histologic tumour and never becomes clinically significant. In other patients, the tumour progresses rapidly, metastasises

5 and kills the patient in a relatively short time period (2-5 years).

The current primary treatment of prostate cancer is prostatectomy. However, due to the extensive spreading of prostate cancer cells the majority of prostatic cancer

10 patients are not cured by local surgery. Patients with non-confined disease eventually receive systemic androgen ablation therapy, but the annual death rate from prostatic cancer has not declined at all over the 50 years since androgen ablation became standard therapy for metastatic disease.

15 PSM is a membrane protein which is highly specific for prostatic tissues, benign as well as malignant. Therefore, if surgery was successful, prostatectomised cancer patients should theoretically no longer express PSM except on residual malignant prostate tumour tissue or metastases originating

20 from the tumour. In other words, in these patients PSM is a true tumour specific antigen. By inducing a strong CTL response and/or a strong polyclonal antibody response towards PSM, it is expected that residual tumour tissue can be eliminated.

25 Interestingly, upregulation of PSM expression is seen following androgen-deprivation therapy of prostate cancer patients (Wright 1996). This would make a PSM-targeted treatment very well-suited to follow the traditional androgen-deprivation therapy.

30 PSM was first identified in 1987 as a result of generating a monoclonal antibody, 7E11-C5.3, raised against an isolated

prostatic cancer cell, LNCaP (Horoszewicz 1987). The antibody
recognised both normal and malignant prostatic epithelium, and
was used in 1993 to purify and microsequence the PSM protein
and eventually clone the gene (Israeli 1993).

5 PSM is a type II transmembrane glycoprotein with a molecular
weight of 84 kD as predicted from the nucleic acid sequence
whereas the glycosylated version has an observed molecular
weight of 100 kD (Israeli 1993). Sequencing of the gene
encoding PSM revealed a putative membrane spanning region in
10 connection with three cytosolic arginine anchor residues. The
extracellular part of PSM constitute 707 of the total 750
amino acids of the protein, whereas the cytoplasmic domain is
predicted to be 19 amino acids long (Israeli 1993). PSM-
specific mRNA has been detected in prostate tumour tissue
15 (Israeli 1994), indicating that the tumour antigen is not an
aberrantly glycosylated protein which is the case with e.g.
the Tn- or sTn-tumour antigens.

The full length PSM cDNA has been transfected into and
expressed in a PSM negative human prostate cancer cell line,
20 PC-3 (Kahn 1994). Furthermore, the full length (2.65
kilobases) cDNA has been transcribed and translated in vitro
(Kahn 1994).

It has recently been demonstrated that PSM possesses
hydrolytic activity resembling that of the N-acetylated α-
25 linked acidic dipeptidase (NAALADase). NAALADase is a
membrane-bound hydrolase of the nervous system, which
catabolises the neuropeptide N-acetylaspartyl glutamate (NAAG)
in order to affect the glutamatergic signalling processes. It
has been shown that PSM possess NAAG-hydrolysing activity and
30 that this activity can be inhibited by the NAALADase
inhibitors quisqualic acid and β-NAAG (Carter 1996). It is

still not known whether this activity of PSM has any relevant biological function.

It is of significant importance to predict whether undesired cross-reactivity with other proteins accessible for antibodies
5 would be expected following treatment with an autovaccine inducing PSM-specific autoantibodies. It has been shown that a part of the coding region of the PSM gene (amino acids positions 418-567) has 54% homology to the human transferrin receptor (Israeli 1993). Also, sequence homology with the
10 NAALADase enzyme has been found. A 1428 bp partial cDNA from a rat brain library isolated using a rat anti-NAALADase antiserum showed 86% sequence identity with 1428 bases of the human PSM cDNA (Carter 1996). However, no identification of a functionally relevant similarity with other known peptidases
15 could be made.

The homology to the transferrin receptor is very low and will preferably be disrupted in some of the inventive constructs. The observed partial homology with a rat brain protein as an obstacle for a PSM-vaccine, partly because of the inability of
20 antibodies to penetrate the blood-brain barrier. Altogether, even with the most PSM-like construct, it is not expected to experience cross-reactivity with other proteins in the patients.

From earlier studies it is clear that PSM is expressed on all
25 prostate cancer cells and prostate originating metastases tested. All other cancers tested, such as carcinomas, sarcomas and melanomas of different tissues as well as a large panel of non-prostatic human cancer cell lines have proven PSM negative.

30 In addition to this, a very large number of other tissues have been found to be PSM negative. These include colon, breast,

lung, ovary, liver, urinary bladder, seminal vesicles, testis, uterus, bronchus, spleen, pancreas, tongue, esophagus, stomach, thyroid, parathyroid, adrenal, lymph node, aorta, vena cava, skin, mammary gland and placenta.

5 Although PSM is predominantly found as a membrane bound molecule on prostate tissue small amounts of PSM can also be detected in the sera of normal individuals and in elevated levels in prostate cancer patients (Rochon 1994, Murphy 1995). The level of circulating PSM in these patients therefore

10 allows a serological monitoring of the effectiveness of a PSM vaccine.

In conclusion, based on the entire amount of data available to date, PSM is a true prostate-specific antigen. This means that in patients who have undergone prostatectomy, PSM is a tumour

15 specific self-antigen. An effective PSM vaccine is therefore likely to target only prostatic or prostate-originating metastatic tissue.

As will be clear from Example 1 the method of the invention is preferably entails that foreign T_H-cell epitope is introduced

20 in a part of the PSM amino acid sequence defined by SEQ ID NO: 2 positions 16-52 and/or 87-108 and/or 210-230 and/or 269-289 and/or 298-324 and/or 442-465 and/or 488-514 and/or 598-630 and/or 643-662 and/or 672-699. Furthermore, a modified PSM molecule which has a foreign T_H-epitope introduced in these

25 positions is also a part of the invention.

Accordingly, the invention also pertains to an analogue of human PSM which is immunogenic in humans, said analogue comprising a substantial part of all known and predicted CTL and B-cell epitopes of PSM and including at least one foreign

30 T_H epitope as discussed herein. Preferred PSM analogues are those wherein the at least one foreign T_H epitope is present as

an insertion in the PSM amino acid sequence or as a
substitution of part of the PSM amino acid sequence or as the
result of deletion of part of the PSM amino acid sequence, and
most preferred analogues are those wherein a foreign T_H-cell
5 epitope is introduced in a part of the PSM amino acid sequence
defined by SEQ ID NO: 2 positions 16-52 and/or 87-108 and/or
210-230 and/or 269-289 and/or 298-324 and/or 442-465 and/or
488-514 and/or 598-630 and/or 643-662 and/or 672-699.

Human Chorionic Gonadotropin (HCG)

10 The relationship between embryonic markers and malignant
phenotypes has been under discussion for many decades. An
increasing body of data suggests that at least one such
marker, human chorionic gonadotropin beta (hCGβ), is
consistently detected on cancer cells of many different
15 histological origins, and that expression of this protein
often correlates with increased metastatic properties. A
humoral immune response directed against this soluble protein
may reduce the chances of tumour spreading and/or may inhibit
the recurrence of new primary growths post-surgery.

20 Human chorionic gonadotropin belongs to a family of
glycoprotein hormones, including follicle-stimulating hormone
(FSH), thyroid-stimulating hormone (TSH), and luteinizing
hormone (LH), all of which are important regulators of
reproductive expression and fetal survival. The members of
25 this family of hormones are heterodimers, which share a common
α-chain. The β-chain is unique to each hormone and provides
the specificity, with the β-chain of LH exhibiting the
strongest sequence homology to hCGβ (approximately 80%). The
apparent molecular weight of hCG-holo, is 37 kD, of which one
30 third is contributed by carbohydrate. The post-translational
sugar modifications include both N-linked and O-linked
carbohydrate. Abundant sialic acid residues are present and

these give the protein a large negative charge. The crystal structure of hCG-holo has been solved (Lapthorn et al., 1994).

Based on the crystal structure it was found that hCG exhibits homology to a family of growth factors, including PDGF and
5 TGFβ (Lapthorn et al., 1994). This suggests that hCG expression may help regulating cancer cell growth.

Human chorionic gonadotropin is a glycoprotein hormone, which is produced by the placental syncytiotrophoblasts soon after conception, and it is essential for successful gestation in
10 the pregnant woman.

The pathophysiological role of embryonic markers for the development or maintenance of a cancer mass is not known. However, it is of interest to note that trophoblasts (where these proteins are normally produced) have both *angiogenic* and
15 *invasive* characteristics, both of which are also necessary properties for a cancer cell. Further, it has been suggested that hCG (or its subunits) can inhibit maternal cellular immune responses to fetal tissue. For example, studies have shown that hCG directly suppresses T cell responses (Jacoby et
20 al., 1984) and it has been proposed that because the lymph nodes draining (in this case) a primary melanoma tumour, are immunosuppressed, a more favourable environment for metastatic tumours to establish themselves may result. As a consequence, expression of hCGβ may help cancer cells spread into the
25 secondary lymphoid organs. Finally, as mentioned above, structural homology between hCG and a number of growth factors have been demonstrated. Another possibility is therefore that secretion of hCG by cancer cells may give the tumour a growth advantage.
30

Expression of hCGβ has been shown in many different types of cancer, for example: a) Prostate adenocarcinoma: positivity

for hCGβ on tissue sections were seen for patients with poor
prognosis, irrespective of the histological grade of the
tumour (Sheaff et al., 1996), b) different kinds of lung
carcinomas; squamous cell (SQCC), adenocarcinoma (AC), and
5 large cell (LCC), all showed a high percentage of reactivity
for hCGβ (Boucher et al. 1995), c) pancreatic adenocarcinoma
(Syrigos et al., 1998), d) neuroblastomas, brain cancers,
retinoblastomas (Acevedo et al., 1997), e) malignant melanoma
(Doi et al., 1996), f) bladder carcinomas (Lazar et al.,
10 1995). A recent paper describes a DNA approach, in which mice
were immunized with a hCGβ expression construct (Geissler et
al., 1997). In this in vivo model inhibition of tumour growth
was strongly associated with CTL-activity, however high titers
of antibodies (which neutralized the biological effect of
15 intact hCG on its cellular receptor) were also detected.

The use of hCG as an immunogen has been described in several
papers, focussing on its use as a contraceptive vaccine
(Talwar et al., 1976 and Talwar et al., 1994). A very high
degree of efficacy and safety has been observed in an anti-
20 fertility clinical trial, using a vaccine against hCG-holo
(Talwar et al., 1994). Phase I clinical trials of cancer
patients with a vaccine against a synthetic carboxy-terminal
peptide of hCGβ conjugated to diphteria toxoid have also been
conducted (Triozzi et al., 1994) and phase II trials are
25 underway. Despite the fact that the idea to use hCGβ as a
cancer vaccine target has been around for some time, it has
not been explored in conjunction with the AutoVac technology.

It is known that cells from non-embryonic tissue, or benign
neoplasms, do not express hCGβ. Therefore, there should be no
30 potential side effects from vaccination against this molecule
(apart from the effects on pregnancy). Because it is expressed
by so many different kinds of cancers this molecule has been
proposed to be the "definitive cancer biomarker" (Acevedo et

al., 1995 and Regelson W., 1995) and as such would be an attractive target to go after.

Suitable animal models for Further studies of the efficacy of a hCG based vaccine can be found in Acevedo *et al.*, Cancer
5 Det. and Prev. Suppl. (1987) 1: 477-486, and in Kellen *et al.*, Cancer Immunol. Immun.Ther. (1982) 13: 2-4.

Her-2

The tyrosine kinase receptors Her-2 and EGFr are believed to play a crucial role in the malignant transformation of normal
10 cells and in the continued growth of cancer cells. Overexpression is usually linked to a very poor prognosis. During the past few years there has been many reports concerning the use of antibodies against these receptors as therapy for cancers that overexpress either or both of these
15 receptors. Genentech Inc. has finished several successful clinical trials on breast cancer patients using a monoclonal antibody against Her-2 and has recently obtained an FDA approval for the marketing of the anti-Her-2 monoclonal antibody preparation, Herceptin®.

20 The autovacination technology disclosed herein as applied on the Her-2 molecule would elicit polyclonal antibodies that would predominantly react with Her-2. Such antibodies are expected to attack and eliminate tumour cells as well as prevent metastatic cells from developing into metastases. The
25 effector mechanism of this anti-tumour effect would be mediated via complement and antibody dependent cellular cytotoxicity.

Dependent on the choice of constructs, the induced autoantibodies could also inhibit cancer cell growth through
30 inhibition of growth factor dependent oligo-dimerisation and

internalisation of the receptors. And, most importantly, the
Her-2 analogues are expected to be able to induce CTL
responses directed against known and/or predicted Her-2
epitopes displayed by the tumour cells

5 Her-2 is a member of the epidermal growth factor receptor
family (c-erbB) which consists of four different receptors to
date: c-erbB-1 (EGFr), c-erbB-2 (Her-2, c-Neu), c-erbB-3 and
c-erbB-4 (*Salomon et al, 1995*). C-erbB-3 and c-erbB-4 are less
well characterised than EGFr and Her-2. Her-2 is an integral
10 glycoprotein. The mature protein has a molecular weight of 185
kD with structural features that closely resembles the EGFr
receptor (*Prigent et al, 1992*). EGFr is also an integral
membrane receptor consisting of one subunit. It has an
apparent molecular weight of 170 kD and consists of a surface
15 ligand-binding domain of 621 amino acids, a single hydrophobic
transmembrane domain of 23 amino acids, and a highly conserved
cytoplasmic tyrosine kinase domain of 542 amino acids. The
protein is N-glycosylated (Prigent et al, 1994).

All proteins in this family are tyrosine kinases. Interaction
20 with the ligand leads to receptor dimerisation, which
increases the catalytic action of the tyrosine kinase
(*Bernard. 1995, Chantry 1995*). The proteins within the family
are able to homo- and heterodimerise which is important for
their activity. The EGFr conveys growth promoting effects and
25 stimulates uptake of glucose and amino acids by cells (*Prigent
et al 1992*). Her-2 also conveys growth promoting signals. Only
EGFr binds EGF and TGF-alpha. These ligands do not bind to the
other receptors in the family (*Prigent et al., 1992*). The
ligands for Her-2 are not fully determined. However, heregulin
30 has been shown to induce phosphorylation by activating Her-2.
This does not appear to be due to a direct binding to the
receptor but it is believed that heregulin is a ligand for

erbB-3 and erbB-4 which then activates Her-2 by oligo-dimerisation (*Solomon et al 1995*).

The homology between the proteins of EGF receptor family is most pronounced in the tyrosine kinase domain at the
5 cytoplasmic part of the molecules (82% between EGFr and Her-2). The homology is less in the extracellular part - from 41% to 46% in different domains (*Prigent et al, 1992*).

The epidermal growth factor receptor is expressed on normal tissues in low amounts, but it is overexpressed in many types
10 of cancers. EGFr is overexpressed in breast cancers (*Earp et al, 1993, Eppenberger 1994*), gliomas (*Schlegel et al, 1994*), gastric cancer (*Tkunaga et al, 1995*), cutaneous squamous carcinoma (*Fujii 1995*), ovarian cancer (*van Dam et al, 1994*) and others. Her-2 is also expressed on few normal human
15 tissues in low amount, most characteristically on secretory epithelia. Over expression of Her-2 occurs in about 30% of breast, gastric, pancreatic, bladder and ovarian cancers.

The expression of these receptors varies depending on the degree of differentiation of the tumours and the cancer type,
20 e.g., in breast cancer, primary tumours overexpress both receptors; whereas in gastric cancer, the overexpression occurs at a later stage in metastatic tumours (*Salomon et al, 1995*). The number of overexpressed receptors on carcinoma cells is greater than 10^6/cell for several head and neck
25 cancers, vulva, breast and ovarian cancer lines isolated from patients (*Dean et al, 1994*).

There are several reasons why the EGFr family of receptors constitute suitable targets for tumour immunotherapy. First, they are overexpressed in many types of cancers, which should
30 direct the immune response towards the tumour. Second, the tumours often express or overexpress the ligands for this

family of receptors and some are hypersensitive to the
proliferative effects mediated by the ligands. Third, patients
with tumours that overexpress growth factor receptors often
have a poor prognosis. The overexpression has been closely
5 linked with poor prognosis especially in breast cancer, lung
cancer and bladder cancer (2) and is apparently associated
with invasive/metastatic phenotypes, which are rather
insensitive to conventional therapies (*Eccles et al, 1994*).

Overexpression of Her-2 is in some cases a result of
10 amplification of the gene and in other cases increased
transcription and translation. The overexpression of Her-2 is
associated with poor prognosis in breast, ovarian cancers,
gastric cancer, bladder cancer and possibly in non-small cell
lung cancers (*Solomon et al, 1995*).

15 Phase I clinical trials have been performed with a bispecific
antibody in patients with advanced breast and ovarian cancer.
The antibody was bispecific against Her-2 and FcγRI (*Weiner et
al, 1995*). Efficient lysis of Her-2 over expressing tumour
cells was observed with a bispecific antibody against Her-2
20 and CD3 (*Zhu et al, 1995*).

Treatment of scid mice xenografted with human gastric cancer
with an anti-Her-2 monoclonal antibody prolonged the survival
of the mice (*Ohniski et al, 1995*). The anti-tumour activities
of monoclonal antibodies against Her-2, *in vitro* and *in vivo*
25 is not due to an identical mechanism; they may act as partial
ligand agonists, alter Her-2 receptor turnover and
phosphorylation or may affect dimerization (*Lupu et al, 1995*).

Similarly, it has been shown that antibodies to EGFr can also
interfere with growth factor interactions. (Baselga *et al*,
30 1994, Modjahedi *et al*, 1993a, Wu *et al*, 1995, Modjahedi *et al*,

1993b, Tosi *et al*, 1995, Dean *et al*, 1994, Bier *et al*, 1995, Modjtahedi *et al*, 1996, Valone 1995).

Hence, an important embodiment of the methods of the invention is one wherein the foreign T-cell epitope is introduced in a
5 part of the Her-2 amino acid sequence defined by SEQ ID NO: 4 positions 61-75 and/or 105-119 and/or 151-165 and/or 212-226 and/or 252-266 and/or 327-341 and/or 371-385) and/or 467-481 and/or 581-595 and/or 72-86 and/or 146-160 and/or 221-235 and/or 257-271 and/or 387-401, cf. the Examples.

10 Accordingly, the invention also relates to an analogue of human Her2 which is immunogenic in humans, said analogue comprising a substantial part of all known and predicted CTL and B-cell epitopes of Her2 and including at least one foreign T_H epitope as discussed herein. It is preferred that the at
15 least one foreign T_H epitope is present as an insertion in the Her2 amino acid sequence or as a substitution of part of the Her2 amino acid sequence or as the result of deletion of part of the Her2 amino acid sequence. Most preferred analogues are those defined above, *i.e.* those wherein the foreign T-cell
20 epitope is introduced in a part of the Her-2 amino acid sequence defined by SEQ ID NO: 4 positions 61-75 and/or 105-119 and/or 151-165 and/or 212-226 and/or 252-266 and/or 327-341 and/or 371-385) and/or 467-481 and/or 581-595 and/or 72-86 and/or 146-160 and/or 221-235 and/or 257-271 and/or 387-401.

25 *FGF8b*

It has been shown by several investigators that FGF8b can induce proliferation, transformation, differentiation and in some cases greatly increase the tumorigenicity of mammalian cells and tissues (Tanaka 1992, Kouhara 1994, Lorenzi 1995,
30 MacArthur 1995a, Crossley 1996a, 1996b, Ghosh 1996, Ohuchi 1997a, Rudra-Ganguly 1998). These effects are primarily

mediated through the binding of FGF8b to members of the fibroblast growth factor receptors FGFR2, FGFR3, and FGFR4 (MacArthur 1995b, Blunt 1997, Tanaka 1998). Thus, cells expressing one of these receptors and FGF8b will provide an

5 autocrine growth-signalling cascade for themselves. We therefore believe that an autovaccine against FGF8b will be a very efficient means of treating FGF8-expressing cancer types.

Prostate cancer

The biological aggressiveness of prostatic cancer is variable.

10 In some patients the detected tumor remains a latent histologic tumor and never becomes clinically significant. In other patients, the tumor progresses rapidly, metastasizes, and kills the patient in a relatively short time (2-5 years).

For the purpose of diagnosis, and to follow the response to

15 therapy of prostate cancer, determination of the circulating levels of two proteins has primarily been used: prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) (Nguyen 1990, Henttu 1989). Due to disrupture of the normal architecture of the prostate gland in response to cancer

20 development, these soluble proteins are released into the circulation where they can be detected as markers for e.g. metastatic spread.

The current primary treatment of prostate cancer is prostatectomy. However, due to the extensive spreading of

25 prostate cancer cells the majority of prostatic cancer patients are not cured by local surgery. Patients with non-confined disease receive systemic androgen ablation therapy, but the annual death rate from prostatic cancer has not declined at all over the 50 years since androgen ablation

30 became standard therapy for metastatic disease.

RT-PCR analysis has shown that FGF8 mRNA is produced by the human prostatic epithelial tumor cell lines LNCaP, PC-3, ALVA-31, and DU145 respectively, with FGF8b being the most prominent isoform (Tanaka 1995, Ghosh 1996). The growth of the
5 androgen-responsive LNCaP cells are stimulated by addition of recombinant FGF8b (Tanaka 1995), while DU145 cells could be growth inhibited by transfection with vira expressing anti-sense FGF8b (Rudra-Ganguly 1998). This, together with evidence from developmental studies discussed below, indicate
10 a role for FGF8b in maintaining the cancerous state of these cell lines.

Using FGF8a cDNA for in situ hybridization experiments, Leung and co-workers have shown that a high proportion (71% (n=31)) of prostatic cancers produce FGF8 mRNA, and that the amount of
15 FGF8 mRNA correlate with the severeness of the tumors (P<0.05) (Leung 1996). Immunohistochemical analysis a monoclonal antibody against FGF8, has detected the protein in 93% (n=43) of human prostate cancers (Tanaka 1998). Normal prostatic tissue or benign prostatic hyperplasia does not produce FGF8
20 mRNA, or contain FGF8 protein (Leung 1996, Yoshimura 1996, Ghosh 1996, Tanaka 1998).

These results indicate that an autovaccine against FGF8b would be reactive against prostatic tumor tissue and thus, extremely valuable in the treatment of prostatic cancer.

25 **Breast cancer**

The current treatment of breast cancer is surgery. However, due to the extensive spreading of breast cancer cells a large part of breast cancer patients are not cured by local surgery. Patients with non-confined disease eventually receive androgen
30 ablation therapy, chemotherapy, and or radiation therapy. The

annual death rate from breast cancer is, however, still
relatively high.

FGF8 was originally isolated from a mouse mammary carcinoma
cell-line (SC-3), from which the expression could be induced
5 by adding androgen to the medium (Nonomura 1990). The protein
is also known to induce the proliferation of these as well as
other mammalian cells. Recently FGF8b mRNA has been shown to
be present in eight (n=8) human breast cancer cell lines
(MDA-MB-231, MDA-MB-415, ZR 75-1, T-47-D, SK-BR-III, PMC-42,
10 HBL-100 and MCF-7) (Tanaka 1995, Payson 1996, Wu 1997, Marsh
1998).

Wnt-1 transgenic mice infected with mouse mammary tumor virus
(MMTV) develop mammary tumors. FGF8 transcription is activated
in 50% of these tumors (MacArthur 1995c, Kapoun 1997).

15 Transgenic mice that are carrying the FGF8b cDNA under control
of the very specific mouse mammary tumor virus (MMTV)
promoter, are shown to spontaneously develop FGF8b expressing
mammary tumors (Coombes, personal communication).

Very recent data strongly indicates that FGF8b expression is
20 related to breast cancer (Tanaka 1998, Marsh 1998). Tanaka and
co-workers utilized a new monoclonal FGF8 antibody in
immunohistochemical studies. They showed that FGF8 was present
in 67% (n=12) of breast cancers, and that androgen receptors
were present in 89% of breast diseases (Tanaka 1998). Using a
25 semi-quantitative RT-PCR method it was shown that elevated
levels of FGF8 mRNA were found in malignant compared to
non-malignant breast tissues. Significantly more malignant
tissues are expressing FGF8 (p=0.019) at significantly higher
levels (p=0.031) (68 breast cancers and 24 non-malignant
30 breast tissues) (Marsh 1998). This is in contrast to a study

where FGF8b mRNA was found in only one of nine breast cancers (Wu 1997).

Although it has not yet been established that FGF8b functions
as an autocrine growth factor, these findings in our opinion
5   suggest that an autovaccine against FGF8b would be reactive
against a large percentage of breast and prostate cancers. The
data presented by Marsh, and Tanaka indicate that an
autovaccine against FGF8b could be used for treatment of both
breast and prostate cancer. A significant proportion of these
10 cancers could, in agreement with the general opinion, be
dependent of FGF8b in maintaining the cancerous state of the
cells.

Description of FGF8b

FGF8 belongs to the family of fibroblast growth factors
15 (FGFs). These growth regulatory proteins are small ~200 amino
acid residue proteins that all are involved in the induction
of proliferation and differentiation of a wide range of cells.
For a recent review of the involvement of the fibroblast
growth factors in vertebrate limb development, see Johnson
20 1997. The FGF family members are evolutionary related and
share 20-50% amino acid sequence identity.

FGF8b is a splice variant of FGF8, originally termed androgen
induced growth factor (AIGF). AIGF was first identified as a
protein secreted by a murine mammary carcinoma derived cell
25 line (SC-3) upon stimulation with androgen (Nonomura 1990).
The murine FGF8 gene contains 6 exons, potentially coding for
eight different FGF8-isoforms (FGF8a-h), differing only in the
N-terminal part of the molecules (Crossley 1995, MacArthur
1995b). Human FGF8 has the same gene structure as the murine
30 gene. However, due to a stop codon in exon 1B, human FGF8 can
possibly exist in four different isoforms namely FGF8a, FGF8b,

FGF8e, and FGF8f (Gemel 1996). The gene structures and the amino acid sequences of the four human isoforms are illustrated in Fig. 5.

Mature FGF8b contains 193 amino acid residues, and has a
5 calculated molecular weight of 22.5kDa. The highly basic protein contains 21 arginine and 14 lysine residues resulting in a calculated isoelectric point of 10.84, and a calculated positive charge of 19,8 at pH 7.0. It contains two cysteine residues, and has two potential N-glycosylation sites. Due to
10 the nature of the investigations performed involving FGF8b very little is known about the FGF8b protein moiety. It has, however, been expressed heterologously from bacteria, purified by the use of a C-terminal hexa-Histidine tag, and *in vitro* refolded to a soluble and biologically active state (MacArthur
15 1995a, Blunt 1997).

Biological activity of FGF8b

As mentioned earlier, FGF8b was first isolated as a factor that was released from a mouse mammary tumour cell line, and it has been shown that this protein can induce the
20 proliferation of these cells. The morphological changes mimic those induced by testosterone, which is also know to induce the synthesis of FGF8b mRNA (Tanaka 1992). The proliferation can be inhibited by FGF8b antisense oligos (Nonomura 1990, Tanaka 1992, Yamanishi 1994). Indeed, a human prostate cancer
25 cell line DU145 could be growth inhibited by transfection with vira expressing anti-sense FGF8b (Rudra-Ganguly 1998).

FGF8b has by several investigators been shown very efficient in inducing the transformation of NIH3T3 cells (Kouhara 1994, Lorenzi 1995, MacArthur 1995a). By using recombinantly
30 expressed proteins, it was shown that this induction of morphological changes is far more efficient with FGF8b than

when using FGF8a or FGF8c (MacArthur 1995a, Ghosh 1996).
Recently, it was shown that the N-terminal half of the FGF8b
molecule is sufficient for transformation of NIH3T3 cells, and
that even the small FGF8b specific peptide (QVTVQSSPNFT) could
5 enable the cells to grow 2-3 times longer than normal in 0.1%
serum (Rudra-Ganguly 1998). Interestingly, NIH3T3 cells stably
transfected with an expression vector encoding FGF8b is very
tumorigenic when injected intraocularly into nude mice
(Kouhara 1994, Ghosh 1996).

10 *in vivo,* FGF8b is known to be expressed at certain stages of
development in vertebrates. A summary of the biological roles
assigned to FGF8b is shown in the following table. An
excellent review of various models for vertebrate limb
development is given by Johnson 1997.

15 Table: Various sites/tissues known to produce FGF8, and the
proposed biological role(s).

Action/mechanism/presence (species)	References
Present in the developing limb buds (mouse)	Heikinheimo 1994, Ohuchi 1994
Limb bud outgrowth (chicken)	Kuwana 1997, Xu 1998
Induction of ectopic limb formation from mesoderm (chicken)	Crossley 1996b
Induction of midbrain formation from the caudal diencephalon (chicken)	Crossley 1996a
Initiation of wing outgrowth in a wingless mutant (chicken)	Ohuchi 1997a
Role in dorsoventral patterning of the gastrula (zebrafish)	Fürthauer 1997

Required during gastrulation, cardiac, craniofacial, forebrain, midbrain and cerebellar development (tissue specific knockout mice)	Meyers 1998
5	Role in tooth morphogenesis (mouse)	Kettunen 1998

It is believed that FGF8b mediates its action through binding to the fibroblast growth factor receptors (FGFR's). Specifically FGF8b is known to be able to activate FGFR2c, FGFR3c, FGFR4c, and to some extent also FGFR1c, but not

10 FGFR1b, -2b or -3b (MacArthur 1995b, Blunt 1997). In case of the induction of outgrowth of ectopic chicken limbs, it is strongly suggested that FGF10, FGFR2, and FGF8 are interacting and that this is sufficient for outgrowth (Kuwana 1997, Xu 1998). These receptor-data are supporting the hypothesis that

15 FGF8b acts in an auto- and paracrine manner, leading to the normal outgrowth and patterning of several anatomical structures during vertebrate development. Importantly, FGF8 "total knock out" mice do not survive probably due to the elaborate involvement of the protein in the development of the

20 embryo.

Homology to other proteins

It is of significant importance to predict whether undesired cross-reactivity with other proteins accessible for antibodies would be expected following treatment with an autovaccine

25 inducing FGF8b specific autoantibodies. Due to the high degree of sequence identity between FGF8b and the other FGF8 molecules, an autovaccine will be expected to cross-react with these proteins. This, however, will presumably be advantageous, since none of these proteins are reported to be

30 expressed in tissues or by cell-lines that do not already express FGF8b.

Amino acid residues 55 through 175 of FGF8b shows a relatively
low but significant degree of sequence identity to the other
FGFs. It is commonly accepted (and several times proven) that
a significant degree of sequence identity between two protein
5 domains is also reflected in a high degree of tertiary
structure similarity. Therefore, the FGF family members are
all generally expected to be structurally similar. The three
dimensional structure of FGF2 has been resolved from crystals
as well as in solution (Ago 1991, Zhang 1991, Zhu 1991,
10 Eriksson 1993, Blaber 1996, Moy 1996). FGF2 is composed
entirely of beta-sheet structure, comprising a three-fold
repeat of a four-stranded antiparallel beta-meander. This
beta-barrel structure is totally conserved between interleukin
1, FGF2 (or basic FGF), and FGF1 (or acidic FGF). Nuclear
15 magnetic resonance analysis of FGF2 in solution has shown that
the N-terminal part of the molecule forms a relatively
flexible structure. The remaining part of FGF8b (amino acid
residues 1-54 and 176-215) only shows a low degree of sequence
identity to known proteins.

20 Based on the structural and alignment data, it is generally
assumed that the three dimensional structural core of the
other fibroblast growth factors closely resemble those of FGF1
and FGF2. These structural considerations are important
factors in our design of the FGF8b mutant autovaccine
25 molecules.

Importantly, due to the relatively low degree of sequence
identity between FGF8 and any of the other members of the FGF
family, the surface of FGF8 would be very different from that
30 of other FGFs, thereby minimizing the cross-reactivity of
FGF8b autovaccine generated antibodies with other FGF family
members. Due to the very low degree of homology to other
proteins than the fibroblast growth factors, we do not expect

an autovaccine against FGF8b to cross-react with any other
proteins.

It should be emphasized, however, that an autovaccine against
FGF8b probably would cross react with all isoforms of FGF8.
5 This will, however, presumably not be a problem since none of
the FGF8 isoforms are expected to be expressed at significant
levels in the adult. It is even possible that this cross
reaction will be beneficial in the treatment of cancer, since
it has been shown that at least some cancer cell lines express
10 other isoforms in addition to FGF8b.

Tissue distribution of FGF8b

Ideally, the induced autoantibodies and the subsequent
effector mechanisms as well as the expected CTL response
raised by autovaccination should only be directed towards
15 tissues that are to be eliminated in the patient. Therefore,
the tissue distribution of the antigen, which is targeted by
an autovaccine, is an issue of great importance concerning the
safety of the vaccine.

Table: Expression of FGF8b in various tissues and cells

20 <u>**Human**</u>

Breast cancer cell lines (MDA-MB-231, MDA-MB-415, ZR 75-1, T-47-D, SK-BR-III, PMC-42, HBL-100, and MCF-7)	((RT-PCR) Tanaka 1995, Payson 1996, Wu 1997, Marsh 1998)
25 Breast tumors	((mAb) Tanaka 1998, (RT-PCR)M arsh 1998)
Normal breast tissue	((RT-PCR)Wu 1997, Marsh 1998 (mAb) Tanaka 1998)

	Prostate cancer (93%)	((in situ hyb.) Leung 1996, (mAb) Tanaka 1998)
	Breast disease	((mAb) Tanaka 1998)
	Prostatic tumor cells (LNCaP, PC-3, DU145, and ALVA-31)	((RT-PCR) Tanaka 1995, Ghosh 1996)
5	fetal kidney	((Northern blot) Ghosh 1996)
	adult prostate, testis, kidney	((RT-PCR) Ghosh 1996, Wu 1997)
	teratocarcinoma cells (Tera-2)	((RT-PCR) Wu 1997)

Murine

10	Breast cancer cell lines (SC-115, RENCA)	((RT-PCR) Yoshimura 1996)
	Hypothalamus, Testis	((RT-PCR) Yoshimura 1996)
	Mammary tumors (Wnt-1 transgenic)	((Northern blot) MacArthur 1995c)
	Embryonic brain	((in situ hyb.) Crossley 1995, Heikinheimo 1994, Ohuchi 1994, Shimamura 1997, (RT-PCR) Blunt 1997)
15	Ovary, testis	((Northern blot) Valve 1997)
	Developing face and limb buds	((pAb) MacArthur 1995b (in situ hyb.) Heikinheimo 1994, Ohuchi 1994, Crossley 1995)
	Gastrula	((in situ hyb.) Crossley 1995)

Chicken

	Embryonic brain	((in situ hyb.) Crossley 1996a)
20	developing limb buds	((in situ hyb.) Ohuchi 1997a,b)

The above table shows a wide selection of tissue distribution, and cell line data of FGF8b expression. As seen from the

table, most of the data regarding tissue distribution is generated using the sensitive RT-PCR method. This is because Northern blotting analysis does not detect any FGF8b mRNA in any normal tissues except from fetal kidney. From this scarce

5 data, it is generally assumed that expression of FGF8b mRNA in the adult is very limited, and thus, an autovaccine against FGF8b would presumably not be reactive against normal tissue. Due to the fact that small amounts of FGF8b could interact in unknown systems in the adult, the tissue distribution of the

10 protein needs further analysis. There are, however, in our opinion no indications that an autovaccine against FGF8b would result in serious unwanted effects on the patients.

Effects of antibodies against FGF8b

So far, no attempts to treat prostate cancer using monoclonal

15 antibodies have been published. Clinical trials with monoclonal antibodies are ongoing in breast cancer therapy studies, however.

Antibodies against FGF8b will probably block the interaction between FGF8b and its receptors, which will inhibit the cell

20 membrane ruffling and cell proliferation, very likely decreasing the motility and invasiveness of the cancer cells.

Hence, the invention also relates to embodiments of the methods described herein where, where the foreign T-cell epitope is introduced in a part of the FGF8b amino acid

25 sequence defined by SEQ ID NO: 6 positions 1-54 and/or 178-215 and/or 55-58 and/or 63-68 and/or 72-76 and/or 85-91 and/or 95-102 and/or 106-111 and/or 115-120 and/or 128-134 and/or 138-144 and/or 149-154 and/or 158-162 and/or 173-177. It should be noted that it is especially preferred *not* to

30 introduce variations or modifications in positions 26-45 and in the C-terminus starting at amino acids 186-215, since these

stretches show the least homology with a recently discovered protein, FGF-18, which seems to be expressed in a variety of non-tumour tissues.

Accordingly, the invention also pertains to an analogue of
5 human/murine FGF8b which is immunogenic in humans, said analogue comprising a substantial part of all known and predicted CTL and B-cell epitopes of FGF8b and including at least one foreign T_H epitope as discussed herein. It is preferred that the at least one foreign T_H epitope is present
10 as an insertion in the FGF8b amino acid sequence or as a substitution of part of the FGF8b amino acid sequence or as the result of deletion of part of the FGF8b amino acid sequence. Most preferred analogues in this embodiment are those where the foreign T-cell epitope is introduced in a part
15 of the FGF8b amino acid sequence defined by SEQ ID NO: 6 positions 1-54 and/or 178-215 and/or 55-58 and/or 63-68 and/or 72-76 and/or 85-91 and/or 95-102 and/or 106-111 and/or 115-120 and/or 128-134 and/or 138-144 and/or 149-154 and/or 158-162 and/or 173-177.

20 Mucins

The invention also pertains to methods of the invention employing specifically modified versions of the human mucins, especially any of MUC-1 through MUC-4, preferably MUC-1. The analogues comprise the following structure

25
$$TR(-S-P-S-(TR)_m)_n$$

-where TR is a tandem repeat derived from the naturally occurring mucin, P is a foreign T_H-epitope as discussed herein, S is an inert spacer peptide having from 0 to 15 amino acid residues, preferably between 0 and 10 amino acid residues, and

n is an integer of from 1 to 30, and m is an integer from 1 to 10, preferably from 3 to 5.

When producing such a mucin analogue, the direct result will normally not have a glycosylation pattern as desired, *i.e.* an
5 aberrant glycosylation pattern resembling that of a tumour derived mucin. However, it is possible to produce the analogue recombinantly in e.g. *E. coli* or by synthetic means, and subsequently glycosylating the product enzymatically so as to achieve a Tn or S-Tn glycosylation pattern. Alternatively, the
10 polypeptide could be prepared in e.g. a CHO cell line lacking the relevant glycosylation enzyme.

It should be noted that preferred analogues of the invention comprise modifications which results in a polypeptide having a sequence identity of at least 70% with the polypeptide antigen
15 or with a subsequence thereof of at least 10 amino acids in length. Higher sequence identities are preferred, e.g. at least 75% or even at least 80% or 85%. The sequence identity for proteins and nucleic acids can be calculated as

$$\left(N_{ref} - N_{dif}\right) \cdot 100/N_{ref}$$, wherein N_{dif} is the total number of non-

20 identical residues in the two sequences when aligned and wherein N_{ref} is the number of residues in one of the sequences. Hence, the DNA sequence AGTCAGTC will have a sequence identity of 75% with the sequence AATCAATC (N_{dif}=2 and N_{ref}=8).

Nucleic acid fragments and vectors of the invention

25 It will be appreciated from the above disclosure that the analogues can be prepared by means of recombinant gene technology but also by means of chemical synthesis or semisynthesis; the latter two options are especially relevant when the modification consists in coupling to protein carriers
30 (such as KLH, diphtheria toxoid, tetanus toxoid, and BSA) and

non-proteinaceous molecules such as carbohydrate polymers and of course also when the modification comprises addition of side chains or side groups to an polypeptide-derived peptide chain.

5 For the purpose of recombinant gene technology, and of course also for the purpose of nucleic acid immunization, nucleic acid fragments encoding the necessary epitopic regions and analogues are important chemical products. Hence, an important part of the invention pertains to a nucleic acid fragment

10 which encodes an analogue described above of any of the relevant tumour-specific polypeptides, preferably a polypeptide wherein has been introduced a foreign T_H-cell epitope by means of insertion and/or addition, preferably by means of substitution and/or deletion. The nucleic acid

15 fragments of the invention are either DNA or RNA fragments.

The nucleic acid fragments of the invention will normally be inserted in suitable vectors to form cloning or expression vectors carrying the nucleic acid fragments of the invention; such novel vectors are also part of the invention. Details

20 concerning the construction of these vectors of the invention will be discussed in context of transformed cells and microorganisms below. The vectors can, depending on purpose and type of application, be in the form of plasmids, phages, cosmids, mini-chromosomes, or virus, but also naked DNA which

25 is only expressed transiently in certain cells is an important vector. Preferred cloning and expression vectors of the invention are capable of autonomous replication, thereby enabling high copy-numbers for the purposes of high-level expression or high-level replication for subsequent cloning.

30 The general outline of a vector of the invention comprises the following features in the 5'-3' direction and in operable linkage: a promoter for driving expression of the nucleic acid

fragment of the invention, optionally a nucleic acid sequence
encoding a leader peptide enabling secretion of or integration
into the membrane of the polypeptide fragment, the nucleic
acid fragment of the invention, and a nucleic acid sequence
5 encoding a terminator. When operating with expression vectors
in producer strains or cell-lines it is for the purposes of
genetic stability of the transformed cell preferred that the
vector when introduced into a host cell is integrated in the
host cell genome. In contrast, when working with vectors to be
10 used for effecting *in vivo* expression in an animal (i.e. when
using the vector in DNA vaccination) it is for security
reasons preferred that the vector is not capable of being
integrated in the host cell genome; typically, naked DNA or
non-integrating viral vectors are used, the choices of which
15 are well-known to the person skilled in the art.

The vectors of the invention are used to transform host cells
to produce the analogue of the invention. Such transformed
cells, which are also part of the invention, can be cultured
cells or cell lines used for propagation of the nucleic acid
20 fragments and vectors of the invention, or used for
recombinant production of the analogues of the invention.
Alternatively, the transformed cells can be suitable live
vaccine strains wherein the nucleic acid fragment (one single
or multiple copies) have been inserted so as to effect
25 secretion or integration into the bacterial membrane or cell-
wall of the analogue.

Preferred transformed cells of the invention are
microorganisms such as bacteria (such as the species
Escherichia [e.g. E.coli], Bacillus [e.g. Bacillus subtilis],
30 Salmonella, or Mycobacterium [preferably non-pathogenic, e.g.
M. bovis BCG]), yeasts (such as Saccharomyces cerevisiae), and
protozoans. Alternatively, the transformed cells are derived
from a multicellular organism such as a fungus, an insect

cell, a plant cell, or a mammalian cell. Most preferred are cells derived from a human being, cf. the discussion of cell lines and vectors below.

For the purposes of cloning and/or optimized expression it is
5   preferred that the transformed cell is capable of replicating the nucleic acid fragment of the invention. Cells expressing the nucleic fragment are preferred useful embodiments of the invention; they can be used for small-scale or large-scale preparation of the analogue or, in the case of non-pathogenic
10 bacteria, as vaccine constituents in a live vaccine.

When producing the analogue of the invention by means of transformed cells, it is convenient, although far from essential, that the expression product is either exported out into the culture medium or carried on the surface of the
15 transformed cell.

When an effective producer cell has been identified it is preferred, on the basis thereof, to establish a stable cell line which carries the vector of the invention and which expresses the nucleic acid fragment encoding the analogue.
20 Preferably, this stable cell line secretes or carries the analogue of the invention, thereby facilitating purification thereof.

In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the
25 host cell are used in connection with the hosts. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. For example, *E. coli* is typically transformed using pBR322, a plasmid derived from an *E. coli*
30 species (see, e.g., Bolivar et al., 1977). The pBR322 plasmid contains genes for ampicillin and tetracycline resistance and

thus provides easy means for identifying transformed cells.
The pBR plasmid, or other microbial plasmid or phage must also
contain, or be modified to contain, promoters which can be
used by the prokaryotic microorganism for expression.

5   Those promoters most commonly used in recombinant DNA
construction include the B-lactamase (penicillinase) and
lactose promoter systems (Chang et al., 1978; Itakura et al.,
1977; Goeddel et al., 1979) and a tryptophan (trp) promoter
system (Goeddel et al., 1979; EP-A-0 036 776). While these are
10 the most commonly used, other microbial promoters have been
discovered and utilized, and details concerning their
nucleotide sequences have been published, enabling a skilled
worker to ligate them functionally with plasmid vectors
(Siebwenlist et al., 1980). Certain genes from prokaryotes may
15 be expressed efficiently in E. coli from their own promoter
sequences, precluding the need for addition of another
promoter by artificial means.

In addition to prokaryotes, eukaryotic microbes, such as yeast
cultures may also be used, and here the promoter should be
20 capable of driving expression. *Saccharomyces cerevisiase*, or
common baker's yeast is the most commonly used among
eukaryotic microorganisms, although a number of other strains
are commonly available such as *Pichia pastoris*. For expression
in *Saccharomyces*, the plasmid YRp7, for example, is commonly
25 used (Stinchcomb et al., 1979; Kingsman et al., 1979;
Tschemper et al., 1980). This plasmid already contains the
trpl gene which provides a selection marker for a mutant
strain of yeast lacking the ability to grow in tryptophan for
example ATCC No. 44076 or PEP4-1 (Jones, 1977). The presence
30 of the trpl lesion as a characteristic of the yeast host cell
genome then provides an effective environment for detecting
transformation by growth in the absence of tryptophan.

Suitable promoting sequences in yeast vectors include the promoters for 3-phosphoglycerate kinase (Hitzman et al., 1980) or other glycolytic enzymes (Hess et al., 1968; Holland et al., 1978), such as enolase, glyceraldehyde-3-phosphate
5 dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. In constructing suitable expression plasmids, the termination
10 sequences associated with these genes are also ligated into the expression vector 3' of the sequence desired to be expressed to provide polyadenylation of the mRNA and termination.

Other promoters, which have the additional advantage of
15 transcription controlled by growth conditions are the promoter region for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and the aforementioned glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and
20 galactose utilization. Any plasmid vector containing a yeast-compatible promoter, origin of replication and termination sequences is suitable.

In addition to microorganisms, cultures of cells derived from multicellular organisms may also be used as hosts. In
25 principle, any such cell culture is workable, whether from vertebrate or invertebrate culture. However, interest has been greatest in vertebrate cells, and propagation of vertebrate in culture (tissue culture) has become a routine procedure in recent years (Tissue Culture, 1973). Examples of such useful
30 host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, and W138, BHK, COS-7 293 and MDCK cell lines.

Expression vectors for such cells ordinarily include (if
necessary) an origin of replication, a promoter located in
front of the gene to be expressed, along with any necessary
ribosome binding sites, RNA splice sites, polyadenylation
5   site, and transcriptional terminator sequences.

For use in mammalian cells, the control functions on the
expression vectors are often provided by viral material. For
example, commonly used promoters are derived from polyoma,
Adenovirus 2, and most frequently Simian Virus 40 (SV40). The
10   early and late promoters of SV40 virus are particularly useful
because both are obtained easily from the virus as a fragment
which also contains the SV40 viral origin of replication
(Fiers et al., 1978). Smaller or larger SV40 fragments may
also be used, provided there is included the approximately 250
15   bp sequence extending from the *Hind*III site toward the *Bgl*I
site located in the viral origin of replication. Further, it
is also possible, and often desirable, to utilize promoter or
control sequences normally associated with the desired gene
sequence, provided such control sequences are compatible with
20   the host cell systems.

An origin of replication may be provided either by
construction of the vector to include an exogenous origin,
such as may be derived from SV40 or other viral (e.g.,
Polyoma, Adeno, VSV, BPV) or may be provided by the host cell
25   chromosomal replication mechanism. If the vector is integrated
into the host cell chromosome, the latter is often sufficient.

Compositions of the invention

The invention also relates to an immunogenic composition which
comprises, as an effective immunogenic agent at least one of
30   the analogues described herein in admixture with a
pharmaceutically and immunologically acceptable carrier,

vehicle, diluent, or excipient, and optionally an adjuvant, cf also the discussion of these entities in the description of the method of the invention above.

Furthermore, the invention also relates to a composition
5 composition for inducing production of antibodies against any one of the above discussed tumour antigens, the composition comprising
   -    a nucleic acid fragment or a vector of the invention, and
   -    a pharmaceutically and immunologically acceptable diluent
10   and/or vehicle and/or carrier and/or excipient and/or
         adjuvant.

Formulation and other specifics concerning such compositions are discussed in the relevant section regarding nucleic acid immunisation above.

15 EXAMPLE 1

Vaccination agains PSM

In the following it will be described how a human autovaccine against PSM can be developed through modification of the molecule by insertion of one or more promiscuous foreign T
20 cell epitopes to reveal a panel of immunogenised PSM molecules.

The constructs will be tested for their ability to induce specific CTL responses against PSM bearing tumour cells. Furthermore, the constructs will be tested for their ability
25 to induce antibodies which are cross-reactive with the native parts of the PSM molecule. Subsequently, in several *in vitro* assays and *in vivo* animal models the efficacy of the different constructs will be evaluated. The induced antibodies will be

tested for their ability to activate complement via the classical pathway and to initiate ADCC via Fc-receptors. Finally, the different molecules will be tested in animal models of human prostate cancer.

5 **Strategy in designing a PSM autovaccine**

Briefly, the PSM vaccination plan entails the following experimental tasks

Design and production of a panel of human PSM mutants
- Cloning of the PSM sequences from human and rat/mouse.
10 - Mutational work to generate immunogenized hPSM molecules.
- Expression of wild type and immunogenized hPSM molecules in *E. coli* and/or *Pichia pastoris*.
- Purification, refolding and characterization of the immunogenized hPSM molecules.

15 DNA vaccination feasibility study

Selection of hPSM candidates
- Immunizations of mice/rabbits.
- ELISA.
- FACS analysis.
20 - Tumor cell proliferative assay.
- T cell presentation assays.

Testing of the hPSM mutants *in vivo*
- solid tumor/metastasis model in mice.

Conceptual study: CTL induction by autovaccination
25 - Construction of immunogenized mouse/rat PSM corresponding to the selected hPSM candidates.
- Testing the antisera raised by mouse/rat PSM mutants in *in vitro* assays: Immunochemical assays, ELISA, FACS analysis,

cellular assays, complement lysis of PSM bearing cells, ADCC assay, CTL activity assay, Tumor cell proliferative assay, T cell presentation assays.

- Testing of the mPSM mutants *in vivo* in a solid
5 tumor/metastasis model in mice.

Nomenclature of the hPSM constructs

PSM is a type II membrane protein of 750 amino acids, cf. SEQ ID NO: 2 which sets forth the wild-type sequence with the exception that Gly substitutes Trp in position 2 due to the
10 introduction of an *Nco*I site and a Kozak sequence in SEQ ID NO: 1, where ggt substitutes tgg in positions 4-6.

In PSM, the extracellular part constitutes the 707 C-terminal amino acids, whereas the cytoplasmic domain is predicted to be 19 amino acids long and the transmembrane part of the protein
15 consists of 24 amino acids (aa 20-43).

All the genetic constructs of human PSM are designated hPSM__.__, where the first __ is the insertion region used for insertion of P2, and the second __ is the insertion region used for P30. If P2 or P30 is not present in the protein, the
20 number 0 (zero) is designated. The full length wild type hPSM is designated hPSM0.0 and the wild type hPSM lacking the cytoplasmic and transmembrane parts is designated hPSM÷0.0. The 13 planned immunogenized hPSM genes which all contain one P2 epitope and one P30 epitope will be named hPSM1.1, hPSM6.1,
25 hPSM8.1, hPSM10.1, hPSM1.6, hPSM1.8, hPSM1.10, hPSM1.2, hPSM1.3, hPSM1.5, hPSM2.1, hPSM3.1, and hPSM5.1, cf. details below.

In hPSM1.1, both the P2 and the P30 epitopes are inserted in tandem in insertion region no. 1 (the membrane spanning
30 region). Theoretically, this mutant, hPSM1.1, can be

considered a very attractive vaccine candidate, because the whole extracellular domain of this molecule is intact.

In order to facilitate the cloning and mutagenesis procedures, much of the molecular construction work is done using either
5 the N-terminal (amino acids 1-436) or the C-terminal (amino acids 437-750) part of the hPSM gene as starting material. These two parts of the hPSM gene are designated hPSMI__.__ and hPSMII__.__, respectively, where the first __ is the insertion region used for insertion of P2, and the second __ is the
10 insertion region used for P30. Again, if P2 or P30 is not present in the protein, the number 0 (zero) is designated, and the wild types are named hPSMI0.0 and hPSMII0.0, respectively. A special variant of hPSMI0.0 without the cytoplasmic part of hPSM is designated hPSMI÷0.0.

15 Practically, most mutagenesis work is being done using hPSMI0.0 and hPSMII0.0 as starting material.

The expressed hPSM mutant proteins will be designated PROS__.__, where the first __ is the insertion region used for insertion of P2, and the second __ is the insertion region
20 used for P30. If P2 or P30 is not present in the protein, the number 0 (zero) is designated. The wild type hPSM is designated PROS0.0. PROSII0.0 is the hPSM amino acids 437-750 protein product. HIS tagged proteins are called HIS-PROS__.__.

Cloning of the human PSM sequence

25 The LNCaP cell line which originates from a metastatic lesion of human prostatic adenocarcinoma was purchased from the American Type Culture Collection (ATCC). mRNA was isolated from this cell line and reverse transcribed using a standard kit in order to obtain cDNA encoding the human PSM sequence.
30 Using different sets of hPSM specific primers, PCR products

encoding PSM(437-750) was obtained and further cloned into pUc19 (plasmid number pMR300) and verified by DNA sequencing. This C-terminal part of wild type PSM is designated hPSM partII (hPSMII0.0).

5 Similarly, the wild type hPSM partI (hPSMI0.0) has been cloned into pUc19 using primers for amplifying partI both with (hPSMI0.0) and without (hPSMI÷0.0) the transmembrane+cytoplasmic domains. The clones were control sequenced and hPSMI0.0 and hPSMII0.0 were fused using ligation

10 at the EcoRI site. The resulting clones of hPSM0.0 (SEQ ID NO: 2) and hPSM÷0.0 have been subcloned into a number of pro- and eucaryotic expression vectors and again sequence verified. For details of the hPSM wild type cloning work.

Cloning of the rat and mouse PSM sequences

15 The sequences of both mouse and rat cDNAs with very high homology to the human PSM sequences have previously been submitted to the Genbank database. The accession numbers are: mouse PSM: AF026380 (submitted 28 October 1997) and rat PSM: U75973 (submitted 23 October 1996). Knowledge of these

20 sequences have facilitated the cloning of the mouse PSM as well as the rat PSM, and it is currently aimed at to clone the murine PSM sequence.

cDNA libraries of rat hippocampus, rat prostate and mouse brain have been purchased commercially. The stocks have all

25 been titrated and their titers determined. Phage DNA was extracted from culture, and PCR amplifications using primers which are totally conserved between the published human and rat PSM sequences was performed in an attempt to obtain mouse/rat PSM specific probes for use in the selection of

30 m/rPSM expressing clones, but with no positive result.

The three libraries were subsequently plated out and screened
for plaques reactive with two probes consisting of the wild
type PCR products comprising hPSMI0.0 and hPSMII0.0,
respectively, which were radioactively labelled by
5   incorporation of ^{35}S-ATP in the PCR reaction. Several plaques
positive for both probes were identified in each of the
screened libraries. Double positive plaques from the rat
hippocampus and mouse brain libraries were picked, but the
second screening of these plaques with radioactive probes came
10 out negative.

600.000 clones from the mouse brain lambda-gt11 cDNA library
has been screened using ^{32}P labelled hPSM÷0.0 as probe. Four
positive clones were identified and used as templates for PCR
reactions with mouse PSM specific primers. Sequencing of such
15 PCR products revealed that one of the clones contains at least
1300 base pairs in the 3´ end of mouse PSM. Since only one
positive clone could be identified in this relatively large
number of plaques, at this point no further work will be done
using this library.

20 In order to isolate PSM directly from mouse tissue, prostate
glands were dissected from male BALB/c mice. Messenger RNA was
isolated from this tissue using an oligo-dT coupled magnetic
bead based commercial kit and subsequently reverse
transcribed. Using this cDNA as template, several PCR products
25 were obtained using different sets of mouse PSM specific
primers. In this way, approximately 1300 base pairs in the 3'
end of mouse PSM was so far identified. Ongoing and upcoming
work includes attempts to identify mouse PSM sequences in the
5' end of the gene using different primer sets as well as cDNA
30 synthesized from mRNA isolated from mouse macrophages and
mouse brain.

Recently, two EST (expressed sequence tag) clones containing
mouse PSM sequences (from fetal mouse kidney and mouse
macrophages, respectively) have been purchased from American
Type Culture Collection (ATCC). From the published sequences
5 it is expected that these clones will cover the 1400 3' base
pairs of the mouse PSM molecule.

Expression of wild type hPSM in *E. coli*

The C-terminal part (amino acids 437-750) of hPSM, hPSMII0.0,
has been cloned into the bacterial expression vector pET28b in
10 order to obtain a product with an N-terminal poly-histidine
(HIS) tail which facilitates easy large scale purification and
identification with anti-poly-HIS antibodies. The protein
product of poly-HIS tagged hPSMII0.0 (protein product
designated HIS-PROSII0.0) was expressed in *E. coli*.

15 The DNA encoding full-length wild type hPSM0.0 (SEQ ID NO: 1)
has also been expressed from pET28b in the *E. coli* strain
BL21(DE3) where the expression product is located in inclusion
bodies. SDS-PAGE analysis of bacterial lysate followed by
Western blotting with rabbit anti-HIS-PROSII0.0 showed a
20 product with the expected migration. N-terminal sequencing of
five amino acids of this product eluted from an SDS-PAGE gel
gave the expected amino acid sequence.

The wild type hPSM constructs hPSM0.0, hPSM÷0.0 (as well as
two hPSM mutants, hPSM1.1 and hPSM6.1, see below) have been
25 cloned into different *E. coli* expression vectors in order to
enable a more efficient expression and some degree of folding
of the recombinant proteins in *E. coli*. The chosen expression
systems are:

pMCT6 which generates N-terminally His-tagged versions of the
30 expressed   recombinant proteins,

pGH433 which express the recombinant proteins in connection to a 22 amino acid pelB leader sequence which should direct the protein to the periplasmic space of the *E. coli* bacteria, and

pMal-p2 in which recombinant proteins are expressed as C-
5 terminal fusions to maltose binding protein (MBP) containing the natural MBP periplasmic leader sequence. Antibodies against MBP can be used for detection of the fusion proteins and a carbohydrate coupled column can be used for affinity purification of the product.

10 However, E.coli expression experiments of the wild type hPSM proteins from these vectors only showed a fair expression level from pMCT6. The problems of getting periplasmic expression of the wild type hPSM proteins are still not solved at present.

15 **Expression of wild type hPSM in *Pichia pastoris***

Because of the relatively high molecular weight of the PSM protein and its relatively high degree of glycosylation (app. 16% of the molecular weight) and in order to facilitate purification by elimination of the refolding step, it has been
20 decided to implement alternative technology for eukaryotic expression of the recombinant proteins. Several well-characterized eukaryotic expression systems have been evaluated, and for the initial screening of hPSM mutants, the yeast *Pichia pastoris* has been chosen as alternative to *E.*
25 *coli* expression.

An expression system based on the yeast *Pichia pastoris* is currently being implemented. The glycosylation pattern of recombinant proteins expressed in this organism is expected to resemble the mammalian glycosylation patterns more than e.g.
30 *Saccharomyces cerevisiae* due to a lesser branched

mannosylation of the recombinant protein. It has recently been shown that mannose receptor-mediated uptake of antigens by dendritic cells results in an approximately 100-fold more efficient presentation to T cells compared to fluid-phase
5 endocytosed uptake. Therefore, mannosylation might play a role for the antigenicity (and especially the ability to induce CTL responses) of the hPSM mutants and other antigens against which a CTL response is desirable.

A strain of *Pichia pastoris* as well as two different
10 expression vectors have been purchased from Invitrogen. The vector pPICZαA carries a methanol inducible promoter upstream of the polycloning site, whereas the pGAPZαA vector express proteins constitutively. Both vectors encode the α-factor secretion signal in order to export the recombinant proteins
15 to the medium. The selection system of these vectors is zeocin resistance. The sequences encoding hPSM0.0, and hPSM÷0.0 (as well as one hPSM mutant, hPSM1.1, cf. below) were subcloned into these vectors.

Four *Pichia pastoris* strains (X-33, SMD1168, GS115, and KM71)
20 differing e.g. in their growth requirements were transformed with each of these (linearized) plasmids using electroporation. The transformation procedure was repeated several times with minor changes in order to obtain a large number of zeocin resistant clones. Currently, the
25 transformation procedure is being optimized and the screening of already obtained zeocin resistant clones is being performed in order to isolate a hPSM secreting clone. Also, the hPSM genetic constructs mentioned above are subcloned into *Pichia pastoris* vectors with another selection system (HIS
30 dependency) as a backup to the zeocin resistance system.

Expression of wild type hPSM in mammalian cells

An expression system using CHO (chinese hamster ovary) cells will also be implemented for the final testing and production of selected molecules.

CHO strains have been obtained from American Type Culture
5 Collection (ATCC) and the hPSM0.0 gene has been subcloned into the mammalian expression vector pcDNA3.1(-). Other selected constructs (hPSM÷0.0, hPSM1.1) are currently being subcloned into pcDNA3.1(+) as well as another mammalian expression vector pZeoSV2 purchased from Invitrogen. A method to monitor
10 transient expression of wild type hPSM from pcDNA3.1(-) in COS-7 and 293 cells is also being set up at the moment in our cell laboratory under biosafety level class II.

Tissue distribution of hPSM

A commercial kit has been purchased in order to determine
15 whether hPSM expression can be detected in various human tissues including prostate, blood and brain. The method is based on a dot blot detection of polyA containing mRNA extracted from 50 different human tissues. Preliminary results do not indicate hyperexpression of hPSM in tissues such as
20 blood or brain, but the test will be repeated.

Design of the hPSM mutants

When designing the mutational work in PSM, some regions of the protein are very important to preserve in the modified constructs, for example potential and identified T cell
25 epitopes, B cell epitopes and disulfide bridge cysteine residues. Therefore, such "forbidden" regions have been identified within the PSM sequence leaving a limited number of "open" regions of 20 amino acids or more available for exchange with the foreign T helper epitopes P2 and/or P30. Per
30 definition, the transmembrane region is also considered an

"open" region since autoantibodies directed against this region are irrelevant and elimination of this sequence is believed to enhance the solubility of the mutated PSM proteins.

5 According to our expectation that the autovaccine will induce a CTL response, it would be important to identify and preserve potentially subdominant CTL epitopes in the constructs. Two such epitopes are already known from the literature: 1) the peptide comprising PSM amino acids 4-12 (LLHETDSAV) can be

10 presented on the human MHC class I molecule HLA-A2.1 (*Tjoa 1996*), and 2) the PSM(711-719) (ALFDIESKV) also binds HLA-A2.1 (*ref 25*). We have also searched the PSM amino acid sequence in order to identify primary anchor residues of HLA class I binding motifs as described by Rammensee et al. (*Rammensee,*

15 *1995*) for the most abundant HLA class I types (HLA-A1, HLA-A2, HLA-A3, HLA-A23, HLA-A24 and HLA-A28), together constituting 80 % of the HLA-A types of the human population. Likewise, potential HLA-B and HLA-C epitopes have been identified and designated as "forbidden" areas.

20 Because the initial intention was to use C57/black x SJL F1 hybrid mice in case it was decided to use transgenic mice for testing the PSM autovaccine constructs, potential mouse H-2^b and H-2^s T helper epitopes has been identified and considered "forbidden" regions (*Rammensee 1995*).

25 It is also important to preserve known antibody binding regions in the PSM molecule, because they could be important in the induction of specific anti-PSM autoantibodies. Five such regions have already been described: PSM(63-68), PSM(132-137), PSM(482-487) (WO 94/09820), PSM(716-723) and PSM(1-7)

30 (Murphy, 1996). Using the computer based method of Hopp and Woods for prediction of antigenic determinants, five regions are predicted: PSM(63-69), PSM(183-191), PSM(404-414),

PSM(479-486) and PSM(716-723) (Hopp 1983), some of these overlapping the experimentally found B cell epitopes. These regions will also be preserved in the PSM vaccine candidate molecules.

5 The PSM protein contains 4 cysteine residues (amino acid positions 22, 196, 466 and 597) which will be preserved in the immunogenized constructs because of their potential importance in the formation of disulfide bridges.

Based on the above mentioned "forbidden" and "open" regions in 10 the hPSM protein, 8 regions suitable for insertion of foreign T helper epitopes were identified:

Insertion regions in **hPSMI** (from initiation site to EcoRI site, aa 1-437):

Region 1:   aa 16-52 (4 aa preceding TM, TM (24 aa) and 9 aa
15   after TM = 37 aa)

Region 2:   aa 87-108 (22 aa)

Region 3:   aa 210-230 (21 aa)

Region 4:   aa 269-289 (21 aa)

Region 5:   aa 298-324 (27 aa)

20 Insertion regions in **hPSMII** (from EcoRI site to termination site, aa 437-750):

Region 6:   aa 442-465 (24 aa)

Region 7:   aa 488-514 (27 aa)

Region 8:   aa 598-630 (33 aa)

Region 9:   aa 643-662 (20 aa)

Region 10:   aa 672-699 (28 aa)

The insertion regions as well as the "forbidden" regions are
5 represented graphically in Fig. 4.

13 different immunogenized PSM constructs will be made by
substitution of a segment of amino acids from two of the above
listed insertion regions with P2 or P30. Each mutant protein
will thus contain both P2 and P30. Experimentally, the
10 mutations will be made in clones of hPSMI and hPSMII cDNA
respectively, and the two mutated parts will subsequently be
combined by ligation (at the EcoRI site). The P2 and P30
epitopes will be inserted into insertion regions 1, 2, 3, 5,
6, 8 and 10 in order to create the 13 mutants.

15 The sequences of P2 and P30 are:

P2: QYIKANSKFIGITEL (15 aa), encoded by the nucleotide
sequence cag tac atc aaa gct aac tcc aaa ttc atc ggt atc acc
gag ctg (45 nucleotides), where the sequence in boldface is an
*Sac*I site.

20 P30: FNNFTVSFWLRVPKVSASHLE (21 aa), encoded by the nucleotide
sequence ttc aac aac ttc acc gt**a agc t**tc tgg ctg cgt gtt ccg
aaa gtt <u>agc g**CT</u> **AGC** ca<u>c ctg g</u>aa (63 nucleotides), where
boldface indicates an *Hind*III site, single underlining
indicates an *Eco*47III site, capital letters indicates a *Bst*NI
25 site, and double underlining indicates an *Nhe*I site.

Molecular constructions of the hPSM mutants

Mutations to insert P2 and P30 encoding sequences have been performed using both hPSMI0.0 and hPSMII0.0 as starting material.

In order to generate a majority of the hPSM mutants, P2 and
5 P30 were initially inserted in hPSMI0.0 at insertion position 1. The resulting material (hPSMI1.0 and hPSMI0.1, respectively) was subsequently used as starting material for mutagenesis to insert P2 and P30 at positions 2,3 and 5 and for ligation with epitope mutated hPSMII. hPSMI1.0 was
10 constructed using SOE (single overlap extension) PCR and subsequently sequence verified. hPSMI0.1 was constructed using the "Quick Change" technique and subsequently sequence verified.

The P2 epitope was inserted into positions 2, 3 and 5 of
15 hPSMI1.0 using SOE-PCR to create hPSMI1.2, hPSMI1.3 and hPSMI1.5. These constructions were combined with hPSMII0.0 to create hPSM1.2, hPSM1.3 and hPSM1.5.

hPSMI2.1, hPSMI3.1 and hPSMI5.1 were constructed by SOE PCR using hPSMI0.1 as starting material. This material has been
20 assembled with hSPMII0.0 by ligation at the EcoRI site in order to create the full length mutants hPSM2.1, hPSM3.1 and hPSM5.1.

The P2 epitope was inserted at three different positions of hPSMII0.0 in order to create hPSMII6.0, hPSMII8.0 and
25 hPSMII10.0 using the "Quick Change" technique, and these clones were subsequently sequence verified.

Subsequently, hPSMI0.1 was ligated with hPSMII6.0, hPSMII8.0 and hPSMII10.0 to obtain hPSM6.1, hPSM8.1 and hPSM10.1, and the clones were sequence verified.

Insertion of the P30 epitope in hPSMII is presently being done
to generate hPSMII0.6, hPSMII0.8 and hPSMII0.10 using SOE PCR.

hPSM1.1 was constructed using two two-step PCR mutations
followed by ligation in a *Hind*III site within the epitope
5 sequence. The full length construct is sequence verified.

In addition to the originally contemplated 13 mutants each
containing both P2 and P30, four mutants which only contain a
single foreign epitope have been constructed and sequence
verified: hPSM1.0, hPSM8.0, hPSM10.0 and hPSM0.1.

10 A schematic overview of all the generated clones and strains
of hPSM wild type DNA and mutants is given in the following
two tables.

Cloning and mutagenesis of the human PSM divided into two parts, hPSMI and hPSMII

hPSM material	clone pUC19	clone pTrc99A	clone pET28b	clone pGEM-T	strain pET/Top10	strain pUC/DH5α	strain pTrc/DH5α	strain pET/DH5α	strain pET/BL21	strain pGEM-T/Top10
hPSMI-0.0			pMR301					MR501	MR505	
hPSMI 0.0			pMR304					MR506		
hPSMII 0.0	pMR300	pMR302	pMR303			MR500	MR502	MR503	MR504	
hPSMI 1.0										
hPSMI 1.2										
hPSMI 1.3										
hPSMI 1.5										
hPSMI 0.1			pMR313					MR515		
hPSMI 2.1			p319#12		MR326					
hPSMI 3.1			p320#8		MR327					
hPSMI 5.1			p321		MR328					
hPSMI 1.1				p349						MR562
hPSMII 6.0			pMR306#17					MR508		
hPSMII 8.0			pMR315#18					MR518		
hPSMII 10.0			pMR305#39					MR511		
hPSMII 0.6										
hPSMII 0.8										
hPSMII 0.10										

Construction of hPSM mutants by combination of mutated hPSMI and hPSMII parts

	clone pET28b	clone pMCT6	clone pGEM-T	clone pMal-p2	clone pGH433	strain pET/DH5α	strain pET/Top10	strain pET/BL21	strain pMCT6/Top10	strain pGEM-T/Top10	strain pMal-p2/Top10	strain pGH433/Top10
hPSM0.0	pMR310	p342#4		p354	p351	MR512			MR555		MR569	MR566
hPSM÷0.0	pMR312	p343#6		p355	p352	MR514			MR560		MR570	MR567
hPSM1.1	p350	p379		p408	p409		MR563	MR564	MR594		MR596	MR595
hPSM6.1	p316#2	p344#1		p356	p353		MR520	MR521	MR561		MR571	MR568
hPSM8.1	p317						MR522	MR523				
hPSM10.1	p318#2						MR524	MR525				
hPSM1.6												
hPSM1.8												
hPSM1.10												
hPSM1.2	p382						MR597	MR600				
hPSM1.3	p383						MR598	MR601				
hPSM1.5	p407						MR599	MR602				
hPSM2.1	p322						MR529	MR530				
hPSM3.1	p323						MR531	MR532				
hPSM5.1	p324						MR533	MR534				
hPSM8.0	p325						MR535	MR536				
hPSM10.0	p327						MR539	MR540				
hPSM0.1	p326						MR537	MR538				
hPSM1.0	p341#16		p348#4				MR554	MR555		MR556		
hPSM÷1.1	p444						MR684					
hPSM-6.1	p445						MR685					

99

Expression of hPSM mutants in *E. coli*

In small-scale experiments, seven hPSM mutants, hPSM1.1,
hPSM6.1, hPSM8.1, hPSM10.1, hPSM2.1, hPSM3.1 and hPSM5.1 were
expressed from pET28b in the *E. coli* strain BL21(DE3), and

5 IPTG inducible products of the expected size were identified
on Coomassie Blue stained SDS-PAGE gels. However, a product of
hPSM1.1 was not detectable. The expression levels of these
hPSM mutants were very low compared to the product of the wild
type construct hPSM÷0.0. At this point, a fair expression

10 level of the hPSM mutants using the pET system in *E. coli*
seems impossible, and the use of other *E. coli* expression
systems and/or other host organisms is thus necessary.

As mentioned above, hPSM6.1 and hPSM1.1 have been subcloned
into different *E. coli* expression vectors in order to generate

15   –   N-terminally His-tagged versions of the expressed
      recombinant proteins using vector pMCT6,
    –   versions of the proteins expressed with the pelB leader
      sequence which directs the protein to the periplasmic
      space of the *E. coli* bacteria using vector pGH433, and

20   –   versions of the recombinant proteins expressed as a C-
      terminal fusion protein to maltose binding protein (MBP)
      using vector pMal-p2.

So far, a sufficient expression level from any of these
constructs has not been obtained.

25 Since hPSM0.0÷cyt is fairly expressed in *E. coli* while a
similar expression level of full length hPSM0.0 or the hPSM
mutants has not been observed, it is possible that presence of
the cytoplasmic part of the hPSM molecule can somehow
"inhibit" the expression of the full-length hPSM constructs in

30 *E. coli*. To test this hypothesis, we made two genetic

constructs of hPSM1.1 and hPSM6.1 without cytoplasmic domains. However, in *E.coli* expression experiments there were only weak expression of these ÷cyt gene products.

Expression of hPSM mutants in *Pichia pastoris*

5 In order to express the hPSM1.1 mutant protein from the yeast *Pichia pastoris*, the hPSM1.1 sequence has been subcloned into the two different expression vectors pPICZαA and pGAPZαA, and the sequences have been verified.

Expression of hPSM mutants in mammalian cells

10 As mentioned above, hPSM1.1 is currently being subcloned into the mammalian expression vectors pcDNA3.1(+) and pZeoSV2 and these constructs could be used for expression in e.g. CHO cells.

DNA vaccination

15 DNA vaccination would, if effective, be very well suited for the PSM autovaccine – especially because this administration form has been shown to promote both CTL mediated immune reactions and antibody production. Therefore, it was the intention to perform a parallel study with the aim of
20 investigating the effect of DNA-vaccination of mice with appropriate vectors encoding immunogenized mouse ubiquitin and/or mouse TNFα. DNA vaccination with hPSM (and/or mutants) encoding naked DNA will also be done.

Feasibility study using immunogenized ubiquitin for DNA
25 vaccination

A feasibility study stating the effect of DNA vaccination with an immunogenized self protein was performed using ubiquitin

with an inserted T helper epitope from ovalbumin (UbiOVA) as a model protein. Sequences encoding UbiOVA as well as wild type ubiquitin were subcloned into the mammalian expression vector pcDNA3.1(-).

5   Groups of 5 BALB/c mice were immunized with 40 µg pcDNA-UbiOVA or pcDNA-ubiquitin construct either intramuscularly in the quadriceps or intradermally. An control control group of received UbiOVA protein in complete Freunds adjuvant. Three and six weeks later, the immunizations were repeated with the
10   only difference that the UbiOVA protein was emulsified in incomplete Freunds adjuvant.

The mice were bled regularly and the anti-ubiquitin antibody titers were determined. In the DNA vaccinated UbiOVA groups, only very weak anti-ubiquitin antibody titers were obtained.
15   Subsequently, all groups were boosted with UbiOVA protein in incomplete Freunds adjuvant and bled in order to determine whether DNA vaccination with UbiOVA (and not ubiquitin) could potentiate the antibody response towards UbiOVA protein. The results of this experiment showed that there was no
20   significant difference between the UbiOVA groups and the control groups, all mice developed strong anti-ubiquitin antibodies upon this single UbiOVA/FIA boost.

DNA vaccination using hPSM constructs

Currently, mammalian expression vectors are constructed for
25   the purpose of performing a DNA vaccination experiment using hPSM constructs. hPSM0.0, hPSM÷0.0 and hPSM1.1 are subcloned into pcDNA3.1(+) and pZeoSV2. We intend also to include leader sequences to allow secretion of the expressed hPSM proteins *in vivo*.

Purification/characterization of HIS-tagged hPSM(437-750) (HIS-PROSII0.0)

HIS-tagged wild type hPSMII (HIS-PROSII0.0) was expressed from pET28b, and solubilized inclusion bodies were applied to a gel
5 filtration FPLC column and eluded in a buffer containing 8 M urea. Fractions predominantly containing hPSMII were subjected to various refolding conditions to optimize the procedure. Solubilized product dialyzed against a Tris buffer was estimated to be more than 90 % pure using silver-stained SDS-
10 PAGE.

Rabbits were immunized with the purified HIS-PROSII0.0 in order to use the resulting antiserum for detection and possibly affinity purification of the hPSM mutants.

Purification/characterization of soluble hPSM (PROS÷0.0)

15 Wild type hPSM lacking the cytoplasmic and transmembrane parts, PROS÷0.0, has been expressed in the *E. coli* strain BL21(DE3) upon induction with IPTG and could be detected in inclusion bodies. SDS-PAGE of this bacterial lysate followed by Western blotting with mouse anti-HIS-PROSII0.0 showed a
20 product with the expected migration. N-terminal sequencing of the first five amino acids of this product eluted from an SDS-PAGE gel showed the expected sequence corresponding to human PSM. The product was subjected to a large series of solubilization and refolding experiments. A product which stay
25 in solution can be obtained in a Tris buffer without denaturant or reductant, but SDS-PAGE analysis reveals that the material probably forms large aggregates. However, it is still the intention to immunize mice and rabbits with this material in order to get antibody against hPSM e.g. for
30 analytical purposes.

Currently, we are trying to apply a refolding system based on a Ni-chelate column to the purification of a HIS-tagged version of PROS÷0.0 (HIS-PROS÷0.0).

A batch of washed *E. coli* inclusion bodies of PROS÷0.0 has
5 been prepared for immunization of rabbits to generate a polyclonal antiserum against PSM (see section 3.5.2). Approximately 50% of the protein content in the wet pelleted material contained was PROS÷0.0.

Preparation of KLH-conjugated hPSM peptides for immunization

10 Three 15-mer peptides were synthesized in order to make an immunogenic conjugate of known hPSM B cell epitopes with an immunological carrier molecule to obtain a polyclonal antiserum which is able to recognize hPSM. These peptides contain the PSM B cell epitope plus 5-6 flanking PSM amino
15 acids in each end.

The peptides were made by automatic synthesis, HPLC purified and control-sequenced using Edman degradation.

A chemically linked conjugate was prepared by cross-linking
20 the B cell epitope containing hPSM peptides KLH using a standard 1-step procedure with glutaraldehyde as the cross-linking agent.

Synthesis of P2 and P30 peptides with flanking hPSM sequences

Six peptides have been designed which correspond to the P2 and
25 P30 epitopes with 5 flanking hPSM amino acids in each end. The flanking amino acids correspond to the epitope insertion sites 6, 8 and 10. The peptides will be used in *e.g.* T cell proliferation assays, but also for other purposes such as ELISA or other *in vitro* assays. The peptide sequences are:

PSMpep007   P2 inserted in hPSM insertion position 6
                 QERGV<u>QYIKANSKFIGITEL</u>RVDCT

PSMpep008   P2 inserted in hPSM insertion position 8
                 AVVLR<u>QYIKANSKFIGITEL</u>EMKTY

5 PSMpep009   P2 inserted in hPSM insertion position 10
                 MFLER<u>QYIKANSKFIGITEL</u>HVIYA

PSMpep010   P30 inserted in hPSM insertion position 6
                 NSRLL<u>FNNFTVSFWLRVPKVSASHLE</u>VDCTP

PSMpep011   P30 inserted in hPSM insertion position 8
10   VVLRK<u>FNNFTVSFWLRVPKVSASHLE</u>SFDSL

PSMpep012   P30 inserted in hPSM insertion position 10
                 LMFLE<u>FNNFTVSFWLRVPKVSASHLE</u>PSSHN

The P2 and P30 epitopes are underlined. The peptides were made
by automatic synthesis and are currently in the process of
15 HPLC purification followed by control-sequencing using Edman
degradation.

Immunogenicity assays

Different experimental setups have been initiated in order to
produce materials and establish immunogenicity assays for the
20 future testing of and selection between the mutated PSM
constructs.

Generation of polyclonal rabbit anti-HIS-PROSII0.0 and anti-KLH-PSM-peptide conjugate antisera

Two rabbits were immunized with purified HIS-PROSII0.0, the HIS-tagged C-terminal part of the hPSM protein (amino acids 437-750) emulsified 1:1 with complete Freunds adjuvant and boosted twice (at days 28 and 55) with the same antigen
5 emulsified in incomplete Freunds adjuvant.

Two rabbits were immunized with a cocktail consisting of the KLH-PSM peptide conjugate plus each of the three free peptides. These three peptides each contain a previously defined B cell epitope of hPSM. The cocktail was emulsified
10 1:1 with complete Freunds adjuvant. The rabbits were boosted twice (at days 28 and 55) with the same antigen emulsified in incomplete Freunds adjuvant.

Cross-reactivity between anti-HIS-PROSII0.0 and PSMpep005 and cross-reactivity between anti-KLH-PSM peptide conjugate plus
15 peptides and HIS-PROSII0.0 was demonstrated in ELISA assays. The anti-HIS-PROSII0.0 antibody has the ability to recognize native hPSM in lysates of LNCaP cells in Western blotting.

Immunization of rabbits with *E. coli* inclusion bodies containing PROS÷0.0

20 Two rabbits have been immunized and boosted several times with washed *E. coli* inclusion bodies of PROS÷0.0. Sera was obtained, but they did not react with hPSM in Western blotting. These rabbits will next time be boosted with with a preparation of soluble, but aggregated PROS÷0.0 (see section
25 3.4.2) to hopefully enhance the hPSM reactivity of the antisera.

Immunization of mice with retrovirally expressed hPSM0.0

At this stage of the PSM project, a serious obstacle is still the lack of antibodies which are able to recognize correctly

folded native hPSM. Therefore, an immunization experiment using retrovirally expressed hPSM0.0 was performed.

Six groups of Balb/c mice were immunized with either: 1) mitomycin C treated BALB/c fibrosarcoma cells (79.24.H8)

5 transduced with hPSM0.0 cDNA (CMV-Koz-hPSM), 2) mitomycin C treated BALB/c fibrosarcoma cells (79.24.H8), transduced with empty vector (CMVBipep), 3) packaging cells (BOSC) transfected with hPSM0.0 cDNA (CMV-Koz-hPSM), 4) packaging cells (BOSC) transfected with empty vector (CMVBipep), 5) retrovirus stock

10 expressing hPSM0.0 cDNA (CMV-Koz-hPSM) or 6) retrovirus stock, empty vector (CMVBipep).

At several time points, the mice were bled and the sera obtained tested for reactivity in ELISA for reactivity against HIS-PROSII0.0. Unfortunately, none of the mice developed

15 antibodies able to specifically recognize the HIS-PROSII0.0 preparation.

Generation of monoclonal anti-hPSM antibodies

In order to produce a panel of monoclonal antibodies for the use in detection and analysis of mutated and wild type hPSM

20 proteins, immunization of mice has been initiated. BALB/c mice were immunized by subcutaneous injection of 100 μg purified HIS-PROSII0.0, the HIS-tagged C-terminal part of the hPSM protein (amino acids 437-750). The protein was emulsified with an equal volume of complete Freund's adjuvant for the initial

25 immunization, and with incomplete Freund's adjuvant for the two following booster injections (at days 14 and 29). The last booster injection at 3 days before the cell fusion will be performed using 5x10^6 irradiated LNCaP cells in PBS per mouse injected intraperitoneally.

However, this experiment was discontinued until a well-
characterized full-length wild type hPSM is expressed and
purified.

Generation of anti-hPSM polyclonal hybridomas

5 We are currently preparing an experiment where mice will be
immunized with a preparation of soluble, but aggregated
PROS÷0.0 in a physiological buffer plus FCA. After several
boostings, spleen cells of these mice will be fused to e.g.
X63 myeloma cells. The intention is to use antibodies secreted
10 from lines of such fused cells directly for analysis purposes
without cloning of the hybridoma cells.

Establishment of an anti-hPSM ELISA

Purified HIS-PROSII0.0 was used for coating polystyrene
microtitre plates (Maxisorp) for the purpose of establishing
15 an ELISA assay for testing e.g. hybridoma supernatants or
mouse and rabbit antisera. Sera from BALB/c mice immunized
with the same preparation of HIS-PROSII0.0 were reactive with
the immobilized HIS-PROSII0.0 at 0.5 µg per well using horse
radish peroxidase labelled rabbit anti-mouse Ig as secondary
20 antibody.

As mentioned above, the ability of an antiserum raised in
rabbits against KLH-PSMpep004-PSMpep005-PSMpep006 conjugate
mixed with the free peptides to react with immobilized HIS-
PROSII0.0 was demonstrated using this ELISA assay.

25 Using AquaBind® microtitre plates (cf. the disclosure in WO
94/03530 describing i.a. microtitre surfaces coated with
tresyl-activated dextran which are now marketed under the
registered trademark AquaBind), an ELISA using immobilized PSM
peptides (PSMpep004, PSMpep005 and PSMpep006) was established.

AquaBind® plates coated with these peptides could detect a rabbit antiserum raised against the same preparation of antigen. As mentioned above, rabbit anti-HIS-PROSII0.0 could be detected on AquaBind® plates coated with PSMpep005.

Establishment of an anti-hPSM Western blot using LNCaP cells and monoclonal antibody 7E11C5

7E11C5 B cell hybridomas which secrete mouse IgG2a monoclonal antibody against an intracellular epitope of human PSM was purchased from ATCC. Culture supernatant from approximately 90 % dead cells was collected and used in Western blotting for detection of human PSM in both membrane enriched preparations of LNCaP cells as well as in LNCaP cell lysates. This antibody was purified using protein G columns, and its reactivity with LNCaP in Western blotting verified.

Establishment of a FACS method to detect hPSM on LNCaP cells

We are currently working on establishing a FACS method to detect hPSM on LNCaP cells. Several problems are being addressed: The LNCaP cells grow very slow and in irregular clumps, and therefore the method to prepare single cell suspensions should be optimized. Secondly, the epitope recognized by the mAb 7E11C5 is in the literature defined to be in the cytoplasmic domain of hPSM. Therefore, the method to fix and permeabilize the cells is being developed. For this purpose, protein G purified 7E11C5 antibody has been FITC conjugated and can thus be used without secondary antibody in FACS analysis.

Generation of mouse CTL target cells expressing mTNFα or FGF8b

Since it will probably take some time until mouse PSM mutants are available, it has been decided to perform a parallel study

with the aim of establishing a conceptual proof that an autovaccine constructed by M&E´s patented technology is able to induce a CTL response in the recipient. Immunogenized mouse FGF8b and TNFα molecules will be used as model autovaccines,

5   and CTLs will be isolated from mice immunized with these molecules and tested for their ability to lyse MHC class I positive target cells which express FGF8b/TNFα.

Current work being performed in this study includes the subcloning of murine wild type FGF8b and TNFα cDNA sequences

10 into retroviral vectors. These vectors will be used for intracellular expression of these molecules in target cells which are necessary tools for the detection of FGF8b and TNFα specific CTLs. Murine TNFα cDNA has been cloned into the retroviral vector CMVBipep using BamHI-NcoI adaptors encoding

15 a Kozak sequence. Transductions of CTL target cells P815 (H-2^d) and EL-4 (H-2^b) have been performed using the TNFα vector, and the presence of the retroviral constructs in the transduced cell lines has been verified by PCR analysis on genomic DNA. However, the expressed TNFα gene products has not been

20 detected yet. In parallel, the same target cell lines have been transfected with pcDNA3.1(-) constructs encoding mTNFα cDNA, and geneticin resistant transfectants are currently being cloned.

Establishing a cytotoxicity assay

25 A method to purify dendritic cells from mouse bone marrow has been implemented. Using model proteins, immunization of mice with dendritic cells pulsed with model class I peptides and protein has been optimized. Also, mice have been immunized with a model protein (β-galactosidase) formulated in the form

30 of ISCOMS. T-cells purified from immunized mice have been *in vitro* restimulated with different forms of the corresponding antigens. The ability of these restimulated CTLs to lyse

different kinds of target cells (including pulsed dendritic
cells as well as transfectants expressing retrovirally
expressed cytosolic class I peptide) was subsequently
measured. Two different *in vitro* assays measuring CTL activity

5 have been established, using either chromium release or and
DNA fragmentation (JAM method) as measures of cytotoxicity.
Very nice results were obtained with the β-galactosidase model
protein and with various combinations of MHC class I and class
II binding model peptides.

10 The conditions for this setup are currently being further
optimized, and subsequently a CTL assay using AutoVac™
antigens could be established.

CTL responses raised in mice using AutoVac™ molecules

Preliminary assays have been set up using mouse TNFα AutoVac™

15 mutants formulated in ICOMS as immunization material, but it
was decided to further optimize the procedures with model
antigens before proceeding to the use of AutoVac™ molecules
for immunization.

***in vivo* PSM tumor models**

20 **Mouse T cell proliferation assays with P2 and P30**

A series of T cell proliferation experiments has been
initiated in order to establish the T cell immunogenicity of
P2 and P30 peptides in various mouse strains (BALB/cA (H-2^d),
C3H/Hen (H-2^k), DBA/1 (H-2^q) and C57BL/6 (H-2^b)). It is well

25 known that these epitopes are promiscuous in humans, but the T
cell promiscuity also needed to be confirmed in mice using
M&Es experimental setup. It was thus shown that P30 is T cell
immunogenic in the BALB/cA and C57BL/6 strains whereas neither

P2 or P30 were shown to be T cell immunogenic in the C3H/Hen strain. In DBA/1, T cells could be raised against P2.

Generation of hPSM expressing mouse tumor cells

For the use of a hPSM specific tumor model in mice as well as
5 for the use in tumor cell proliferative assays, a panel of hPSM expressing mouse tumor cells are being established. The intention was to generate these cell lines by transducing the mouse tumor cell lines with retroviral vectors encoding the full-length wild type hPSM0.0 cDNA.

10 Three different constructs encoding full length wild type cDNA encoding human PSM inserted into the polycloning site of the retroviral vector CMVBipep was constructed, two of these containing a short Kozak sequence upstream of the start codon.

These constructs were transduced into three different mouse
15 tumor cell lines: P815 (mastocytoma, $H-2^d$), B16-F10 (melanoma, $H-2^b$) and 79.24.H8 (fibrosarcoma, $H-2^d$) using the BOSC packaging cell line. Geneticin resistant clones have been obtained for all three cell types, and it was verified in PCR analysis on genomic DNA template that the retroviral
20 constructs were integrated in the host cells. Unfortunately, it has not been possible to detect an expressed PSM gene product in Western blot or FACS analysis using the 7E11C5 monoclonal antibody.

As an alternative to retroviral transduction, traditional
25 stable transfections of the same mouse tumor cell lines was performed using hPSM0.0 cDNA subcloned in the mammalian expression vector pcDNA3.1($\div$) under the control of the CMV promoter. Geneticin resistant transfectants were cloned, and currently, a large panel of clones are being tested in Western
30 blot for reactivity with the 7E11C5 monoclonal antibody.

Establishment of a hPSM specific tumor model in mice

It has been decided to establish at least two *in vivo* tumor
models in immune competent mice in order to determine the
anti-tumor effect of antibodies raised in mice against the
5 immunogenized hPSM molecules. This will hopefully be done by
injecting syngeneic mouse tumor cell lines modified to express
wild type hPSM on the surface membrane. Cells which form solid
tumors and cells which are known to metastasize will be used.
Cell lines which can be implanted in syngeneic mice without
10 being rejected due to the presence of the foreign hPSM
molecule will be used in the model. The ability of the hPSM
vaccines to eliminate such tumor cells will be used for the
selection of the hPSM vaccine candidates.

In parallel with the establishment of hPSM expressing cell
15 lines, two different cancer models in mice are currently being
established using non-transfected mouse tumor cells.
Eventually, the experiences gained from these experiments can
be used when performing the ultimate experiments with mouse
tumor cell lines transfected to express human PSM.

20 In one series of experiments, the metastasis model, different
doses of B16-F10 (H-2^b) melanoma cells were injected
intraveneously in the tail veins of groups of C57Bl/6 (H-2^b)
mice. At different time points, 50% of the mice in each group
were sacrificed, the lungs were dissected and weighed, and
25 metastases were counted under a dissection microscope. Using
these parameters, the metastasis progression was quantified
and compared for the two groups, and the result was used for
optimizing the number of injected cells to a treatable dose.

In the initial experiments of the solid tumor model, different
30 doses of P815 (H-2^d) mastocytoma cells were injected
subcutaneously at the lower right flank of groups of metofane-

anaestesized DBA/2 (H-2^d) mice. The sizes of the established
tumors were measured with a caliber measuring two different
diameters which were multiplied to give the tumor size in mm^2.
These values were compared for the two groups.

5 Next step will be to optimize the dosage of tumor cells and
investigate more tumor models, e.g. the Sa1N model in the
congenic A/j mouse strain.

Conclusions

In the molecular construction work we have succeeded in
10 cloning of the human PSM gene and cloning of the mouse PSM
cDNA is proceeding, although at a slower pace. Fourteen fully
sequenced immunogenized hPSM constructs have been constructed.
The finished hPSM mutants as well as different wild type hPSM
molecules have been expressed in *E. coli*, and it was found and
15 verified that the expression level in *E. coli* is very low.
Polyclonal antibodies against the C-terminal half of hPSM have
been induced in rabbits. Efforts are being made in order to
implement different expression tags (His-tag and maltose
binding protein fusion) as well as expression systems
20 alternative to *E. coli* inclusion bodies (*E. coli* periplasmic
space, *Pichia pastoris* and CHO cells). The purification,
refolding and characterization procedures for the *E. coli*
expressed recombinant wild type molecule is ongoing. Useful
considerations regarding the DNA vaccine technology have been
25 made, and a preliminary feasibility study was performed. The
establishment of several *in vitro* assays which will be used
for testing of and selection between the mutated PSM
constructs is ongoing, including immunochemical assays and
FACS analysis. The establishment of *in vivo* solid tumor and
30 metastasis models in mice using hPSM bearing syngeneic mouse
tumor cells has been initiated and cell lines for this purpose
are currently being established. An array of T cell

proliferation assays have been performed in order to select the mouse strains for the tumour models. CTL assays are being optimized, and nice results with model antigens have been obtained using different immunization methods and assay
5 conditions. Furthermore, target cells for use in the conceptual study to demonstrate CTL induction by autovaccines are being established.

EXAMPLE 2

Production of a Her-2 autovaccine

10 A human autovaccine against Her-2 can be developed through modification of the molecule by insertion of one or more promiscuous foreign T cell epitopes to reveal a panel of immunogenised Her-2 molecules. These modified proteins will be tested for their ability to induce antibodies which are cross-
15 reactive with the native parts of the Her-2 molecule. Subsequently, in several *in vitro* assays and *in vivo* animal models, the efficacy of the different constructs (as may be the case with the DNA vaccinnation) and modified proteins will be evaluated. The induction of specific CTL responses against
20 Her-2 bearing tumour cells will be analysed. Also, the induced antibodies will be tested for their ability to activate complement via the classical pathway and to initiate ADCC via Fc-receptors. Finally, the different modified molecules will be tested in animal models of human breast cancer to examine
25 their effects on the treatment of tumours.

Immunogenic rat and human molecules will be constructed with promiscuous T-cell epitopes at different positions in the molecule.

During vaccination against the entire extracellular domain of
Her-2 there is a possibility of some degree of cross reaction
of the antibodies with other EGFr receptors since some of
these receptors are homologous by up to 40-46% in the

5 extracellular domains. Therefore it is planned that the
conserved regions of Her-2 would be disrupted by inserting
foreign T cell epitopes at least in some of the modified
proteins (see below for details).

Regions of Her-2 that may potentially be CTL or B-cell

10 epitopes are avoided in designing of constructs are seen in
Fig. 3. The rationale for using these positions is as follows:

The human Her-2 sequence can be divided into a number of
domains based solely on the primary structure of the protein.

Extracellular (receptor) part:

15 1-173:   Domain I (N-terminal domain of mature polypeptide).

174-323:   Domain II (Cysteine rich domain, 24 cysteine
              residues).

324-483: Domain III (ligand binding domain i the homologous

20   EGF receptor).

484-623: Domain IV (Cysteine rich domain, 20 cysteine
              residues).

624-654:   Transmembrane domain (TM resudues from 654 - 675).

Intracellular (kinase) part:

25 655-1010:   Tyrosine kinase domain (core TK domain from 725 -
              992).

1011-1235: C-terminal domain.

Selection of sites in the amino acid sequence of HER2 to be displaced by either the P2 or P30 human T helper epitopes has been done considering the following parameters (loosely

5 prioritised):

1. Known and predicted CTL epitopes
2. Homology to related receptors (EGFR in particular)
3. Conservation of cysteine residues
4. Predicted loop, α-helix and β-sheet structures

10 5. Potential N-glycosylation sites
6. Prediction of exposed and buried amino acid residues
7. Domain organisation

The CTL epitopes appear to be clustered in domain I, domain III, the TM domain and in two or three "hot spots" in the TK

15 domain. According to the invention, these should be largely conserved.

Regions with a high degree of homology with other receptors are likely to be structurally important for the "overall" tertiary structure of Her-2, and hence for antibody

20 recognition, whereas regions with low homology possibly can be exchanged with only local alterations of the structure as the consequence.

Cysteine residues are often involved in intramolecular disulphide bridge formation and are thus crucial for the

25 tertiary structure and should preferably not be changed.

Regions predicted to form α-helix or β-sheet structures should preferably be avoided as insertion points of foreign epitopes, as these regions are probably important for the folding of the protein.

Potential N-glycosylation sites should preferably also be conserved because mannosylation of the protein (for example by expression in yeast) is desired, cf. the presence of mannose receptors on APCs.

5   Regions predicted (by their hydrophobic properties) to be interior in the molecule preferably should be conserved as these could be involved in the folding. In contrast, solvent exposed regions could serve as candidate positions for insertion of the model T_H epitopes P2 and P30.

10 Finally, the domain organisation of the protein has also been taken into consideration because of its relevance for protein structure and function.

The focus of the strategy has been to conserve the structure of the extracellular part of Her-2 as much as possible,
15 because this is the part of the protein which is relevant as target for neutralising antibodies. By contrast, the intracellular part of native membrane bound Her-2 on the surface of cancer cells is inaccessible for the humoral immune system.

20 Hence, only the presence of CTL epitopes gives reason to include this part in a vaccine. It is therefore obvious to place one or more epitopes here. If it turns out that it is impossible to express the full length Her-22 molecule in *E. coli* or in yeast, the intracellular part could be truncated
25 after the first CTL epitope "hot spot" (around position 800). Additional CTL epitopes can hereafter be added to the C-terminal end of the truncated molecule.

The transmembrane region probably is an independent folding unit and substitution of this with T_H epitopes such as P2 or
30 P30 will probably not affect the HER2 structure and folding.

In addition, the TM domain might cause great problems for the expression in yeast and coli and should in any case be susbstituted. Thus, an epitope should preferably be placed in this domain in all constructions (perhaps leaving it intact in
5 1 construction as it contains several CTL epitopes and because it is somehow involved in transmission of signals upon ligand binding).

The extracellular domain could principally be kept intact by placing P2 and P30 in the intracellular and transmembrane
10 domains, thereby maximising the number of potential B-cell epitopes and interfering as little as possible with the structure. However, the high degree of homology to EGFR and Her-3 and Her-4 make a risk for cross reactivity to these receptors which may (or may not) be undesirable. In addition,
15 some monoclonal antibodies have been described which function as agonists for the receptor (perhaps by stimulating heterodimerisation or ligand binding) and increase tumour size, *in vivo*. Positions in the extracellular domain have therefore been selected which thereby hopefully will reduce
20 these risks.

This selection has involved all of the before mentioned parameters and has been based on two different assumptions: (i) Insertion in non-conserved (with respect to related receptors) regions will help to maintain the tertiary
25 structure and might reduce unwanted activation by antibodies. (ii) Insertion in the well conserved regions can alter the structure, but might at the same time reduce the risk of cross reactivity by destroying the most related sequences. Both assumptions are speculative, but as it is very difficult to
30 predict the effect of placing an epitope in any position of the protein some of these positions have been included in the constructions.

It has been speculated that it could be an advantage to remove the two cysteine rich domains completely. These are predicted to form solvent exposed loop structures and could form independent folding units perhaps involved in dimerisation (as

5 indicated by the many cysteines that could serve to keep a rigid structure necessary to form a dimerisation domain). Deleting these structures might therefore eliminate the risk of activation by antibodies as well as reduce the number of cross reacting antibodies as these domains are the most well

10 conserved of the extracellular part of the protein. In addition, such cysteine risch domains could be problematic to produce in *E. coli* or yeast cells.

The details of constructs are as follows using the P2 and P30 epitopes as non-limiting examples: the P2 epitope will be

15 placed in the extracellular domain of Her-2 in combination with the P30 epitope substituting part of or all of the membrane spanning region. The P2 epitope will be placed in the 9 region based on the criteria discussed above. The 9 highest and the 5 low priority contstructs are listed below. Also see

20 figure 3 for a diagramatic representation of the construct with highest priorities.

The highest priority Her-2 constructs are:
Her-2 (P2 in positions 61-75), Her-2 (P2 at 105-119), Her-2 (P2 at 151-165), Her-2 (P2 at 212-226), Her-2 (P2 at 252-266),

25 Her-2 (P2 at 327-341), Her-2 (P2 at 371-385), Her-2 (P2 at 467-481), and Her-2 (P2 at 581-595).

The lower priority Her-2 constructs are:
Her-2 (P2 at 72-86), Her-2 (P2 at 146-160), Her-2 (P2 at 221-235), Her-2 (P2 at 257-271), and Her-2 (P2 at 387-401).

30 Below are described the models that are intended for use in the screening and selection of modified Her-2 proteins.

1. Induction of antibodies in transgenic rat Her-2 mice and in rabbits to rat and human Her-2, respectively, will be investigated by conventional ELISA technology after at least three immunisations. Commercially available
5   antibodies to human and rat Her-2 will be used as positive controls.

2. These rabbit antibodies will be used to study the putative inhibition of growth of human and transgenic mouse tumour cells overexpressing Her-2 in an *in vitro* model.

10 3. T cell proliferation of PBL from tetanus immunised patients towards selected human Her-2 molecules will be investigated by conventional methods.

4. The ability of modified rat Her-2 molecules to induce CTL responses in rat Her-2 transgenic mice will be studied
15 using tumours from these mice as targets.

5. It is intended to synthesise a selected set of peptides in the transmembrane region of human Her-2 encompassing P2 and P30 epitopes. These peptides will be tested in proliferation of PBL from humans previously immunized with
20 tetenus toxoid to determine whether P2 and P30 epitopes could be efficiently processed out from within the Her-2 sequences and presented to T cells.

6. It is quite possible that selected human modified Her-2 proteins will be tested to generate neutralising
25 antibodies in a mouse that has been genetically constructed to only expresses human VDJ genes. Such a mouse is available from Abgenix, Fremont, CA, U.S.A. as a collaboration.

122

Four well-characterised transgenic mouse models for breast
cancer that contains rat Her-2 oncogene have been described.
The first three transgenic mice express activated Her-2
oncogene while the fourth model utilises inactivated Her-2.
5 All models utilise an MMTV promoter to drive expression in
mammary glands.

We have decided to use two transgenic mice models: 1) a more
aggressive tumour model described by Muller et al using
activated Her-2 oncogene (*Muller et al, 1989*) and 2) a less
10 aggressive tumour model in which inactivated Her-2 is used to
create focal mammary tumours with long latency (*Guy et al,
1992*). Both transgenic mice are purchased from Jackson and/or
Charles Rivers Laboratories.

In the initial experiments, these mice are allowed to produce
15 antibodies and CTL responses by immunising and boosting with
modified rat Her-2 proteins. Incidence of tumours will then be
investigated as described by others (*Muller et al, 1989; Guy
et al, 1992;* Katsumata et al, 1995). Antibody levels will be
measured by an ELISA assay. The CTL activity would be
20 determined by generating target cells expressing rat Her-2 as
mentioned above.

Alternatively, the nude mouse xenograft carcinoma model can be
used for passive vaccination experiments. Nude mice can be
transplanted with human tumours and inhibition of tumours
25 could be attempted with passive transfer of serum from normal
or humanised mice immunised with modified Her-2 proteins.
While this would be useful for studying the role of antibody
in suppressing tumours, CTL activity cannot be directly
measured in this system.

30 In the second *in vivo* model, tumours in mice would also be
generated by transplanting cells lines from tumours of

transgenic mice described above. Cell lines generated from these mice would be transferred into relevant mouse strain and localisation established using standard protocols.

Transfer of mouse tumours cells over expressing rat Her-2:
5 In this system, cells will be transfected with rat genes and transferred into MHC compatible mice. Inhibition of tumour growth would be achieved by generating anti-Her-2 responses.

In these systems; modified Her-2 proteins would be used as vaccine in adjuvants to generate antibodies and CTL responses.

10 DNA vaccination has been used successfully in several systems to mount an effective immune response. We are currently investigating means of DNA delivery using modified self proteins. It is our intention to utilise DNA vaccination approach to determine effects of modified Her-2 constructs in
15 inhibiting tumours in transgenic mouse models of breast cancer. Similar approach can than possibly be applied in humans for the treatment of this disease.

EXAMPLE 3

Production of an anti-FGF8b vaccine

20 In the following it will be described how a human autovaccine against FGF8b can be developed through modification of the molecule by insertion of one or more promiscuous foreign T cell epitopes to reveal a panel of immunogenized "FGF8b" molecules. The constructs will be tested for their ability to
25 induce antibodies that are cross-reactive with the authentic parts of the FGF8b molecule. Subsequently, in several in vitro assays and in vivo animal models the efficacy of the different constructs will be evaluated. The induced antibodies will be

tested for their ability to activate complement via the classical pathway and to initiate ADCC via Fc-receptors. Finally, the different molecules will be tested in animal models of human prostate and breast cancers.

5 Construction of an autovaccine against FGF8b

Due to the complete identity of the murine and human FGF8b polypeptides, all constructs can be used for experiments in both humans and mice.

The promiscuous tetanus toxin T helper cell epitopes P2 and
10 P30 used with success in the human TNFα vaccine will be inserted into the FGF8b polypeptide. Due to the small size of FGF8b, constructs will be made with one epitope per molecule. Other promiscuous T helper cell epitopes such as the influenza haemagglutinin epitope HA(307-319) and other T-cell epitopes
15 discussed herein could also be considered (O'Sullivan 1991).

4 different immunogenized FGF8b constructs will be made, with the epitopes distributed along the molecule. These four constructs are made on the basis of the multiple and pairwise alignments shown in Figure 2. The pairwise alignment of FGF2
20 and FGF8b (Figure 2) is used as basis for an analysis of the presumed secondary structure (i.e. beta-sheet distribution) along the FGF8b molecule. As seen from Figure 4, the residues that are conserved between FGF2 and FGF8b does not cluster anywhere on the three-dimensional structure, which indicates
25 that there are no particular regions of the molecule that cannot be replaced without having deleterious effects on the folding capabilities. The amino acid residues in FGF2 that align to the cysteine residues in FGF8b are positioned very close to each other three-dimensionally (not shown),
30 indicating that they form a disulfide bond in FGF8b. The

flexibility of the N-terminal part of FGF2 was also considered.

The variant of FGF8b with the P30 epitope in the N-terminal (F30N) was designed on the basis of no-gap alignments of the
5 amino acid residues of the FGF8b protein and the P30 epitope (FNNFTVSFWLRVPKVSASHLE), and scoring the different positions with regard to chemical properties of every amino acid residue. Only the region N-terminally of the predicted beta-barrel structure was considered. In the case of F30N,
10 there are 9 similar out of 21 residues. Using this pseudo-algorithm, the substitutions would be expected to result in minimal overall structural changes. The sequences of the four different constructs, as well as three-dimensional representations of the replaced amino acids are shown in
15 Figure 6.

The variant of FGF8b with the P2 epitope (QYIKANSKFIGITEL) in the C-terminal (F2C) was initially designed as F30N. There is, however, predicted a good Kd epitope at positions 195-203. Therefore, the P2 epitope is inserted just C-terminal of this
20 epitope. Again, only the region C-terminal of the predicted beta-barrel was considered.

The internal variants of FGF8b (F30I and F2I) were constructed by replacing external loops in the FGF2 structure with the epitopes P2 and P30, respectively, whereby the beta-barrel
25 structural backbone of the FGF structure presumably will remain unchanged.

The immunogenized FGF8b molecules will be expressed in *Eschericia coli*, which facilitates large scale production of the proteins at minimal costs. Appropriate expression vectors
30 will be obtained commercially. Although, FGF8b contains two potential N-glycosylation sites (Asn31 and Asn177),

bacterially expressed recombinant FGF8b has been shown to be biologically active (MacArthur 1995a, Blunt 1997). In order to facilitate purification and refolding, the FGF8b variants will be produced in a His-tagged version, thereby rendering

5 coupling to a Ni-charged column possible (REFERENCE...)

Purification of the molecules will be performed utilizing the high positive charge of the protein molecules or the His-tag, and refolding will be performed using standard procedures taking the formation of the disulfide bridge into account.

10 **Screening and selection of the modified FGF8b molecules**

The four immunogenized FGF8b molecules will be expressed in bacteria and subsequently purified from total cell-lysates or purified inclusion bodies. The different constructs will then be compared for their ability to induce various effects, which

15 are desired in the treatment of prostate and breast cancer patients. Such investigations will be performed using several different *in vitro* and *in vivo* assays. Finally, the results of the experiments will form the basis for the ultimate selection of one or two candidates for a FGF8b vaccine in humans.

20 *in vitro* **models**

Analyses in the murine system

Mice of different haplotypes as well as rabbits will be immunized with the different FGF8b constructs in Complete Freund's Adjuvant and subsequently boosted at least twice with

25 the same antigens emulsified in Incomplete Freunds Adjuvant. Thus, the ability of the different constructs to break B-cell tolerance can be compared.

Serum samples will be obtained at several time points during the immunization schedule, and the ability of the different constructs to induce FGF8b specific antibodies will be determined using a conventional ELISA method (Rochon 1994). A

5 commercial polyclonal antiserum raised against FGF8b (R&D) would be used for positive controls. One monoclonal antibody is described in the literature (Tanaka 1998). Unfortunately, this antibody is not commercially available. The FGF8b protein is commercially available (R&D) but will also be produced

10 along with the other FGF8b constructs and subsequently purified/refolded. This product can then be used for coating of plates in a direct ELISA for testing the sera from mice/rabbits immunized with FGF8b variant proteins.

A valuable tool for investigating the effects of vaccinating

15 against FGF8b will be a FGF8b dependent cancer cell line. Several FGF8b positive cancer cell lines, e.g. MCF-7 or SC-3, are described in the literature. The dependency on FGF8b will be tested in cell proliferation assays using antiserum raised against FGF8b mutants.

20 The presence of FGF8b ligated to a FGF receptor on the cell surface will be detected with FGF8b specific antibodies in FACS or ELISA analysis. Antibodies directed against several of the different FGF receptors are commercially available (R&D).

The constructs will be compared with respect to their ability

25 to induce antibodies capable of activating complement lysis of FGF8b producing / bearing cells. This can be detected with one of the mouse tumor cell lines expressing FGF8b described earlier. Sera from normal or transgenic mice (see below) immunized with the human FGF8b constructs will be incubated

30 with the cell line and subsequently incubated with fresh guinea pig complement. Antibody mediated complement lysis of the cells can be detected by standard procedures.

The ability of the induced antibodies to mediate ADCC can be studied by measuring the 51Cr-release from labeled FGF8b expressing cells. The effector cells will be PBMC from syngeneic mice. For establishing the assay, it may be

5 convenient to use a mouse cell line capable of mediating ADCC (positive for Fc(-receptors) as effector cell with an antibody against human FGF8b.

In order to show that the FGF8b candidate vaccines do not somehow promote autoantibody induced tumor growth we will also

10 perform a tumor proliferation assay. Serum samples from immunized mice will be incubated with FGF8b expressing tumor cells. Proliferation of the tumor cells can then be detected by their ability to incorporate 3H-thymidine, which subsequently is added to the cells.

15 Since FGF8b is known to induce proliferation of a range of mammalian cells, it will also be necessary to examine the growth promoting effects of the variant proteins. This can be done using cell proliferation assays as the one used by Marsh 1998.

20 The biological effect of FGF8b on mammalian cells should be neutralized by the autoantibodies. This can be demonstrated by using recombinant FGF8b and e.g. NIH3T3 in cell proliferation (and morphology changes) studies. Addition of the autoantibodies should abolish the transforming activity of

25 FGF8b.

Immunization protocol

The number of animals that are to enter a FGF8b AutoVac immunization experiment must depend on the expected penetrance of the disease in the model, and thus, the numbers needed to

30 obtain statistically significant information. The immunization

protocol must be based on the experience we have from the TNFa
AutoVac project. Various immunization protocols have been used
for immunizing mice with the various TNFa analogs for specific
purposes, but most experiments were performed using the
5 following protocol:

1. The mice should be individually marked either by earmarks
or with transponders, 10 animals in each cage. Presumably,
males and females must be evaluated separately, but in any
case, we will not have both sexes in the same cage. The
10 animals should be left to rest at least 3 days after transport
and marking.

2. Antigen 1 mg/ml in PBS buffer was emulsified with an equal
volume Freunds complete antigen (CFA) (Difco or Sigma). The
emulsion is checked by placing a drop of the emulsion on a
15 water surface and it is observed whether the drop holds
together or disperses. Mixing is maintained until the drop
does not disperse.

3. The standard immunization dose is 100µg antigen in a 100µl
volume + 100 µl of adjuvant. Thus, the total immunization
20 volume is 200µl, administered s.c. (sub cutaneously) over the
back of the animal.

4. Boostings are performed 2-3 weeks after the primary
immunization, and subsequently at 2-3 week intervals. The
boosting/immunization material is prepared and administered
25 exactly as the immunization material, but Freunds incomplete
adjuvant is used. Probably three boosts will induce the
maximal titer. Thus, the highest titers will be obtained 6-9
weeks after the first immunization.

5. Bleedings are orbital bleeds of 50-100 µl usually taken
30 before the first immunization and one week after each

boosting. Tail bleeds can also be used, and 10-20 µl can be sufficient for titre determinations.

The initiation point of the immunization program will depend on the development of the disease, and the strategy we want to
5 adopt. Initially, we suggest that it is attempted to generate the maximal immunity as soon as possible, but it is difficult to start immunizations sooner than at approx. 5 weeks of age. Hereafter, high titres should be maintained by boosting at 6-8 week intervals, after the three initial boosts. There is a
10 potential problem if the FGF8b is necessary for the normal development of the young mouse, and therefore one could argue in favor of starting the immunizations later in the adult mouse.

Analyses in the human system

15 In the selection between the different FGF8b constructs the ability of human antigen presenting cells to present the inserted immunogenic T cell epitopes to human T cells will be investigated. ..nis will be done by using the same *in vitro* processing assays for P2 and P30 presentation that were used
20 for the TNFa vaccine. Human T cell lines, which are specific for P2 and P30, will be established from donors vaccinated against tetanus. Antigen presenting cells (PBMCs) from the same donors will be incubated with the different constructs and T cell lines will be added. The level of presentation of
25 the inserted T cell epitopes can then be compared by measuring the stimulation of the T cell lines.

***in vivo* animal models**

At least two different systems will be used to monitor whether the induced FGF8b antibodies are capable of controlling a
30 FGF8b dependent *in vivo* effect.

The mouse xenograft carcinoma model will be used for passive
vaccination experiments. Nude mice will be transplanted with
human tumors, and inhibition of tumors would be attempted with
transfer of serum from normal or humanized mice immunized with
5 modified FGF8b proteins. This would be very useful for
studying the ability of the raised antibodies to suppress
tumors.

The other approach to achieve proof of concept will involve
the use of mice transgenic for FGF8b. These mice, that are
10 carrying the FGF8b cDNA under control of the very specific
mouse mammary tumor virus (MMTV) promoter, are shown to
spontaneously develop FGF8b expressing mammary tumors (Coombes
personal communication). Autovaccination of these mice with
the FGF8b variant proteins would enable us to show if the
15 autovaccine will enable the mice to suppress or reject the
tumors.

A third possible approach to obtain proof of concept would be
to use the Wnt-1 transgenic mice (MacArthur 1995c). Induction
of breast cancers by MMTV virus is reported to activate FGF8
20 expression in more than half of the mice developing tumors.
FGF8b-dependency of the tumors, could be established if our
autovaccine(s) could suppress the incidence or growth rate of
the tumors.

The fact that transgenic mice often show non-physiological
25 immunological tolerance patterns will most likely not affect
this project since the FGF8b polypeptides are identical for
human and mouse.

When, and if, a beneficial effect of the induced polyclonal
FGF8b antibodies eventually has been demonstrated in the mouse
30 model and suitable human vaccine candidates have been selected
it will be possible to perfom a limited number of toxicology

studies. Subsequently, to obtain a final proof of concept, vaccine studies on breast, and prostate cancer patients can be carried out.

Molecular construction work

5   Four human/murine FGF8b mutants will be constructed.

Mutant construction

A. Construction of the 4 mutant cDNA's (two P2 and two P30) into a bacterial expression vector.

B. Construction of the wild type FGF8b cDNA into a

10   bacterial expression vector

Protein purification

The FGF8b variant proteins will be expressed and purified from E. coli.

Protein purification, refolding, and characterization.

15   This will be continuous work throughout the project starting as soon as the first genetic constructions are made.

in vitro assays

20   A number of relevant *in vitro* assays will be established for the screening and selection procedure.

ELISA assays

A. Establishment of ELISAs for FGF8b antibodies, both commercial antibodies and autovaccine-generated

25   antibodies. Prove that FGF8b mutant molecules can induce antibody generation.

Cellular assays

A. Establishment of a neutralizing effect of the biological effect of recombinant FGF8b, mediated by

30   the autoantibodies using e.g. NIH3T3 cells.

B. Identification of human breast and prostate cancer cell lines that produce, and are dependent on FGF8b, using antibodies and cell proliferation assays.

C. Inhibition of growth of at least one of these FGF8b dependent cell lines by autovac-cine-generated antibodies, using cell proliferation assays.

D. Development of T cell epitope presentation assays,
5   PBMC T cell assays towards the modified FGF8b antigens and peptides containing the T cell epitopes + flanking regions.

in vivo assays

Suppression or elimination of FGF8b dependent tumors in
10   FGF8 transgenic mice.

Suppression or elimination of FGF8b dependent tumors transplanted into nude mice using autoantibodies.

Critical decision points

Selection of an FGF8b mutant that can induce
15   autoantibodies.

The ability of these autoantibodies to neutralize the biological effect of FGF8b.

Identification of a significant percentage of breast and or prostate tumors that produce and are dependent on
20   FGF8b.

The ability of the autoantibodies to suppress or eliminate FGF8b dependent tumors in FGF8b transgenic mice.

The ability of the autoantibodies to suppress or eliminate FGF8b dependent tumors in nude mice.

25 If the experiments using *in vivo* models have positive outcome, more mutants will be constructed based on the data available.

LIST OF REFERENCES

Ago H *et al.* (1991). J Biochem (Tokyo), 110, 360-3.

Abdel-Nabi H *et al.* (1992). Sem. Urol. 10, 45-54.

Acevedo *et al.* (1995), Cancer 76; 1467-1475.

5   Acevedo *et al.*(1997), Cancer Detect. Prev. 21; 295-303.

Adelstein S *et al.* (1991), Science 251: 1223-1225.

Babaian RJ *et al.* (1994), J. Urol 152, 1952-1955.

Barnard JA *et al.* (1995) Gastroenterol. 108(2):564-580.

Bier H *et al.* (1995), Eur. Arch. Otorhinolaryngol. 252(7):
10 433-9.

Bouchard L *et al.* (1989), Cell 57(6): 931-36.

Blaber M *et al.* (1996), Biochemistry 35, 2086-94.

Blunt AG *et al.* (1997), J Biol Chem 272, 3733-8.

Boring CC *et al.* (1993), CA Cancer J. Clin. 43:7-26.

15 Boucher *et al.* (1995), Hum. Pathol. 26; 1201-1206.

Callahan R (1996), Breast Cancer Res Treat, 39, 33-44.

Carter RE (1996), Proc. Natl. Acad. Sci. U.S.A., 93, 749-753.

Chang *et al.*, (1981), Fertil. Steril. 36; 659-663.

Chantry A, 1995, J.Biol. Chem. 270(7): 3068-73.

20 Crossley PH *et al.* (1996b), Cell, 84, 127-36.

Crossley PH *et al.* (1995), Development, 121, 439-51.

Crossley PH, Martinez, S. and Martin, G.R. (1996a) Midbrain
development induced by FGF8 in the chick embryo. Nature, 380,
66-8.

25 Dean C *et al.* (1994), Int. J. Cancer, suppl 8: 103-107.

Dillioglugil Ö *et al.* (1995), Eur. Urol. 28, 85-101.

Doi *et al.* (1996), Int. J. Cancer 65; 454-459.

Douglas TH *et al.* (1995), J. Surg. Oncol. 59(4), 246-250.

Earp HS *et al.* (1995), Breast Cancer Res. Treat. 35(1):115-32.

Eccles SA (1994), Invasion Metastasis 14 (1-6):337-48.

Eppenberger U *et al.* (1994),. J. Neurooncol. 22(3):249-54.

5 Eriksson AE *et al.* (1993), Protein. Sci. 2, 1274-84.

Fernandez-Teran M. *et al.* (1997), Dev. Biol. 189, 246-55.

Fujii K *et al.* (1995), Exp. Cell. Res. 216(1): 261-72.

Furst J *et al.* (1994), Urol. Res. 22, 107-113.

Furthauer M *et al.* (1997), Development 124: 4253-64.

10 Geissler *et al.* (1997), Lab. Invest. 76: 859-871.

Gemel J *et al.* (1996), Genomics 35: 253-7.

Ghosh AK *et al.* (1996), Cell Growth Differ 7: 1425-34.

Goldfarb M *et al.* (1996), Cytokine Growth Factor Rev 7: 311-25.

15 Goodnow CC *et al.* (1988), Nature 334: 676-682.

Goodnow CC *et al.* (1991), Nature 352: 532-536.

Greenberg NM *et al.* (1995), Proc. Natl. Acad. Sci. USA 92: 3439-3443.

Guy CT *et al.* (1992), Proc. Natl. Acad. Sci, USA 89: 10578-
20 10582.

Heikinheimo M *et al.* (1994),. Mech Dev, 48: 129-38.

Henttu P and Vihko P (1989), Bioch. Biophys. Res. Comm. 160: 903-910.

Hopp TP and Woods KR (1983), Mol. Immunol. 20: 483-9.

25 Horoszewicz JSH *et al.* (1983), Cancer Res. 43: 1803-1818.

Horoszewicz JSH *et al.* (1987), Anticancer Res. 7: 927-936.

Hoshikawa M *et al.* (1998), Biochem Biophys Res Commun 244: 187-91.

Husmann I *et al.* (1996), Cytokine Growth Factor Rev 7: 249-58.

136

Israeli RS *et al.* (1994), Cancer Res. 54: 1807-1811.

Israeli RS *et al.* (1993), Cancer Res. 53: 227-230.

Israeli RS *et al.* (1994), Cancer Res. 54: 6306-6310.

Jacoby *et al.* (1984), Adv. Immunol. 35: 157-208.

5 Johnson RL and Tabin CJ (1997), Cell 90: 979-90.

Kahn D *et al.* (1994), J. Urol. 152: 1490-1495.

Kapoun AM and Shackleford GM (1997), Oncogene 14: 2985-9.

Kettunen P and Thesleff I (1998), Dev Dyn 211: 256-68.

Koga M *et al.* (1995), J Steroid Biochem Mol Biol 54: 1-6.

10 Kouhara H *et al.*, (1994), Oncogene 9: 455-62.

Kozak M (1991), J Cell Biol 115: 887-903.

Lapthorn *et al.* (1994), Nature 369: 455-461.

Lazar *et al.* (1995), Cancer Res. 55: 3735-3738.

Leek J *et al.* (1995), British Journal of Cancer 72: 583-588.

15 Leung HY *et al.* (1996), Oncogene 12: 1833-5.

Lopes AD (1990), Cancer Res. 50: 6423-6429.

Loric S *et al.* (1995), Clin.Chem. 41(12): 1698-1704.

Lupu R *et al.* (1995), Semin. Cancer. Biol. 6: 135-145.

MacArthur CA *et al.* (1995a), Cell Growth Differ 6: 817-25.

20 MacArthur CA *et al.* (1995b), Development 121: 3603-13.

MacArthur CA *et al.* (1995c), J Virol 69: 2501-7.

Manabe *et al.* (1985), Gastroenterology 89: 1319-1325.

Marsh SK *et al.* (1998), Increased expression of fibroblast growth factor 8 in human breast cancer may result in increased 25 invasiveness rather than proliferation. Submitted.

Martin L *et al.* (1993), J. Immunol. 150(49): 1234-43.

Mattei MG *et al.* (1995), Mamm Genome 6: 196-7.

McDonnell WM and Askari FD (1996), New Engl. J. Med 334: 42-45.

Meyers EN et al. (1998), Nat Genet 18: 136-41.

Milich DR et al. (1994), J. Immunol. 153(1): 429-435.

5 Milner PG et al. (1989), Biochem Biophys Res Commun 165: 1096-103.

Miyashita Y et al. (1994), Jpn J Cancer Res 85: 1117-23.

Modjtahedi H et al. (1993a), Br. J. Cancer 67(2): 254-261.

Modjtahedi H et al. (1993b), Cell. Biophys. 22(1-3): 129-46.

10 Modjtahedi H et al. (1996), Br. J. Cancer 73(2): 228-35.

Moy FJ et al. (1996), Biochemistry, 35: 13552-13561.

Muller WJ et al. (1988), Cell 54(1): 105-115.

Murphy GP et al. (1996), Prostate 28: 266-271.

Murphy GP et al. (1995), Prostate 26: 164-168.

15 Murphy GP et al. (1995), Anticancer Research 15(4): 1473-1379.

Nguyen L et al. (1990), Clin. Chem. 35: 1450-1455.

Nonomura N et al. (1990), Cancer Res 50: 2316-21.

O'Sullivan D et al. (1991), J. Immunology 147: 2663-9.

Ohnishi Y et al. (1995), Br. J. Cancer 71(5): 969-73.

20 Ohuchi H et al. (1997a), Development 124: 2235-44.

Ohuchi H et al. (1997b), Mech Dev 62: 3-13.

Ohuchi H et al. (1994), Biochem Biophys Res Commun 204: 882-8.

Payson RA et al. (1996), Oncogene 13: 47-53.

Pillai et al. (1996), FEBS Lett. 387: 23-26.

25 Pollard M and Luckert PH (1994), Anticancer Res. 14: 901-903.

Prigent SA and Lemoine NR (1992), Progress in Growth Factor Research 4: 1-24.

R&D focus, Drug News, (1996) 5, 21, 9.

Rammensee H-G. *et al.* (1995), Immunogenetics 41: 178-228.

Regelson W (1995), Cancer 76: 1299-1301.

Ries LAG *et al.* (1996), SEER Cancer Statistics Review, 1973-1993: Tables and Graphs, National Cancer Institute,
5 Bethesda, MD.

Rinker-Schaeffer CW *et al.* (1995), Genomics, 30(1): 105-108.

Rochon YP *et al.* (1994), Prostate 25: 219-223.

Rock KL *et al.* (1996), Vaccine 14: 1560-1568.

Rock KL and Clark K (1996), J. Immunol. 156: 3721-3726.

10 Rudra-Ganguly N *et al.* (1998), Oncogene 16: 1487-92.

Salomon DS *et al.* (1995), Critical reviews in Oncology/Hematology 19: 183-232.

Sato B *et al.* (1993), J Steroid Biochem Mol Biol 47: 91-8.

Schlegel J *et al.* (1994), J. Neurooncol. 22(3): 249-54.

15 Schmitt JF *et al.* (1996), J Steroid Biochem Mol Biol 57: 173-8.

Sheaff *et al.* (1996), J. Clin. Pathol. 49: 329-332.

Sherman L *et al.* (1998), Genes Dev 12: 1058-71.

Shimamura K and Rubenstein JL (1997), Development 124:
20 2709-18.

Shirai A and Klinman DM (1993), AIDS Res. Hum. Retroviruses 9, 979-983.

Sokoloff M *et al.* (1996), Cancer 77(9): 1862-1872.

Steinhoff U *et al.* (1994), Eur. J. Immunol. 24(3): 773-76.

25 Stevens VC (1986), Ciba Found. Symp. 119: 200-225.

Su SL *et al.* (1995), Cancer Res. 55: 1441-1443.

Syrigos *et al.* (1998), Gut 42: 88-91.

Talwar *et al.* (1976), PNAS 73: 218-222.

Talwar *et al.* (1994), PNAS 91: 8532-8536.

Tanaka A *et al.* (1992), Proc Natl Acad Sci USA 89: 8928-32.

Tanaka A *et al.* (1998), Cancer Research 58: 2053-56.

Tanaka A *et al.* (1995), FEBS Lett 363: 226-30.

Thomas H *et al.* (1996), Br. J. Cancer, 73(1): 65-72.

5 Tjoa B *et al.* (1996), Prostate 28: 65-69.

Tjoa B *et al.* (1995), Prostate 27: 63-69.

Tokunaga A *et al.*, (1995), Cancer 75(6 suppl.): 1418-25.

Tosi E *et al.* (1995), Int. J. Cancer 62(5):643-50.

Triozzi *et al.* (1994), Int. J. Onc. 5: 1447-1453.

10 Troyer JK *et al.* (1995), Int. J. Cancer 62: 552-558.

Valone FH *et al.* (1995), J. Clin. Oncol. 13(9): 2281-92.

Valve E *et al.* (1997), Biochem Biophys Res Commun 232: 173-7.

van Dam PA *et al.* J. Clin. Pathol. 1994 47(10): 914-19.

Weiner LM *et al.* (1995), Cancer Res. 55(20): 4586-4593.

15 Wright GL Jr *et al.* (1996), Urology 48: 326-334.

Wu J *et al.* (1997), J Steroid Biochem Mol Biol 62: 1-10.

Wu X *et al.* , Fan, Z., Masui, H., Rosen, N., Mendelsohn, J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line
20 and its delay by insulin.

Wynant GE *et al.* (1991), Prostate 18: 229-241.

Xu X *et al.* (1998), Development 125: 753-65.

Yamanishi H *et al.* (1995), J Steroid Biochem Mol Biol 52: 49-53.

25 Yogeeswaran and Salk (1981), Science 212: 1514-1516.

Yokoyama H *et al.* (1998), Dev Biol 196: 1-10.

Yoshimura K *et al.* (1996), Cancer Lett 103: 91-7.

Yoshiura K *et al.* (1997), Am J Med Genet 72: 354-62.

Young RA and Davis RW (1983), Proc. Natl. Acad. Sci. U.S.A. 80: 1194-1198.

Yule TD (1993), J. Immunol. 151(6): 3057-3069.

Zhang JD *et al.* (1991), [published erratum appears in Proc Natl Acad Sci USA 88(12):5477], Proc Natl Acad Sci USA 88, 3446-50.

Zhu Z *et al.* (1995), Int. J. Cancer 62(3): 319-324.

Zhu X *et al.* (1991), Science 251: 90-3.

SEQUENCE LISTING

<110> M&E Biotech A/S

<120> Novel Methods For Therapeutic Vaccination

<130> AutoVaCTL DK 1

<140>
<141>

<160> 6

<170> PatentIn Ver. 2.0

<210> 1
<211> 2253
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)..(2250)

<400> 1

```
atg ggt aat ctc ctt cac gaa acc gac tcg gct gtg gcc acc gcg cgc    48
Met Gly Asn Leu Leu His Glu Thr Asp Ser Ala Val Ala Thr Ala Arg
 1               5                  10                  15

cgc ccg cgc tgg ctg tgc gct ggg gcg ctg gtg ctg gcg ggt ggc ttc    96
Arg Pro Arg Trp Leu Cys Ala Gly Ala Leu Val Leu Ala Gly Gly Phe
             20                  25                  30

ttt ctc ctc ggc ttc ctc ttc ggg tgg ttt ata aaa tcc tcc aat gaa   144
Phe Leu Leu Gly Phe Leu Phe Gly Trp Phe Ile Lys Ser Ser Asn Glu
         35                  40                  45

gct act aac att act cca aag cat aat atg aaa gca ttt ttg gat gaa   192
Ala Thr Asn Ile Thr Pro Lys His Asn Met Lys Ala Phe Leu Asp Glu
     50                  55                  60

ttg aaa gct gag aac atc aag aag ttc tta tat aat ttt aca cag ata   240
Leu Lys Ala Glu Asn Ile Lys Lys Phe Leu Tyr Asn Phe Thr Gln Ile
 65                  70                  75                  80

cca cat tta gca gga aca gaa caa aac ttt cag ctt gca aag caa att   288
Pro His Leu Ala Gly Thr Glu Gln Asn Phe Gln Leu Ala Lys Gln Ile
             85                  90                  95

caa tcc cag tgg aaa gaa ttt ggc ctg gat tct gtt gag cta gca cat   336
Gln Ser Gln Trp Lys Glu Phe Gly Leu Asp Ser Val Glu Leu Ala His
            100                 105                 110

tat gat gtc ctg ttg tcc tac cca aat aag act cat ccc aac tac atc   384
```

```
          Tyr Asp Val Leu Leu Ser Tyr Pro Asn Lys Thr His Pro Asn Tyr Ile
              115                 120             125

tca ata att aat gaa gat gga aat gag att ttc aac aca tca tta ttt      432
Ser Ile Ile Asn Glu Asp Gly Asn Glu Ile Phe Asn Thr Ser Leu Phe
    130                 135                 140

gaa cca cct cct cca gga tat gaa aat gtt tcg gat att gta cca cct      480
Glu Pro Pro Pro Pro Gly Tyr Glu Asn Val Ser Asp Ile Val Pro Pro
145                 150                 155                 160

ttc agt gct ttc tct cct caa gga atg cca gag ggc gat cta gtg tat      528
Phe Ser Ala Phe Ser Pro Gln Gly Met Pro Glu Gly Asp Leu Val Tyr
                165                 170                 175

gtt aac tat gca cga act gaa gac ttc ttt aaa ttg gaa cgg gac atg      576
Val Asn Tyr Ala Arg Thr Glu Asp Phe Phe Lys Leu Glu Arg Asp Met
            180                 185                 190

aaa atc aat tgc tct ggg aaa att gta att gcc aga tat ggg aaa gtt      624
Lys Ile Asn Cys Ser Gly Lys Ile Val Ile Ala Arg Tyr Gly Lys Val
            195                 200                 205

ttc aga gga aat aag gtt aaa aat gcc cag ctg gca ggg gcc aaa gga      672
Phe Arg Gly Asn Lys Val Lys Asn Ala Gln Leu Ala Gly Ala Lys Gly
    210                 215                 220

gtc att ctc tac tcc gac cct gct gac tac ttt gct cct ggg gtg aag      720
Val Ile Leu Tyr Ser Asp Pro Ala Asp Tyr Phe Ala Pro Gly Val Lys
225                 230                 235                 240

tcc tat cca gat ggt tgg aat ctt cct gga ggt ggt gtc cag cgt gga      768
Ser Tyr Pro Asp Gly Trp Asn Leu Pro Gly Gly Gly Val Gln Arg Gly
                245                 250                 255

aat atc cta aat ctg aat ggt gca gga gac cct ctc aca cca ggt tac      816
Asn Ile Leu Asn Leu Asn Gly Ala Gly Asp Pro Leu Thr Pro Gly Tyr
            260                 265                 270

cca gca aat gaa tat gct tat agg cgt gga att gca gag gct gtt ggt      864
Pro Ala Asn Glu Tyr Ala Tyr Arg Arg Gly Ile Ala Glu Ala Val Gly
            275                 280                 285

ctt cca agt att cct gtt cat cca att gga tac tat gat gca cag aag      912
Leu Pro Ser Ile Pro Val His Pro Ile Gly Tyr Tyr Asp Ala Gln Lys
    290                 295                 300

ctc cta gaa aaa atg ggt ggc tca gca cca cca gat agc agc tgg aga      960
Leu Leu Glu Lys Met Gly Gly Ser Ala Pro Pro Asp Ser Ser Trp Arg
305                 310                 315                 320

gga agt ctc aaa gtg ccc tac aat gtt gga cct ggc ttt act gga aac     1008
Gly Ser Leu Lys Val Pro Tyr Asn Val Gly Pro Gly Phe Thr Gly Asn
                325                 330                 335
```

```
ttt tct aca caa aaa gtc aag atg cac atc cac tct acc aat gaa gtg    1056
Phe Ser Thr Gln Lys Val Lys Met His Ile His Ser Thr Asn Glu Val
        340             345             350

aca aga att tac aat gtg ata ggt act ctc aga gga gca gtg gaa cca    1104
Thr Arg Ile Tyr Asn Val Ile Gly Thr Leu Arg Gly Ala Val Glu Pro
        355             360             365

gac aga tat gtc att ctg gga ggt cac cgg gac tca tgg gtg ttt ggt    1152
Asp Arg Tyr Val Ile Leu Gly Gly His Arg Asp Ser Trp Val Phe Gly
        370             375             380

ggt att gac cct cag agt gga gca gct gtt gtt cat gaa att gtg agg    1200
Gly Ile Asp Pro Gln Ser Gly Ala Ala Val Val His Glu Ile Val Arg
385             390             395             400

agc ttt gga aca ctg aaa aag gaa ggg tgg aga cct aga aga aca att    1248
Ser Phe Gly Thr Leu Lys Lys Glu Gly Trp Arg Pro Arg Arg Thr Ile
            405             410             415

ttg ttt gca agc tgg gat gca gaa gaa ttt ggt ctt ctt ggt tct act    1296
Leu Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly Leu Leu Gly Ser Thr
            420             425             430

gag tgg gca gag gag aat tca aga ctc ctt caa gag cgt ggc gtg gct    1344
Glu Trp Ala Glu Glu Asn Ser Arg Leu Leu Gln Glu Arg Gly Val Ala
        435             440             445

tat att aat gct gac tca tct ata gaa gga aac tac act ctg aga gtt    1392
Tyr Ile Asn Ala Asp Ser Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val
        450             455             460

gat tgt aca ccg ctg atg tac agc ttg gta cac aac cta aca aaa gag    1440
Asp Cys Thr Pro Leu Met Tyr Ser Leu Val His Asn Leu Thr Lys Glu
465             470             475             480

ctg aaa agc cct gat gaa ggc ttt gaa ggc aaa tct ctt tat gaa agt    1488
Leu Lys Ser Pro Asp Glu Gly Phe Glu Gly Lys Ser Leu Tyr Glu Ser
            485             490             495

tgg act aaa aaa agt cct tcc cca gag ttc agt ggc atg ccc agg ata    1536
Trp Thr Lys Lys Ser Pro Ser Pro Glu Phe Ser Gly Met Pro Arg Ile
            500             505             510

agc aaa ttg gga tct gga aat gat ttt gag gtg ttc ttc caa cga ctt    1584
Ser Lys Leu Gly Ser Gly Asn Asp Phe Glu Val Phe Phe Gln Arg Leu
            515             520             525

gga att gct tca ggc aga gca cgg tat act aaa aat tgg gaa aca aac    1632
Gly Ile Ala Ser Gly Arg Ala Arg Tyr Thr Lys Asn Trp Glu Thr Asn
        530             535             540

aaa ttc agc ggc tat cca ctg tat cac agt gtc tat gaa aca tat gag    1680
Lys Phe Ser Gly Tyr Pro Leu Tyr His Ser Val Tyr Glu Thr Tyr Glu
```

144

```
          545                          550                          555                          560
    ttg gtg gaa aag ttt tat gat cca atg ttt aaa tat cac ctc act gtg    1728
    Leu Val Glu Lys Phe Tyr Asp Pro Met Phe Lys Tyr His Leu Thr Val
                        565                          570                          575

    gcc cag gtt cga gga ggg atg gtg ttt gag cta gcc aat tcc ata gtg    1776
    Ala Gln Val Arg Gly Gly Met Val Phe Glu Leu Ala Asn Ser Ile Val
                        580                          585                          590

    ctc cct ttt gat tgt cga gat tat gct gta gtt tta aga aag tat gct    1824
    Leu Pro Phe Asp Cys Arg Asp Tyr Ala Val Val Leu Arg Lys Tyr Ala
                        595                          600                          605

    gac aaa atc tac agt att tct atg aaa cat cca cag gaa atg aag aca    1872
    Asp Lys Ile Tyr Ser Ile Ser Met Lys His Pro Gln Glu Met Lys Thr
                    610                          615                          620

    tac agt gta tca ttt gat tca ctt ttt tct gca gta aag aat ttt aca    1920
    Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr
    625                          630                          635                          640

    gaa att gct tcc aag ttc agt gag aga ctc cag gac ttt gac aaa agc    1968
    Glu Ile Ala Ser Lys Phe Ser Glu Arg Leu Gln Asp Phe Asp Lys Ser
                            645                          650                          655

    aac cca ata gta tta aga atg atg aat gat caa ctc atg ttt ctg gaa    2016
    Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln Leu Met Phe Leu Glu
                        660                          665                          670

    aga gca ttt att gat cca tta ggg tta cca gac agg cct ttt tat agg    2064
    Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg Pro Phe Tyr Arg
                        675                          680                          685

    cat gtc atc tat gct cca agc agc cac aac aag tat gca ggg gag tca    2112
    His Val Ile Tyr Ala Pro Ser Ser His Asn Lys Tyr Ala Gly Glu Ser
                    690                          695                          700

    ttc cca gga att tat gat gct ctg ttt gat att gaa agc aaa gtg gac    2160
    Phe Pro Gly Ile Tyr Asp Ala Leu Phe Asp Ile Glu Ser Lys Val Asp
    705                          710                          715                          720

    cct tcc aag gcc tgg gga gaa gtg aag aga cag att tat gtt gca gcc    2208
    Pro Ser Lys Ala Trp Gly Glu Val Lys Arg Gln Ile Tyr Val Ala Ala
                        725                          730                          735

    ttc aca gtg cag gca gct gca gag act ttg agt gaa gta gcc taa    2253
    Phe Thr Val Gln Ala Ala Ala Glu Thr Leu Ser Glu Val Ala
                        740                          745                          750
```

<210> 2
<211> 750
<212> PRT

<213> Homo sapiens

<400> 2

```
Met Gly Asn Leu Leu His Glu Thr Asp Ser Ala Val Ala Thr Ala Arg
 1               5                  10                  15

Arg Pro Arg Trp Leu Cys Ala Gly Ala Leu Val Leu Ala Gly Gly Phe
            20                  25                  30

Phe Leu Leu Gly Phe Leu Phe Gly Trp Phe Ile Lys Ser Ser Asn Glu
            35                  40                  45

Ala Thr Asn Ile Thr Pro Lys His Asn Met Lys Ala Phe Leu Asp Glu
        50                  55                  60

Leu Lys Ala Glu Asn Ile Lys Lys Phe Leu Tyr Asn Phe Thr Gln Ile
 65                  70                  75                  80

Pro His Leu Ala Gly Thr Glu Gln Asn Phe Gln Leu Ala Lys Gln Ile
                85                  90                  95

Gln Ser Gln Trp Lys Glu Phe Gly Leu Asp Ser Val Glu Leu Ala His
            100                 105                 110

Tyr Asp Val Leu Leu Ser Tyr Pro Asn Lys Thr His Pro Asn Tyr Ile
            115                 120                 125

Ser Ile Ile Asn Glu Asp Gly Asn Glu Ile Phe Asn Thr Ser Leu Phe
        130                 135                 140

Glu Pro Pro Pro Pro Gly Tyr Glu Asn Val Ser Asp Ile Val Pro Pro
145                 150                 155                 160

Phe Ser Ala Phe Ser Pro Gln Gly Met Pro Glu Gly Asp Leu Val Tyr
                165                 170                 175

Val Asn Tyr Ala Arg Thr Glu Asp Phe Phe Lys Leu Glu Arg Asp Met
            180                 185                 190

Lys Ile Asn Cys Ser Gly Lys Ile Val Ile Ala Arg Tyr Gly Lys Val
            195                 200                 205

Phe Arg Gly Asn Lys Val Lys Asn Ala Gln Leu Ala Gly Ala Lys Gly
            210                 215                 220

Val Ile Leu Tyr Ser Asp Pro Ala Asp Tyr Phe Ala Pro Gly Val Lys
225                 230                 235                 240

Ser Tyr Pro Asp Gly Trp Asn Leu Pro Gly Gly Gly Val Gln Arg Gly
                245                 250                 255

Asn Ile Leu Asn Leu Asn Gly Ala Gly Asp Pro Leu Thr Pro Gly Tyr
            260                 265                 270
```

```
Pro Ala Asn Glu Tyr Ala Tyr Arg Arg Gly Ile Ala Glu Ala Val Gly
    275                 280                 285

Leu Pro Ser Ile Pro Val His Pro Ile Gly Tyr Tyr Asp Ala Gln Lys
    290             295             300

Leu Leu Glu Lys Met Gly Gly Ser Ala Pro Pro Asp Ser Ser Trp Arg
305             310             315                 320

Gly Ser Leu Lys Val Pro Tyr Asn Val Gly Pro Gly Phe Thr Gly Asn
            325             330             335

Phe Ser Thr Gln Lys Val Lys Met His Ile His Ser Thr Asn Glu Val
            340             345             350

Thr Arg Ile Tyr Asn Val Ile Gly Thr Leu Arg Gly Ala Val Glu Pro
    355             360             365

Asp Arg Tyr Val Ile Leu Gly Gly His Arg Asp Ser Trp Val Phe Gly
    370             375             380

Gly Ile Asp Pro Gln Ser Gly Ala Ala Val Val His Glu Ile Val Arg
385             390             395             400

Ser Phe Gly Thr Leu Lys Lys Glu Gly Trp Arg Pro Arg Arg Thr Ile
            405             410             415

Leu Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly Leu Leu Gly Ser Thr
            420             425             430

Glu Trp Ala Glu Glu Asn Ser Arg Leu Leu Gln Glu Arg Gly Val Ala
            435             440             445

Tyr Ile Asn Ala Asp Ser Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val
    450             455             460

Asp Cys Thr Pro Leu Met Tyr Ser Leu Val His Asn Leu Thr Lys Glu
465             470             475             480

Leu Lys Ser Pro Asp Glu Gly Phe Glu Gly Lys Ser Leu Tyr Glu Ser
            485             490             495

Trp Thr Lys Lys Ser Pro Ser Pro Glu Phe Ser Gly Met Pro Arg Ile
            500             505             510

Ser Lys Leu Gly Ser Gly Asn Asp Phe Glu Val Phe Phe Gln Arg Leu
            515             520             525

Gly Ile Ala Ser Gly Arg Ala Arg Tyr Thr Lys Asn Trp Glu Thr Asn
    530             535             540

Lys Phe Ser Gly Tyr Pro Leu Tyr His Ser Val Tyr Glu Thr Tyr Glu
545             550             555             560
```

```
Leu Val Glu Lys Phe Tyr Asp Pro Met Phe Lys Tyr His Leu Thr Val
            565             570             575

Ala Gln Val Arg Gly Gly Met Val Phe Glu Leu Ala Asn Ser Ile Val
            580             585             590

Leu Pro Phe Asp Cys Arg Asp Tyr Ala Val Val Leu Arg Lys Tyr Ala
            595             600             605

Asp Lys Ile Tyr Ser Ile Ser Met Lys His Pro Gln Glu Met Lys Thr
    610             615             620

Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr
625             630             635             640

Glu Ile Ala Ser Lys Phe Ser Glu Arg Leu Gln Asp Phe Asp Lys Ser
            645             650             655

Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln Leu Met Phe Leu Glu
            660             665             670

Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg Pro Phe Tyr Arg
            675             680             685

His Val Ile Tyr Ala Pro Ser Ser His Asn Lys Tyr Ala Gly Glu Ser
            690             695             700

Phe Pro Gly Ile Tyr Asp Ala Leu Phe Asp Ile Glu Ser Lys Val Asp
705             710             715             720

Pro Ser Lys Ala Trp Gly Glu Val Lys Arg Gln Ile Tyr Val Ala Ala
            725             730             735

Phe Thr Val Gln Ala Ala Ala Glu Thr Leu Ser Glu Val Ala
            740             745             750


<210> 3
<211> 3768
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)..(3765)

<400> 3
atg gag ctg gcg gcc ttg tgc cgc tgg ggg ctc ctc ctc gcc ctc ttg      48
Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu
 1               5                  10                  15

ccc ccc gga gcc gcg agc acc caa gtg tgc acc ggc aca gac atg aag      96
Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys
            20                  25                  30
```

```
ctg cgg ctc cct gcc agt ccc gag acc cac ctg gac atg ctc cgc cac    144
Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His
        35              40              45

ctc tac cag ggc tgc cag gtg gtg cag gga aac ctg gaa ctc acc tac    192
Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr
        50              55              60

ctg ccc acc aat gcc agc ctg tcc ttc ctg cag gat atc cag gag gtg    240
Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val
65              70              75              80

cag ggc tac gtg ctc atc gct cac aac caa gtg agg cag gtc cca ctg    288
Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu
                85              90              95

cag agg ctg cgg att gtg cga ggc acc cag ctc ttt gag gac aac tat    336
Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
            100             105             110

gcc ctg gcc gtg cta gac aat gga gac ccg ctg aac aat acc acc cct    384
Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro
            115             120             125

gtc aca ggg gcc tcc cca gga ggc ctg cgg gag ctg cag ctt cga agc    432
Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
        130             135             140

ctc aca gag atc ttg aaa gga ggg gtc ttg atc cag cgg aac ccc cag    480
Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln
145             150             155             160

ctc tgc tac cag gac acg att ttg tgg aag gac atc ttc cac aag aac    528
Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn
                165             170             175

aac cag ctg gct ctc aca ctg ata gac acc aac cgc tct cgg gcc tgc    576
Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
            180             185             190

cac ccc tgt tct ccg atg tgt aag ggc tcc cgc tgc tgg gga gag agt    624
His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser
            195             200             205

tct gag gat tgt cag agc ctg acg cgc act gtc tgt gcc ggt ggc tgt    672
Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys
        210             215             220

gcc cgc tgc aag ggg cca ctg ccc act gac tgc tgc cat gag cag tgt    720
Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys
225             230             235             240

gct gcc ggc tgc acg ggc ccc aag cac tct gac tgc ctg gcc tgc ctc    768
Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu
```

```
cac ttc aac cac agt ggc atc tgt gag ctg cac tgc cca gcc ctg gtc   816
His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val
            260                 265                 270

acc tac aac aca gac acg ttt gag tcc atg ccc aat ccc gag ggc cgg   864
Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg
        275                 280                 285

tat aca ttc ggc gcc agc tgt gtg act gcc tgt ccc tac aac tac ctt   912
Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu
    290                 295                 300

tct acg gac gtg gga tcc tgc acc ctc gtc tgc ccc ctg cac aac caa   960
Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln
305                 310                 315                 320

gag gtg aca gca gag gat gga aca cag cgg tgt gag aag tgc agc aag   1008
Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys
                325                 330                 335

ccc tgt gcc cga gtg tgc tat ggt ctg ggc atg gag cac ttg cga gag   1056
Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu
            340                 345                 350

gtg agg gca gtt acc agt gcc aat atc cag gag ttt gct ggc tgc aag   1104
Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys
        355                 360                 365

aag atc ttt ggg agc ctg gca ttt ctg ccg gag agc ttt gat ggg gac   1152
Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp
    370                 375                 380

cca gcc tcc aac act gcc ccg ctc cag cca gag cag ctc caa gtg ttt   1200
Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe
385                 390                 395                 400

gag act ctg gaa gag atc aca ggt tac cta tac atc tca gca tgg ccg   1248
Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro
                405                 410                 415

gac agc ctg cct gac ctc agc gtc ttc cag aac ctg caa gta atc cgg   1296
Asp Ser Leu Pro Asp Leu Ser Val Phe Gln Asn Leu Gln Val Ile Arg
            420                 425                 430

gga cga att ctg cac aat ggc gcc tac tcg ctg acc ctg caa ggg ctg   1344
Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu
        435                 440                 445

ggc atc agc tgg ctg ggg ctg cgc tca ctg agg gaa ctg ggc agt gga   1392
Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly
    450                 455                 460
```

```
ctg gcc ctc atc cac cat aac acc cac ctc tgc ttc gtg cac acg gtg    1440
Leu Ala Leu Ile His His Asn Thr His Leu Cys Phe Val His Thr Val
465             470             475             480

ccc tgg gac cag ctc ttt cgg aac ccg cac caa gct ctg ctc cac act    1488
Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr
                485             490             495

gcc aac cgg cca gag gac gag tgt gtg ggc gag ggc ctg gcc tgc cac    1536
Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His
                500             505             510

cag ctg tgc gcc cga ggg cac tgc tgg ggt cca ggg ccc acc cag tgt    1584
Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys
            515             520             525

gtc aac tgc agc cag ttc ctt cgg ggc cag gag tgc gtg gag gaa tgc    1632
Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys
            530             535             540

cga gta ctg cag ggg ctc ccc agg gag tat gtg aat gcc agg cac tgt    1680
Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys
545             550             555             560

ttg ccg tgc cac cct gag tgt cag ccc cag aat ggc tca gtg acc tgt    1728
Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys
                565             570             575

ttt gga ccg gag gct gac cag tgt gtg gcc tgt gcc cac tat aag gac    1776
Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp
                580             585             590

cct ccc ttc tgc gtg gcc cgc tgc ccc agc ggt gtg aaa cct gac ctc    1824
Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu
            595             600             605

tcc tac atg ccc atc tgg aag ttt cca gat gag gag ggc gca tgc cag    1872
Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln
    610             615             620

cct tgc ccc atc aac tgc acc cac tcc tgt gtg gac ctg gat gac aag    1920
Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys
625             630             635             640

ggc tgc ccc gcc gag cag aga gcc agc cct ctg acg tcc atc gtc tct    1968
Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile Val Ser
                645             650             655

gcg gtg gtt ggc att ctg ctg gtc gtg gtc ttg ggg gtg gtc ttt ggg    2016
Ala Val Val Gly Ile Leu Leu Val Val Val Leu Gly Val Val Phe Gly
            660             665             670

atc ctc atc aag cga cgg cag cag aag atc cgg aag tac acg atg cgg    2064
Ile Leu Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys Tyr Thr Met Arg
```

```
              675                    680                    685

aga ctg ctg cag gaa acg gag ctg gtg gag ccg ctg aca cct agc gga    2112
Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly
    690                    695                    700

gcg atg ccc aac cag gcg cag atg cgg atc ctg aaa gag acg gag ctg    2160
Ala Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu
705                    710                    715                    720

agg aag gtg aag gtg ctt gga tct ggc gct ttt ggc aca gtc tac aag    2208
Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys
                    725                    730                    735

ggc atc tgg atc cct gat ggg gag aat gtg aaa att cca gtg gcc atc    2256
Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile
                    740                    745                    750

aaa gtg ttg agg gaa aac aca tcc ccc aaa gcc aac aaa gaa atc tta    2304
Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu
                    755                    760                    765

gac gaa gca tac gtg atg gct ggt gtg ggc tcc cca tat gtc tcc cgc    2352
Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg
                    770                    775                    780

ctt ctg ggc atc tgc ctg aca tcc acg gtg cag ctg gtg aca cag ctt    2400
Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln Leu
785                    790                    795                    800

atg ccc tat ggc tgc ctc tta gac cat gtc cgg gaa aac cgc gga cgc    2448
Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg
                    805                    810                    815

ctg ggc tcc cag gac ctg ctg aac tgg tgt atg cag att gcc aag ggg    2496
Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly
                    820                    825                    830

atg agc tac ctg gag gat gtg cgg ctc gta cac agg gac ttg gcc gct    2544
Met Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala
                    835                    840                    845

cgg aac gtg ctg gtc aag agt ccc aac cat gtc aaa att aca gac ttc    2592
Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe
    850                    855                    860

ggg ctg gct cgg ctg ctg gac att gac gag aca gag tac cat gca gat    2640
Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp
865                    870                    875                    880

ggg ggc aag gtg ccc atc aag tgg atg gcg ctg gag tcc att ctc cgc    2688
Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg
                    885                    890                    895
```

```
cgg cgg ttc acc cac cag agt gat gtg tgg agt tat ggt gtg act gtg    2736
Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val
        900             905             910

tgg gag ctg atg act ttt ggg gcc aaa cct tac gat ggg atc cca gcc    2784
Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala
        915             920             925

cgg gag atc cct gac ctg ctg gaa aag ggg gag cgg ctg ccc cag ccc    2832
Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro
        930             935             940

ccc atc tgc acc att gat gtc tac atg atc atg gtc aaa tgt tgg atg    2880
Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met
945             950             955             960

att gac tct gaa tgt cgg cca aga ttc cgg gag ttg gtg tct gaa ttc    2928
Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe
                965             970             975

tcc cgc atg gcc agg gac ccc cag cgc ttt gtg gtc atc cag aat gag    2976
Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu
                980             985             990

gac ttg ggc cca gcc agt ccc ttg gac agc acc ttc tac cgc tca ctg    3024
Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu
        995             1000            1005

ctg gag gac gat gac atg ggg gac ctg gtg gat gct gag gag tat ctg    3072
Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr Leu
    1010            1015            1020

gta ccc cag cag ggc ttc ttc tgt cca gac cct gcc ccg ggc gct ggg    3120
Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly Ala Gly
1025            1030            1035            1040

ggc atg gtc cac cac agg cac cgc agc tca tct acc agg agt ggc ggt    3168
Gly Met Val His His Arg His Arg Ser Ser Ser Thr Arg Ser Gly Gly
            1045            1050            1055

ggg gac ctg aca cta ggg ctg gag ccc tct gaa gag gag gcc ccc agg    3216
Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu Glu Ala Pro Arg
            1060            1065            1070

tct cca ctg gca ccc tcc gaa ggg gct ggc tcc gat gta ttt gat ggt    3264
Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser Asp Val Phe Asp Gly
        1075            1080            1085

gac ctg gga atg ggg gca gcc aag ggg ctg caa agc ctc ccc aca cat    3312
Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro Thr His
        1090            1095            1100

gac ccc agc cct cta cag cgg tac agt gag gac ccc aca gta ccc ctg    3360
Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu
```

```
        1105                  1110                  1115                  1120
        ccc tct gag act gat ggc tac gtt gcc ccc ctg acc tgc agc ccc cag    3408
        Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser Pro Gln
                      1125                  1130                  1135

        cct gaa tat gtg aac cag cca gat gtt cgg ccc cag ccc cct tcg ccc    3456
        Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser Pro
                      1140                  1145                  1150

        cga gag ggc cct ctg cct gct gcc cga cct gct ggt gcc act ctg gaa    3504
        Arg Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu
                  1155                  1160                  1165

        agg gcc aag act ctc tcc cca ggg aag aat ggg gtc gtc aaa gac gtt    3552
        Arg Ala Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val
            1170                  1175                  1180

        ttt gcc ttt ggg ggt gcc gtg gag aac ccc gag tac ttg aca ccc cag    3600
        Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln
        1185                  1190                  1195                  1200

        gga gga gct gcc cct cag ccc cac cct cct cct gcc ttc agc cca gcc    3648
        Gly Gly Ala Ala Pro Gln Pro His Pro Pro Pro Ala Phe Ser Pro Ala
                      1205                  1210                  1215

        ttc gac aac ctc tat tac tgg gac cag gac cca cca gag cgg ggg gct    3696
        Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg Gly Ala
                  1220                  1225                  1230

        cca ccc agc acc ttc aaa ggg aca cct acg gca gag aac cca gag tac    3744
        Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr
              1235                  1240                  1245

        ctg ggt ctg gac gtg cca gtg tga                                    3768
        Leu Gly Leu Asp Val Pro Val
            1250                  1255
```

<210> 4
<211> 1255
<212> PRT
<213> Homo sapiens

<400> 4
```
Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu
  1               5                  10                  15

Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys
              20                  25                  30

Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His
          35                  40                  45
```

```
Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr
     50              55                  60

Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val
 65              70              75                      80

Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu
             85              90                  95

Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
             100             105             110

Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro
             115             120             125

Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
     130             135             140

Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln
145             150             155             160

Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn
             165             170             175

Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
             180             185             190

His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser
     195             200             205

Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys
210             215             220

Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys
225             230             235             240

Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu
             245             250             255

His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val
             260             265             270

Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg
             275             280             285

Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu
     290             295             300

Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln
305             310             315             320

Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys
             325             330             335
```

Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu
     340   345   350

Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys
     355   360   365

Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp
     370   375   380

Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe
385   390   395   400

Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro
        405   410   415

Asp Ser Leu Pro Asp Leu Ser Val Phe Gln Asn Leu Gln Val Ile Arg
        420   425   430

Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu
        435   440   445

Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly
     450   455   460

Leu Ala Leu Ile His His Asn Thr His Leu Cys Phe Val His Thr Val
465   470   475   480

Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr
        485   490   495

Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His
        500   505   510

Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys
     515   520   525

Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys
     530   535   540

Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys
545   550   555   560

Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys
        565   570   575

Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp
        580   585   590

Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu
        595   600   605

Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln
        610   615   620

Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys
625   630   635   640

Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile Val Ser
          645   650   655

Ala Val Val Gly Ile Leu Leu Val Val Val Leu Gly Val Val Phe Gly
          660   665   670

Ile Leu Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys Tyr Thr Met Arg
          675   680   685

Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly
     690   695   700

Ala Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu
705   710   715   720

Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys
          725   730   735

Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile
          740   745   750

Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu
          755   760   765

Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg
     770   775   780

Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln Leu
785   790   795   800

Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg
          805   810   815

Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly
          820   825   830

Met Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala
          835   840   845

Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe
     850   855   860

Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp
865   870   875   880

Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg
          885   890   895

Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val
     900   905   910

```
Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala
        915                 920             925
```

```
Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro
        930                 935             940
```

```
Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met
945                 950             955                 960
```

```
Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe
                965                 970             975
```

```
Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu
            980                 985                 990
```

```
Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu
            995                 1000                1005
```

```
Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr Leu
    1010                1015                1020
```

```
Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly Ala Gly
1025                1030                1035                1040
```

```
Gly Met Val His His Arg His Arg Ser Ser Ser Thr Arg Ser Gly Gly
                1045                1050                1055
```

```
Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu Glu Ala Pro Arg
            1060                1065                1070
```

```
Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser Asp Val Phe Asp Gly
            1075                1080                1085
```

```
Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro Thr His
    1090                1095                1100
```

```
Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu
1105                1110                1115                1120
```

```
Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser Pro Gln
            1125                1130                1135
```

```
Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser Pro
        1140                1145                1150
```

```
Arg Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu
        1155                1160                1165
```

```
Arg Aia Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val
    1170                1175                1180
```

```
Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln
1185                1190                1195                1200
```

```
Gly Gly Ala Ala Pro Gln Pro His Pro Pro Pro Ala Phe Ser Pro Ala
            1205              1210              1215

Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg Gly Ala
            1220              1225              1230

Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr
         1235              1240              1245

Leu Gly Leu Asp Val Pro Val                    '
    1250              1255
```

<210> 5
<211> 648
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)..(645)

<400> 5
```
atg ggc agc ccc cgc tcc gcg ctg agc tgc ctg ctg ttg cac ttg ctg   48
Met Gly Ser Pro Arg Ser Ala Leu Ser Cys Leu Leu Leu His Leu Leu
 1               5                  10                  15

gtt ctc tgc ctc caa gcc cag gta act gtt cag tcc tca cct aat ttt   96
Val Leu Cys Leu Gln Ala Gln Val Thr Val Gln Ser Ser Pro Asn Phe
             20                  25                  30

aca cag cat gtg agg gag cag agc ctg gtg acg gat cag ctc agc cgc  144
Thr Gln His Val Arg Glu Gln Ser Leu Val Thr Asp Gln Leu Ser Arg
         35                  40                  45

cgc ctc atc cgg acc tac cag ctc tac agc cgc acc agc ggg aag cac  192
Arg Leu Ile Arg Thr Tyr Gln Leu Tyr Ser Arg Thr Ser Gly Lys His
     50                  55                  60

gtg cag gtc ctg gcc aac aag cgc atc aac gcc atg gca gaa gac gga  240
Val Gln Val Leu Ala Asn Lys Arg Ile Asn Ala Met Ala Glu Asp Gly
 65                  70                  75                  80

gac ccc ttc gcg aag ctc att gtg gag acc gat act ttt gga agc aga  288
Asp Pro Phe Ala Lys Leu Ile Val Glu Thr Asp Thr Phe Gly Ser Arg
                 85                  90                  95

gtc cga gtt cgc ggc gca gag aca ggt ctc tac atc tgc atg aac aag  336
Val Arg Val Arg Gly Ala Glu Thr Gly Leu Tyr Ile Cys Met Asn Lys
            100                 105                 110

aag ggg aag cta att gcc aag agc aac ggc aaa ggc aag gac tgc gta  384
Lys Gly Lys Leu Ile Ala Lys Ser Asn Gly Lys Gly Lys Asp Cys Val
        115                 120                 125
```

```
ttc aca gag atc gtg ctg gag aac aac tac acg gcg ctg cag aac gcc    432
Phe Thr Glu Ile Val Leu Glu Asn Asn Tyr Thr Ala Leu Gln Asn Ala
    130             135             140

aag tac gag ggc tgg tac atg gcc ttt acc cgc aag ggc cgg ccc cgc    480
Lys Tyr Glu Gly Trp Tyr Met Ala Phe Thr Arg Lys Gly Arg Pro Arg
 145             150             155             160

aag ggc tcc aag acg cgc cag cat cag cgc gag gtg cac ttc atg aag    528
Lys Gly Ser Lys Thr Arg Gln His Gln Arg Glu Val His Phe Met Lys
             165             170             175

cgc ctg ccg cgg ggc cac cac acc acc gag cag agc ctg cgc ttc gag    576
Arg Leu Pro Arg Gly His His Thr Thr Glu Gln Ser Leu Arg Phe Glu
             180             185             190

ttc ctc aac tac ccg ccc ttc acg cgc agc ctg cgc ggc agc cag agg    624
Phe Leu Asn Tyr Pro Pro Phe Thr Arg Ser Leu Arg Gly Ser Gln Arg
         195             200             205

act tgg gcc ccg gag ccc cga tag                                    648
Thr Trp Ala Pro Glu Pro Arg
    210             215
```

<210> 6
<211> 215
<212> PRT
<213> Mus musculus

<400> 6

```
Met Gly Ser Pro Arg Ser Ala Leu Ser Cys Leu Leu Leu His Leu Leu
 1               5                   10                  15

Val Leu Cys Leu Gln Ala Gln Val Thr Val Gln Ser Ser Pro Asn Phe
            20                  25                  30

Thr Gln His Val Arg Glu Gln Ser Leu Val Thr Asp Gln Leu Ser Arg
            35                  40                  45

Arg Leu Ile Arg Thr Tyr Gln Leu Tyr Ser Arg Thr Ser Gly Lys His
    50                  55                  60

Val Gln Val Leu Ala Asn Lys Arg Ile Asn Ala Met Ala Glu Asp Gly
 65                  70                  75                  80

Asp Pro Phe Ala Lys Leu Ile Val Glu Thr Asp Thr Phe Gly Ser Arg
                85                  90                  95

Val Arg Val Arg Gly Ala Glu Thr Gly Leu Tyr Ile Cys Met Asn Lys
            100                 105                 110

Lys Gly Lys Leu Ile Ala Lys Ser Asn Gly Lys Gly Lys Asp Cys Val
            115                 120                 125
```

```
Phe Thr Glu Ile Val Leu Glu Asn Asn Tyr Thr Ala Leu Gln Asn Ala
    130                 135             140

Lys Tyr Glu Gly Trp Tyr Met Ala Phe Thr Arg Lys Gly Arg Pro Arg
145             150                 155                 160

Lys Gly Ser Lys Thr Arg Gln His Gln Arg Glu Val His Phe Met Lys
                165             170                 175

Arg Leu Pro Arg Gly His His Thr Thr Glu Gln Ser Leu Arg Phe Glu
            180             185                 190

Phe Leu Asn Tyr Pro Pro Phe Thr Arg Ser Leu Arg Gly Ser Gln Arg
        195             200             205

Thr Trp Ala Pro Glu Pro Arg
    210             215
```

CLAIMS

1. A method for inducing an immune response against a polypeptide antigen in an animal, including a human being, said polypeptide antigen being weakly immunogenic or non-immunogenic
5 in the animal, the method comprising effecting simultaneous presentation by antigen presenting cells (APCs) of the animal's immune system of an immunogenically effective amount of

1) at least one CTL epitope derived from the polypeptide antigen and/or at least one B-cell epitope derived from the
10 cell-associated polypeptide antigen, and

2) at least one first T helper cell epitope (T_H epitope) which is foreign to the animal.

2. A method for down-regulating a cell-associated polypeptide antigen in an animal, including a human being, said polypeptide
15 antigen being weakly immunogenic or non-immunogenic in the animal, by inducing a specific cytotoxic T-lymphocyte (CTL) response against cells carrying the cell-associated polypeptide antigen on their surface or harbouring the cell-associated polypeptide antigen in their intracellular compartment, the
20 method comprising effecting, in the animal, simultaneous presentation by a suitable antigen presenting cell (APC) of

1) at least one CTL epitope derived from the cell-associated polypeptide antigen, and

2) at least one first T-helper lymphocyte (T_H) epitope which is
25 foreign to the animal.

3. The method according to claim 1 or 2, wherein said at least one CTL epitope when presented is associated with an MHC Class I molecule on the surface of the APC.

4. The method according to any of the preceding claims, wherein
30 said at least one first foreign T_H epitope when presented is

associated with an MHC Class II molecule on the surface of the APC.

5. The method according to any of the preceding claims, wherein the APC is a dendritic cell or a macrophage.

5   6. The method according to any of the preceding claims, wherein the cell-associated antigen is selected from a tumour-associated antigen, a viral antigen, and an antigen derived from an intracellular parasite or bacterium.

7. The method according to any of the preceding claims, wherein
10 presentation by the APC of the CTL epitope and the first foreign T_H epitope is effected by presenting the animal's immune system with at least one first analogue of the cell-associated polypeptide antigen, said first analogue comprising a variation of the amino acid sequence of the cell-associated polypeptide
15 antigen, said variation containing at least the CTL epitope and the first foreign T_H epitope.

8. The method according to claim 7, wherein the at least first analogue contains a substantial fraction of known and predicted CTL epitopes of the cell-associated polypeptide antigen.

20 9. The method according to claim 8, wherein the substantial fraction of known and predicted CTL epitopes in the amino acid sequence of the analogue are recognized by at least 90% of the MHC-I haplotypes recognizing all known and predicted CTL epitopes in the cell-associated polypeptide antigen.

25 10. The method according to any of claims 7-9, wherein substantially all known CTL epitopes of the cell-associated polypeptide antigen are present in the analogue.

11. The method according to any of claims 7-10, wherein substantially all predicted CTL epitopes of the cell-associated polypeptide antigen are present in the at least first analogue.

12. The method according to any of claims 7-11, wherein the at
5 least one first analogue further comprises a part consisting of a modification of the structure of the cell-associated polypeptide antigen, said modification having as a result that immunization of the animal with the first analogue induces production of antibodies in the animal against the cell-
10 associated polypeptide antigen.

13. The method according to any one of the preceding claims, which comprises effecting presentation to the animal's immune system of an immunogenically effective amount of at least one second analogue of the cell-associated polypeptide antigen, said
15 second analogue containing a modification of the structure of the cell-associated polypeptide antigen, said modification having as a result that immunization of the animal with the second analogue induces production of antibodies against the cell-associated polypeptide antigen.

20 14. The method according to claim 13, wherein the modification comprises that at least one second foreign T_H epitope is included in the second analogue.

15. The method according to any one of claims 7-14, wherein the first and/or second analogue(s) comprise(s) a substantial
25 fraction of the cell-associated polypeptide antigen's B-cell epitopes.

16. The method according to any one of claims 7-15, wherein the variation and/or modification involves amino acid substitution and/or deletion and/or insertion and/or addition.

17. The method according to claim 16, wherein the variation and/or modification involves amino acid substitution and/or insertion.

18. The method according to any one of claims 7-17, wherein the
5 variation and/or modification comprises that
- at least one first moiety is included in the first and/or second analogue(s), said first moiety effecting targeting of the analogue to an antigen presenting cell (APC), and/or
- at least one second moiety is included in the first and/or
10 second analogue(s), said second moiety stimulating the immune system, and/or
- at least one third moiety is included in the first and/or second analogue(s), said third moiety optimizing presentation of the analogue to the immune system.
15
19. The method according to any one of claims 7-18, wherein the variation and/or modification includes duplication of at least one B-cell epitope or of at least one CTL epitope of the cell-associated polypeptide antigen

20 20. The method according to any one of claims 7-19, wherein the variation and/or modification includes introduction of a hapten.

21. The method according to any of the preceding claims, wherein the first and/or second foreign T_H epitope is/are immunodominant.

25 22. The method according to any of the preceding claims, wherein the first and/or second foreign T_H epitope(s) is/are promiscuous.

23. The method according to any of claims 14-22, wherein the first and/or second foreign T_H epitope(s) is/are selected from a

natural T_H epitope and an artificial MHC-II binding peptide sequence.

24. The method according to claim 23, wherein the natural T_H epitope is selected from a Tetanus toxoid epitope such as P2 or
5 P30, a diphtheria toxoid epitope, a influenza virus hemagluttinin epitope, and a *P. falciparum* CS epitope.

25. The method according to any one of claims 14-24, wherein the first and/or second T_H epitopes and/or first and/or second and/or third moieties are present in the form of
10 - side groups attached covalently or non-covalently to suitable chemical groups in the amino acid sequence of the cell-associated polypeptide antigen or a subsequence thereof, and/or
   - fusion partners to the amino acid sequence derived from the
15   cell-associated polypeptide antigen.

26. The method according to claim 25, wherein the first moiety is a substantially specific binding partner for an APC specific surface antigen.

27. The method according to claim 26, wherein the first moiety
20 is a carbohydrate for which there is a receptor on the APC, such as mannan or mannose.

28. The method according to any one of claims 18-27, wherein the second moiety is selected from interferon γ (IFN-γ), Flt3L, interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 4 (IL-
25 4), interleukin 6 (IL-6), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 15 (IL-15), and granulocyte-macrophage colony stimulating factor (GM-CSF), or an effective part thereof.

29. The method according to any one of claims 18-28, wherein the third moiety is a lipid such as a palmitoyl residue or a myristyl residue.

30. The method according to claim any one of claims 7-29,
5 wherein the first and/or second analogue(s) has/have substantially the overall tertiary structure of the cell-associated polypeptide antigen.

31. The method according to any one of claims 7-30, wherein presentation by the APC is effected by administering, to the
10 animal, an immunogenically effective amount of the at least one first analogue.

32. The method according to claim 31, wherein is also administered an immunologically effective amount of the at least one second analogue.

15 33. The method according to claim 31 or 32, wherein said at least one first and/or second analogue(s) is/are formulated together with a pharmaceutically and immunologically acceptable carrier and/or vehicle and/or diluent and/or excipient and, optionally an adjuvant.

20 34. The method according to claim 30, wherein said adjuvant facilitates uptake by APCs, such as dendritic cells, of the at least first and/or second analogues.

35. The method according to claim 31, wherein the adjuvant is selected from the group consisting of an immune targeting
25 adjuvant; an immune modulating adjuvant such as a toxin, a cytokine, and a mycobacterial derivative; an oil formulation; a polymer; a micelle forming adjuvant; a saponin; an immunostimulating complex matrix (ISCOM matrix); a particle;

DDA; aluminium adjuvants; DNA adjuvants; γ-inulin; and an encapsulating adjuvant.

36. The method according to claim 35, wherein the cytokine is selected from interferon γ (IFN-γ), Flt3L, interleukin 1 (IL-1),
5 interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 15 (IL-15), and granulocyte-macrophage colony stimulating factor (GM-CSF), or an effective part thereof.

37. The method according to claim 35 or 36, wherein the toxin is
10 selected from the group consisting of listeriolycin (LLO), Lipid A (MPL, L180.5/RalLPS), and heat-labile enterotoxin.

38. The method according to any one of claims 35-37, wherein the mycobacterial derivative is selected from the group consisting of muramyl dipeptide, complete Freund's adjuvant, RIBI, and a
15 diester of trehalose such as TDM and TDE.

39. The method according to any one of claims 35-38, wherein the immune targeting adjuvant is selected from the group consisting of CD40 ligand, CD40 antibodies or specifically binding fragments thereof, mannose, a Fab fragment, and CTLA-4.

20 40. The method according to any one of claims 35-39, wherein the oil formulation comprises squalene or incomplete Freund's adjuvant.

41. The method according to any one of claims 35-40, wherein the polymer is selected from the group consisting of a carbohydrate
25 such as dextran, PEG, starch, mannan, and mannose; a plastic polymer such as; and latex such as latex beads.

42. The method according to any one of claims 35-41, wherein the saponin is *Quillaja saponaria* saponin, Quil A, and QS21.

43. The method according to any one of claims 35-42, wherein the particle comprises latex or dextran.

44. The method according to any one of claims 31-43, which includes administration via a route selected from the oral route
5 and the parenteral route such as the intradermal, the subdermal, the intracutaneous, the subcutaneous; the peritoneal, the buccal, the sublinqual, the epidural, the spinal, the anal, and the intracranial routes.

45. The method according to any of claim 31-44, which includes
10 at least one administration a year, such as at least 2, 3, 4, 5, 6, and 12 administrations a year.

46. The method according to any of claims 1-6, wherein presentation is effected by administering, to the animal, a non-pathogenic microorganism or virus which is carrying a nucleic
15 acid fragment encoding and expressing the at least one CTL epitope and the at least one T_H epitope.

47. The method according to any of claims 7-17, wherein presentation is effected by administering, to the animal, a non-pathogenic microorganism or virus which is carrying at least one
20 nucleic acid fragment which encodes and expresses the at least first analogue.

48. The method according to any of claims 18-30, wherein the T_H epitope and/or the first and/or second and/or third moieties are present in the form of fusion partners to the amino acid
25 sequence derived from the cell-associated polypeptide antigen, and wherein presentation is effected by administering, to the animal, a non-pathogenic microorganism or virus which is carrying at least one nucleic acid fragment encoding and expressing the first analogue.

49. The method according to any of claims 13-17 or 47, wherein presentation is effected by administering, to the animal, a non-pathogenic microorganism or virus which is carrying at least one nucleic acid fragment which encodes and expresses the at least
5   first analogue.

50. The method according to any of claims 18-30 or 48, wherein the T_H epitope and/or the first and/or second and/or third moieties are present in the form of fusion partners to the amino acid sequence derived from the cell-associated polypeptide
10   antigen, and wherein presentation is effected by administering, to the animal, a non-pathogenic microorganism or virus which is carrying at least one nucleic acid fragment encoding and expressing the first analogue.

51. The method according to any of claims 46-50, wherein the
15   non-pathogenic microorganism is a bacterium.

52. The method according to claim 51, wherein the bacterium is selected from the genera *Escherichia*, *Bacillus*, *Salmonella*, and *Mycobacterium*.

53. The method according to claim 52, which is an *E. coli* cell
20   or a *Mycobacterium bovis* BCG cell.

54. The method according to any of claims 46-50, wherein the non-pathogenic virus is a vaccinia virus strain.

55. The method according to any of claims 46-54, wherein the non-pathogenic microorganism or virus is administered once to
25   the animal.

56. The method according to any one of claims 1-6, wherein presentation is effected by *in vivo* introducing, into the APC, at least one nucleic acid fragment which encodes and expresses

the at least one CTL epitope and/or the at least one B-cell epitope, and the at least one first foreign T_H epitope.

57. The method according to any one of claims 7-17, wherein presentation is effected by *in vivo* introducing, into the APC,
5 at least one nucleic acid fragment encoding and expressing the first analogue.

58. The method according to any one of claims 18-30, wherein the T_H epitope and/or the first and/or second and/or third moieties are present in the form of fusion partners to the amino acid
10 sequence derived from the cell-associated polypeptide antigen, and wherein presentation is effected by *in vivo* introducing, into the APC, at least one nucleic acid fragment encoding and expressing the first analogue.

59. The method according to any one of claims 13-17 and 57,
15 which further comprises *in vivo* introduction, into the APC, of at least one nucleic acid fragment encoding and expressing the second analogue.

60. The method according to any one of claims 18-30 and 48,
20 wherein the T_H epitope and/or the first and/or second and/or third moieties are present in the form of fusion partners to the amino acid sequence derived from the cell-associated polypeptide antigen, and which further comprises *in vivo* introduction, into the APC, of at least one nucleic acid fragment encoding and
25 expressing the second analogue.

61. The method according to any one of claims 1-6, wherein presentation is effected by *in vivo* co-introducing, into the APC, at least two nucleic acid fragments, wherein one encodes and expresses the at least one CTL epitope and wherein another
30 encodes and expresses the at least one first foreign T_H epitope,

and wherein the first foreign T_H epitope is as defined in any one of claims 1, 2 and 21-24.

62. The method according to any one of claims 46-61, wherein the nucleic acid fragment(s) introduced is/are selected from naked
5 DNA, DNA formulated with charged or uncharged lipids, DNA formulated in liposomes, DNA included in a viral vector, DNA formulated with a transfection-facilitating protein or polypeptide, DNA formulated with a targeting protein or polypeptide, DNA formulated with a targeting carbohydrate, DNA
10 formulated with Calcium precipitating agents, DNA coupled to an inert carrier molecule, and DNA formulated with an adjuvant.

63. The method according to claim 62, wherein the adjuvant is selected from the group consisting of the adjuvants defined in any one of claims 34-43.

15 64. The method according to any one of claims 46-63, wherein the mode of administration is as defined in claim 44 or 45.

65. A method for selection of an immunogenic analogue of a cell-associated polypeptide antigen which is weakly immunogenic or non-immunogenic in an animal, said immunogenic analogue being
20 capable of inducing a CTL response in the animal against cells displaying an MHC Class I molecule bound to an epitope derived from the cell-associated polypeptide antigen, the method comprising
   - identifying at least one subsequence of the amino acid
25   sequence of the cell-associated polypeptide antigen which does not contain known or predicted CTL epitopes,
   - preparing at least one putatively immunogenic analogue of the cell-associated polypeptide antigen by introducing, in the amino acid sequence of the cell-associated polypeptide
30   antigen, at least one T_H epitope foreign to the animal in a

position within the at least one subsequence identified in step a), and

- selecting the/those analogues prepared in step b) which are verifiably capable of inducing a CTL response in the animal.

5 66. The method according to claim 65, wherein the subsequence identified in step a) further does not contain cysteine residues, or, alternatively, wherein the T_H epitope introduced in step b) does not substantially alter the pattern of cystein residues.

10 67. The method according to claim 65 or 66, wherein the subsequence identified in step a) further does not contain known or predicted glycosylation sites, or, alternatively, wherein the T_H epitope introduced in step b) does not substantially alter the glycosylation pattern.

15 68. The method according to any of claims 65-67, wherein the subsequence identified in step a) contributes significantly to a patophysiological effect exerted by the cell-associated polypeptide antigen, and wherein the introduction in step b) of the foreign T_H epitope reduces or abolishes said
20 patophysiological effect.

69. The method according to any of claims 65-68, wherein the subsequence identified in step a) is homologous to an amino acid sequence of a different protein antigen of the animal, and wherein the introduction of the T_H epitope in step b)
25 substantially removes the homology.

70. The method according to any of claims 55-59, wherein introduction in step b) of the foreign T_H epitope results in preservation of a substantial fraction of B-cell epitopes of the cell-associated polypeptide antigen.

71. The method according to claim 70, wherein the analogue has the overall tertiary structure of the cell-associated polypeptide antigen.

72. The method according to any of claims 55-71, wherein the
5 preparation in step b) is accomplished by molecular biological means or by means of solid or liquid phase peptide synthesis.

73. A method for the preparation of cell producing an analogue of a cell-associated polypeptide antigen, the method comprising introducing, into a vector, a nucleic acid sequence encoding an
10 analogue which has been selected according to the method of any of claims 55-72 and transforming a suitable host cell with the vector.

74. A method for the preparation of an analogue of a cell-associated polypeptide antigen, the method comprising culturing
15 the cell obtained according to the method of claim 73 under conditions facilitating expression of the nucleic acid sequence encoding the cell-associated polypeptide antigen, and recovering the analogue from the culture supernatant or from the cells.

75. The method according to claim 74 which further comprises the
20 step of purifying the recovered analogue and, optionally subjecting the purified product to artificial post-translational modifications such as refolding, treatment with enzymes, chemical modification, and conjugation.

76. Use of an analogue of a cell-associated polypeptide antigen
25 which is weakly immunogenic or non-immunogenic in an animal, said analogue comprising
- an amino acid sequence containing a substantial fraction of known and predicted CTL epitopes of the cell-associated polypeptide antigen, and
30 - at least one T_H epitope which is foreign to the animal,

for the preparation of a pharmaceutical composition for down-
regulating the cell-associated polypeptide antigen in the
animal.

77. The use according to claim 76, wherein the analogue further
5 has the overall tertiary structure of the cell-associated
polypeptide antigen and/or lacks putatively pathophysiologi-
related amino acid residues of the cell-associated polypeptide
antigen.

78. The use according to claim 76 or 77, wherein the substantial
10 fraction of known and predicted CTL epitopes in the amino acid
sequence of the analogue are recognized by at least 90% of the
MHC-I haplotypes recognizing all the known and predicted CTL
epitopes in the cell-associated polypeptide antigen.

79. The use according to any of claims 76-78, wherein
15 substantially all known CTL epitopes of the cell-associated
polypeptide antigen are present in the analogue.

80. The method according to any of claims 1-65 or the use
according to any of claims 66-69, wherein the weak cell-
associated antigen is selected from the group consisting of
20 prostate-specific membrane antigen (PSM),
Her2,
fibroblast growth factor, e.g. FGF-8 such as FGF-8A and FGF-8b,
human chorionic gonadotropin (hCG)
BAGE,
25 beta-actinin,
Carcino Embryonic Antigen (CEA),
Cathepsins
CD33,
CDK-4,
30 E6,
E7,

EGFR,

EGP40 (KSA),

GAGE,

Gastrin-releasing peptide (bombesin),

5 GnTV,

GP1,

gp100 (melanoma-associated),

gp75 (melanoma-associated),

IGFR1,

10 K3,

MAGE such as MAGE1 and MAGE3,

MART,

Matrix Metalloproteinase such as MMP2, MMP3, MMP7, and MMP9,

Mucin, such as MUC-1, MUC-2, MUC-3, and MUC-4, which is

15 aberrantly glycosylated,

MUM-1,

p15 (melanoma-associated),

PAI-1,

PDGF,

20 Plasminogen such as uPA,

RAGE,

TGF-α,

TRP-1/gp-75

TRP-2,

25 Tyrosinase, and

ZAG.

81. The method or use according to claim 80, wherein the cell-associated polypeptide antigen is PSM

82. The method or use according to claim 81, wherein the foreign
30 T-cell epitope is introduced in a part of the PSM amino acid
sequence defined by SEQ ID NO: 2 positions 16-52 and/or 87-108
and/or 210-230 and/or 269-289 and/or 298-324 and/or 442-465
and/or 488-514 and/or 598-630 and/or 643-662 and/or 672-699.

83. The method or use according to claim 81 or 82 used in the treatment or amelioration of prostate cancer.

84. The method or use according to claim 80, wherein the cell-
5 associated polypeptide antigen is fibroblast growth factor 8b (FGF8b).

85. The method or use according to claim 84, where the foreign T-cell epitope is introduced in a part of the FGF8b amino acid sequence defined by SEQ ID NO: 6 positions 1-54 and/or 178-215
10 and/or 55-58 and/or 63-68 and/or 72-76 and/or 85-91 and/or 95-102 and/or 106-111 and/or 115-120 and/or 128-134 and/or 138-144 and/or 149-154 and/or 158-162 and/or 173-177, and wherein the introduction preferably does not substantially involve amino acids 26-45 and amino acids 186-215.

15 86. The method or use according to claim 84 or 85 used in the treatment or amelioration of cancer such as prostate cancer and breast cancer.

87. The method or use according to claim 80, wherein the cell-associated polypeptide antigen is Her-2.

20 88. The method or use according to claim 87, wherein the foreign T-cell epitope is introduced in a part of the Her-2 amino acid sequence defined by SEQ ID NO: 4 positions 61-75 and/or 105-119 and/or 151-165 and/or 212-226 and/or 252-266 and/or 327-341 and/or 371-385) and/or 467-481 and/or 581-595 and/or 72-86
25 and/or 146-160 and/or 221-235 and/or 257-271 and/or 387-401.

89. The method or use according to claim 87 or 88 used in the treatment or amelioration of breast cancer.

90. An analogue of human PSM which is immunogenic in humans, said analogue comprising a substantial part of all known and predicted CTL and B-cell epitopes of PSM and including at least one foreign T_H epitope as defined in any of claims 21-24.

5   91. The analogue according to claim 90, wherein the at least one foreign T_H epitope is present as an insertion in the PSM amino acid sequence or as a substitution of part of the PSM amino acid sequence or as the result of deletion of part of the PSM amino acid sequence.

10 92. The analogue according to claim 91, wherein the foreign T_H epitope is introduced in the positions defined in claim 72.

93. An analogue of human Her2 which is immunogenic in humans, said analogue comprising a substantial part of all known and predicted CTL and B-cell epitopes of Her2 and including at least 15 one foreign T_H epitope as defined in any of claims 21-24.

94. The analogue according to claim 93, wherein the at least one foreign T_H epitope is present as an insertion in the Her2 amino acid sequence or as a substitution of part of the Her2 amino acid sequence or as the result of deletion of part of the Her2 20 amino acid sequence.

95. The analogue according to claim 94, wherein the foreign T_H epitope is introduced in the positions defined in claim 75.

96. An analogue of human/murine FGF8b which is immunogenic in humans, said analogue comprising a substantial part of all known 25 and predicted CTL and B-cell epitopes of FGF8b and including at least one foreign T_H epitope as defined in any of claims 21-24.

97. The analogue according to claim 96, wherein the at least one foreign T_H epitope is present as an insertion in the FGF8b amino

acid sequence or as a substitution of part of the FGF8b amino acid sequence or as the result of deletion of part of the FGF8b amino acid sequence.

98. The analogue according to claim 97, wherein the foreign T_H
5 epitope is introduced in the positions defined in claim 78.

99. An immunogenic composition which comprises, as an effective immunogenic agent the analogue according to any of claims 90-98 in admixture with a pharmaceutically and immunologically acceptable carrier, vehicle, diluent, or excipient, and
10 optionally an adjuvant.

100. The immunogenic composition according to claim 99, wherein the adjuvant is as defined in any of claims 34-43

101. The analogue according to any of claims 90-97 or the composition according to claim 99 or 100 for use as a
15 pharmaceutical.

102. A nucleic acid fragment which encodes an analogue according to any of claims 90-97.

103. A vector carrying the nucleic acid fragment according to claim 102.

20 104. The vector according to claim 103 which is capable of autonomous replication.

105. The vector according to claim 103 or 104 which is selected from the group consisting of a plasmid, a phage, a cosmid, a mini-chromosome, and a virus.

25 106. The vector according to any of claims 103-105, comprising, in the 5'-3' direction and in operable linkage, a promoter for

driving expression of the nucleic acid fragment according to claim 102, optionally a nucleic acid sequence encoding a leader peptide enabling secretion of or integration into the membrane of the polypeptide fragment, the nucleic acid fragment according 5 to claim 102, and a nucleic acid sequence encoding a terminator.

107. The vector according to any of claims 103-106 which, when introduced into a host cell, is integrated in the host cell genome.

108. The vector according to any of claims 103-106 which, when 10 introduced into a host cell, is not capable of being integrated in the host cell genome.

109. The vector according to any of claims 106-108, wherein the promoter drives expression in a eukaryotic cell.

110. The vector according to any of claims 106-109, wherein the 15 promoter drives expression in a prokaryotic cell.

111. A transformed cell carrying the vector of any of claims 103-100.

112. The transformed cell according to claim 111 which is capable of replicating the nucleic acid fragment according to 20 claim 102.

113. The transformed cell according to claim 102, which is a microorganism selected from a bacterium, a yeast, a protozoan, or a cell derived from a multicellular organism selected from a fungus, an insect cell, a plant cell, and an mammalian cell.

25 114. The transformed cell according to claim 113 which is a bacterium of the genus *Escherichia*, *Bacillus*, *Salmonella*, or *Mycobacterium*.

115. The transformed cell according to claim 114, which is an *E. coli* cell.

116. The transformed cell according to claim 115, which is a non-pathogenic *Mycobacterium* cell such as *M. bovis* BCG.

5 117. The transformed cell according to any of claims 111-116, which expresses the nucleic acid fragment according to claim 102.

118. The transformed cell according to claim 117, which secretes or carries on its surface, the analogue according to any of
10 claims 90-97.

119. A composition for inducing production of antibodies against PSM, Her2 or FGF8b, the composition comprising
13) a nucleic acid fragment according to claim 102 or a vector according to any of claims 103-108, and
15 14) a pharmaceutically and immunologically acceptable diluent and/or vehicle and/or carrier and/or excipient and/or adjuvant.

120. The composition according to claim 119, wherein the nucleic acid fragment is formulated as defined in any of claims 33-43.

20 121. A stable cell line which carries the vector according to any of claims 103-110 and which expresses the nucleic acid fragment according to claim 102, and which optionally secretes or carries the analogue according to any of claims 90-97 on its surface.

25 122. A method for the preparation of the cell according to any of claims 111-118, the method comprising transforming a host cell with the nucleic acid fragment according to claim 102 or with the vector according to any of claims 103-110.

Fig. 1

APC

T_h cell

Modified Self Protein

B cell

CYTOKINE HELP

A

B

C

Fig. 2

APC

T_h cell

Modified Self Protein

CTL

CYTOKINE HELP

A

B

C

Extracellular domain

DOMAIN I   DOMAIN II (Cys rich)   DOMAIN III (LIGAND BINDING)   DOMAIN IV (Cys rich)   TM

Intracellular domain

TK DOMAIN   C-TERMINAL DOMAIN

—— High homology
···· Low homology
···· Very low homology

⬆ Experimentally determined CTL epitopes
⬆ Predicted CTL epitopes

⬇ N-glycosylation. Sites (predicted)

Fig. 3

Human PSM constructs

FIG. 4

Fig. 5A

```
                      FGF8e and -f                        FGF8b and -f
MGSPRSALSC LLLHLLVLCL QAQEGPGRGP ALGRELASLF RAGREPQGVS QQVTVQSSPN  31
FTQHVREQSL VTDQLSRRLI RTYQLYSRTS GKHVQVLANK RINAMAEDGD PFAKLIVETD  91
TFGSRVRVRG AETGLYICMN KKGKLIAKSN GKGKDCVFTE IVLENNYTAL QNAKYEGWYM 151
AFTRKGRPRK GSKTRQHQRE VHFMKRLPRG HHTTEQSLRF EFLNYPPFTR SLRGSQRTWA 211
PEPR                                                             215
```

Fig. 5B

F30N.

F2I.

F30I.

F2C

```
WT     MGSPRSALSCLLLHLLVLCLQAQVTVQSSPNFTQHVREQSLVTDQLSRRLIRTYQLYSRTSGKHVQ   66
F30N               MAQVTVFNNFTVSFWLRVPKVSASHLERRLIRTYQLYSRTSGKHVQ   46
F2I                MAQVTVQSSPNFTQHVREQSLVTDQLSRRLIRTYQLYSRTSGKHVQ   46
F30I               MAQVTVQSSPNFTQHVREQSLVTDQLSRRLIRTYQLYSRTSGKHVQ   46
F2C                MAQVTVQSSPNFTQHVREQSLVTDQLSRRLIRTYQLYSRTSGKHVQ   46

WT     VLANKRINAMAEDGDPFAKLIVETDTF                  GSRVRVRGAETGLYICMNKKGKLIAK 119
F30N   VLANKRINAMAEDGDPFAKLIVETDTF                  GSRVRVRGAETGLYICMNKKGKLIAK  99
F2I    VLANKRINAMAEDGDPFAKLIVETDQYIKANSKFIGITELGSRVRVRGAETGLYICMNKKGKLIAK 112
F30I   VLANKRINAMAEDGDPFAKLIVETDTF                  GSRVRVRGAETGLYICMNKKGKLIAK  99
F2C    VLANKRINAMAEDGDPFAKLIVETDTF                  GSRVRVRGAETGLYICMNKKGKLIAK  99

WT     SNG              KGKDCVFTEIGLENNYTALQNAKYEGWYMAFTRKGRPRKGSKTRQ 167
F30N   SNG              KGKDCVFTEIGLENNYTALQNAKYEGWYMAFTRKGRPRKGSKTRQ 147
F2I    SNG              KGKDCVFTEIGLENNYTALQNAKYEGWYMAFTRKGRPRKGSKTRQ 160
F30I   SNGFNNFTVSFWLRVPKVSASHLEDCVFTEIGLENNYTALQNAKYEGWYMAFTRKGRPRKGSKTRQ 165
F2C    SNG              KGKDCVFTEIGLENNYTALQNAKYEGWYMAFTRKGRPRKGSKTRQ 147

WT     HQREVHFMKRLPRGHHTTEQSLRFEFLNYPPFT   RSLRGSQRTWA   PEPR 215
F30N   HQREVHFMKRLPRGHHTTEQSLRFEFLNYPPFT   RSLRGSQRTWA   PEPR 195
F2I    HQREVHFMKRLPRGHHTTEQSLRFEFLNYPPFT   RSLRGSQRTWA   PEPR 208
F30I   HQREVHFMKRLPRGHHTTEQSLRFEFLNYPPFT   RSLRGSQRTWA   PEPR 213
F2C    HQREVHFMKRLPRGHHTTEQSLRFEFLNYPPFTQYIKANSKFIGITELPEPR 199
```

Fig. 6